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Abstract 
The biomedical applications of carbon nanomaterials are under intensive investigation for the development 
of next-generation therapeutics. Although much focus has been placed on carbon nanotubes (CNTs) and 
graphene, other carbon nanomaterials including carbon nanohorns (CNHs), nanodiamonds (NDs) and 
fullerenes have emerged as suitable candidates for biomedical applications. Among these multi-shell 
fullerenes, also known as carbon nano-onions (CNOs), are the less studied carbon nanomaterials in 
biomedicine. The unique properties of carbon nano-onions, such as high surface area-to-volume ratio, 
thermal conductivity, electrical conductance, mechanical stiffness and ease of chemical functionalization 
render them fascinating materials for diverse applications including drug-delivery, diagnostics, biological 
imaging and tissue engineering. Carbon nanomaterials are emerging as smart nanostructures for 
biomedicine due to the possibility to incorporate multiple functionalities and moieties internally or externally. 
They can be modified at a precise physicochemical level to optimize targeting in the complex in vivo 
environment and also engineered for fluorescence detection, magnetic resonance imaging and ablation of 
tumor cells. Herein, robust and versatile synthetic strategies for the modification of carbon nano-onions 
(CNOs) are reported. The development of novel CNO conjugates represent a promising platform for the 
realization of novel technology scaffold for molecular imaging, photodynamic therapy and molecular 
transporter of fully synthetic carbohydrate-based vaccines for immunotherapy due to the large specific 
surface area and unique optical and electrochemical properties of CNOs. Through the methodologies 
described, these smart nano-materials can envisage the realization of multi stimuli-responsive and dynamic 
architectures capable of changing their physicochemical behavior upon encountering specific micro-
environmental signals becoming relevant for diagnosis, imaging and therapies of specific disease 
applications. 
 
 
 
 
 iv 
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APCs antigen-presenting cells 
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FT-IR fourier transform infrared spectroscopy 
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GQDs graphene quantum dots 
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UDD ultra- disperse diamonds 
XPS X-ray photoelectron spectroscopy 
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1. Introduction 
 
1.1 Carbon Nano Materials 
In the past decade nanomaterials have begun to emerge as valuable opportunities in biomedical research 
and clinical applications.1 This has become possible by coupling their inherent properties 2,3 with the 
established knowledge of molecular and biomolecular recognition. In particular, carbon nanomaterials 
(CNMs) are among the most broadly discussed, researched and applied synthetic nanomaterials.4,5,6,This is 
due to their diverse intrinsic electronic, magnetic and optical properties, chemical versatility and ease of 
manipulation, biocompatibility as well as their performance as a chemically robust platform. Carbon 
nanomaterials typically range from 1 nm to 100 nm in size, which is comparable to the sizes of proteins 
(1−100 nm) and DNA (2−3 nm in width) in biological environments, and the sizes of natural biological 
barriers in vivo including ion channels (a few nanometers) and the glomerular filtration barrier (5−10 nm).7 
The favorable sizes of carbon nanomaterials have made them ideal nanocapsules and nanocarriers to load 
and deliver drugs and genes to specific targets in vivo. Moreover, the optical properties unique to some 
carbon nanomaterials have also attracted a lot of interest for a variety of biological and medical applications 
including biosensing, imaging, and therapy. R&D in different areas of nanomedicine is expected to 
revolutionize the disease diagnosis and treatment approaches in the near future. Nanosized contrast agents 
are anticipated to lead way to advancements in understanding biological processes at the molecular level. 
Nanomedical approaches to drug delivery focuses on developing nanoscale particles or molecules to 
improve the bioavailability of a drug. Special attention has been given to bioassay applications such as 
biosensors, biomedical devices, and biofuel cells using nanomaterials. Nanotechnology on a chip is a new 
paradigm for total chemical analysis systems. Nanorobotics and nanomanipulation technologies will 
eventually allow moving and manipulating nanoscale materials and assemble them into nanosytems such as 
nanoscale robotics.  
CNMs exhibit huge diversity in structure, existing in many forms such as, diamond, graphene, amorphous 
carbon, C60 and carbon nanotubes (CNTs). These materials can be classified according to the number of 
dimensions in zero-dimensional (0-D) nanoparticles such as fullerens, carbon nano-onions and 
nanodiamonds one-dimensional (1-D) nanotubes, two-dimensional (2-D) layered materials such as graphene 
(Figure 1).  
 
1.1.1 Fullerene 
The discovery of C60 fullerene by Smalley, Kroto, Curl et al. in 1985 can be considered as the starting point 
of the CNM revolution.4 The nanometer size of the C60 molecules can impart various unconventional 
capabilities to afford stealth nanoparticles for imaging and drug/gene delivery. First of all, the hollow cavity of 
the C60 sphere can be used to load certain metal ions such as Gd3+ or 99mTc, resulting in contrast agents for 
magnetic resonance imaging (MRI) as well as nuclear medicine.8,9 Furthermore, it is found that the 
hydrophobic surface of the C60 molecules binds strongly to oligodeoxynucleotide10 leading to efficient gene 
delivery vehicles that can pass through both the cell membrane and the nuclear membrane to improve the 
efficacy of gene therapy.11 
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Figure 1. The world of synthetic carbon allotropes.  
 
1.1.2 Nanodiamond 
Another type of CNM in this size regime are carbon nanodiamonds (NDs), which combine the characteristics 
of diamond; optical transparency, chemical stability and biological compatibility, with the attractive 
nanomaterial’s properties such as small size, large surface area and high adsorption capacity.12 One 
important additional feature of NDs is their low toxicity.13 NDs are primarily made through the controlled 
detonation of explosives to yield core–shell particles with diameters of 4–5 nm. The synthesis of fluorescent 
NDs is also possible through the introduction of nitrogen vacancies (N-V centres), which are typically 
introduced by electron irradiation (2 MeV) of 100 nm NDs followed by annealing (900 1C) in vacuum.14 In 
addition, ultrasmall (1.6 nm) fluorescent NDs of roughly 400 carbon atoms and containing Si vacancies have 
been also reported. For bioimaging and therapy purposes, nanodiamond has several advantages. Firstly, 
nanodiamond is a highly photostable fluorophore that is almost nonphotobleachable, allowing for long-time 
imaging without concerns of signal decay.15 Secondly, the fluorescence quantum efficiency is surprisingly 
high, usually ranging from 0.7 to 1, significantly higher than molecular fluorophores with similar emission 
wavelengths.16 Thirdly, nanodiamond has been reported to be highly biocompatible and non-toxic to 
biological tissues and organisms.15 Moreover, the abundant dangling bonds on the surface of nanodiamonds 
allow for easy surface functionalization via both covalent and noncovalent means without affecting the 
intrinsic optical properties of the N−V centers in the core, rendering them employed as fluorescent labels for 
in vitro imaging of subcellular structures and certain biomarkers,17,18 in vivo whole animal imaging,19,20 drug 
and gene delivery,21,22 and tissue engineering.23,24  
 
1.1.3 Carbon Dot 
The most recent addition to the 0-D family of CNMs are carbon dots (Cdots), also referred to as graphene 
quantum dots (GQDs). The earliest reported syntheses of Cdots was by the laser ablation of a carbon 
target25 and from candle soot.26 Today, Cdots can be prepared by pyrolysis,27 hydrothermal and 
electrochemical treatments,28 and microwave synthesis of a wide variety of carbon sources such as biomass 
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and waste materials.29,30 These methods provide access to Cdots whose luminescence spans the visible 
spectrum.31,32  
 
1.1.4 Graphene 
Graphene comprises a single, layer of sp2 carbon and as such can be considered the molecular parent of the 
sp2 CNMs. Graphene’s ability to absorb light of all wavelengths coupled to its excellent electron transport 
properties has generated enormous interest. Typically, graphene is prepared by mechanical and liquid phase 
exfoliation of graphite;33,34 recently large scale preparation of graphene using surfactants has been 
reported.35 In addition to pristine graphene several surface treated forms such as photoluminescent 
graphene oxide (GO) and reduced graphene oxide (RGO) have also been used for biosensing applications, 
tumor imaging and drug/gene delivery.36,37 
 
1.1.5 Carbon nanotube 
Carbon nanotubes, are tubular structures of rolled-up sheets of graphene comprising single-wall (SWCNTs) 
and multi-wall (MWCNTs) species. SWCNTs exhibit metallic, semi-metallic and semiconducting, properties 
which may be exploited for several applications.38 These properties depend on the nature of the rolled 
graphene sheet, which dictates the chirality of the species. The general synthesis of CNTs employs chemical 
vapour deposition of carbon in the presence of a transition metal catalyst.  
 
1.1.6 Carbon nanohorn 
Closely related to SWCNTs are single-walled carbon nanohorns (CNHs). These are conical structures with 
diameters of 2–5 nm and lengths of 40–50 nm which typically assemble into dahlia-flower like or bud-like 
aggregates with a diameter of about 100 nm. CNHs possess good porosity and high surface area which can 
be exploited for biomedical applications.39 Importantly, CNHs can be produced in high yield in the absence of 
metal catalyst by either CO2 laser ablation of pure graphite or pulsed arc discharge of carbon rods.  
 
The purity of synthetized CNMs is an essential consideration for any possible biological and medical 
application. Impurities may interfere with the detection of analytes and a polydisperse sample influences both 
the optical properties and the ability to form ordered assemblies. Of the CNMs, fullerene derivatives are the 
only members that can synthetized with precisely known composition. For example, CNTs must be rigorously 
purified to remove the transition metal catalyst species.40,41 Furthermore, in vivo applications require the 
removal of carbonaceous fragments which can act as reactive oxygen species. The size dependent optical 
properties of CNMs also necessitates the use of separation procedures to obtain monodisperse samples.42 
Techniques for the separation of chiral CNTs include ultracentrifugation43 and gel permeation 
chromatography.44 Centrifugation techniques have also been used for the length separation of CNTs45 and 
the size-selective purification of dispersed graphene flakes.46 In addition, Cdots have been separated from 
non-luminescent materials using C-18 HPLC.  
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1.2 Surface Functionalization 
In order to employ for various nanomedicinal applications, nanomaterials should be subjected to suitable 
surface modifications. The aim of such surface modification strategies is to enhance the solubility and 
stability of nanosized materials in aqueous media as well as to impart them with biological properties and 
functionalities. As a brief note, CNMs are typically covalently functionalized through chemical reactions 
directly with the carbon atoms in the sp2 carbon shell, and a library of standard chemical reactions have been 
developed for carbon nanomaterials chemistry. They can be either covalently or non-covalently 
functionalized to impart water solubility, depending on the need for specific biological applications. Carbon 
dots are by nature rich in –OH and −COOH functional groups, which can easily form hydrogen bonds with 
water molecules and thus endow carbon dots with good solubility in aqueous environment; nonetheless, it is 
still desired to further functionalize them with PEG or other functional groups to increase biocompatibility. 
Nanodiamond, on the other hand, is similar to fullerenes, carbon nanotubes and graphene because of their 
poor solubility in aqueous solvents which render them prone to aggregation due to hydrophobic interactions. 
However, this can be addressed through surface functionalization by covalent47,48 or non-covalent 
methods.49,50 In the following chapters, I will illustrate covalent and non-covalent surface treatments for CNO 
functionalization. 
 
1.2.1 Covalent Surface Functionalization 
Most carbon nanomaterials are insoluble in water due to their hydrophobic surfaces made of sp2 carbon 
atoms. Covalent surface functionalization introduces heteroatoms (mostly O and N) and functional groups to 
the pristine carbon nanostructures and thus increases water solubility. The functional groups also provide 
handles for further conjugation with other functional molecules to improve biocompatibility and impart certain 
functions to the original carbon nanomaterials. In the case of sp2 carbon species covalent functionalization 
results in the permanent disruption of the π-electronic network which can influence the optical properties of 
the material. This can be avoided through the use of noncovalent methods which largely reply on π−π 
stacking interactions between the CNM surface and molecules such as pyrenes and porphyrins and can be 
used to modulate the CNM optical properties.  
 
1.2.2 Noncovalent Surface Functionalization 
Non-covalent surface functionalization works by supramolecular interactions between the pristine carbon 
nanomaterial and the coating molecule/polymer, which impart minimum structural damage and disturbance 
to the intrinsic properties of the functionalized carbon nanomaterials. The supramolecular interactions 
employed for non-covalent surface functionalization include π−π stacking and hydrophobic interactions. 
Strong non-covalent binding of pyrene moieties to the sidewalls of SWCNTs due to π−π stacking is useful 
for functionalization of nanotubes for biological applications. The π-stacking chemistry has been widely 
utilized in the past decade for functionalization of not only nanotubes, but also various forms of graphene 
and carbon materials.51,52 Besides non bioactive molecules, polymeric biomolecules such DNA and proteins 
have also be employed for solubilization of SWCNTs. Single-stranded DNA (ssDNA) was used to assist the 
dispersion and suspension of SWCNTs in water by helically wrapping to the surface of the nanotube, as first 
reported by Zheng et al.53 It was suggested that strong π−π stacking between nanotube surface and the 
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aromatic bases of ssDNA is responsible for the formation of hybrid between nanotube and DNA, which is 
elegant since DNA is a molecule of central importance in biology and the carbon nanotube represents an 
artificial 1D carbon nanocrystal.53  
 
1.3 Carbon nano-onion 
Although carbon nano-onions were discovered before fullerenes and nanotubes, they stayed for a long time 
in the shadow of more popular and better investigated nanocarbons. Carbon nano-onions, which are the 
main materials investigated in my Ph.D. project, consist of spherical closed carbon shells and owe their 
name to the concentric layered structure resembling that of an onion. During my Ph. D. course, the physico-
chemical properties of CNOs have been studied and novel technology platforms based on carbon nano-
onions for bioimaging, synthetic nano-vaccine carriers and photo-dynamic therapy applications have been 
developed. CNOs have been shown to be ideal for the future rational design of carbon nanomaterial based 
medical technologies because of their unique 0-D structure, small (5 nm) diameter, good biocompatibility and 
efficient cell-uptake compared to 1-D nanotubes and 2-D graphene. The exclusive properties of the material, 
such as high surface area-to-volume ratio, thermal conductivity, electrical conductance, mechanical stiffness 
and ease of chemical functionalization render CNOs fascinating materials for diverse applications including 
drug-delivery, diagnostics, biological imaging and tissue engineering. The high biocompatibility and the 
efficient cellular uptake of these nanomaterials together with their high fluorescence reveal great promises 
for the development of new architectures for targeted imaging nanotherapeutics and antigen delivery 
devices. Furthermore, CNO can envisage the realization of multi stimuli-responsive and dynamic materials 
capable of changing their physicochemical behavior upon encountering specific micro-environmental signals 
becoming relevant for diagnosis, imaging and therapies of specific disease applications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
1.4 Synthetic pathways for CNO preparation 
Since the discovery of the fullerene C60 in 1985 by Curl, Kroto and Smalley using laser desorption 
experiments4, several allotropes of carbon were discovered in the following years. This includes carbon 
nano-onions, also known as multi-shell fullerenes which were discovered in 1992 by Ugarte utilizing intense 
electron-beam irradiation54. Toward this, carbon soot particles were irradiated in a 300-kV high-resolution 
electron microscope (HREM) using an electron dose 10-20 times higher than under normal operating 
conditions (the usual dose was 10-20 A cm-2). It is worth to highlight that electron-beam heating did not lead 
to the same result as thermal heating, because of the contribution of the excitation process. Strong 
irradiation heats the sample by energy absorption and ruptures bonds through electron excitations. 
Furthermore, high-energy particles can transfer momentum to the nuclei, displacing atoms to interstitial 
lattice sites. The formation mechanism of these multiple-shell spheres rely on the graphitic structure 
stimulated by irradiation. By increasing irradiation, there is a gradual reorganization of the initial material into 
quasi-spherical particles composed of concentric graphitic shells and consequently the separation of the 
graphitic spheres as single units (Figure 2). These multilayered particles exhibit a diameter of about 5nm and 
the distance between the carbon layers was determined to be about 0.34 nm, which approximately 
corresponds to the distance between two graphitic planes54 (Figure 3).  
 
 
Figure 2. HRTEM image of a quasi-spherical onion-like graphitic particles generated by electron irradiation. 
(dark lines represent graphitic shells, and the distance between layers is 0.34 nm). Reprinted with 
permission from reference54. Copyright 1995 Elsevier.  
 
However, this synthetic procedure is a low yield process. After the discovery of carbon onions, many efforts 
have been focused on synthetic pathways to obtain these concentric spherical shell structures with higher 
yield and to understand the formation mechanism of such materials. Over the last years, different methods of 
synthesis have been developed including high-temperature nanodiamonds annealing, arc discharge, laser 
ablation, chemical vapor deposition and their physical properties have been widely investigated. 
 
5 nm 
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1.4.1 Annealing of nanodiamonds 
A detailed analysis of the effects of the annealing temperature on carbon nano-onions has been reported by 
Kuznetsov et al. in 19995. Annealing of nanodiamonds with a sp3 diamond framework and a diameter of 
typically 2-5 nm was performed in a tube furnace using vacuum at high temperature. It has been proven by 
many researchers that upon heating to high temperatures (at least 900°C), a transformation of the diamond 
phase to a graphitic phase begins because enough kinetic energy is required to keep on breaking C-C bonds 
in the diamond core55. Indeed, a structural rearrangement of the particles including the elimination of 
dangling bonds at the nanodiamond surface and the closure of graphite sheets results in the decrease of the 
surface energy, which is supposed to be the driving force to form closed graphite shells continuously.56 
According to this, when the temperature is lower than 900°C, CNOs cannot be effectively generated. The 
amorphous carbon and the nanodiamond crystals coexist. Moreover, the non-carbonaceous material traces 
are still present in the sample. Thermal desorption data indicates that hydrogen – the last non-carbon 
contaminant - desorbs from the nanodiamond surface at approximately 850°C. At temperatures between 
900°C and 1100°C, the CNOs are formed but still a small amount of nanodiamonds can be detected within 
the core of the particles. Only above 1400°C, nanodiamonds are completely transformed into CNOs56. The 
main product obtained by this synthetic method is a perfectly spherical multi-layered structure with 6 to 7 
graphitic shells. It is worth to mention that the formation process of CNOs under annealing conditions 
includes a sequence of essential steps. The core step involves the formation of graphite fragments. The 
graphitization initiated by a significant thermal displacement of a single carbon atom at temperatures close to 
the Debye temperature initiates at the external surface of the nanodiamond particles and progresses towards 
its crystal bulk. Therefore, graphite fragments with different numbers of carbon atoms exfoliate from the 
external surface of any diamond plane and surround the nanodiamond particles – see Figure 3. Secondly, 
the connection and curvature of graphite sheets between diamond planes and especially the closure of 
graphite layers play a key role. The graphite fragments increased with increasing annealing temperature and 
gradually connected up into curved graphitic sheets close to diameters of C60 and higher fullerenes. 
Basically, in the case of high-temperature-treated or electron-irradiated amorphous carbon particles, the 
multiple-shell spheres were formed based on irradiation-stimulated graphitization.  
 
 
 
 
 
 
 
 
 
Figure 3. (a) HRTEM of abundant nanodiamonds. Marked lattice spacing is measured to be 0.206 nm, which 
coincides with the d value of the (111) lattice plane of diamond with cubic structure. (b) Spherical particle 
consisting of onion shells with a diamond core (pointed by the white arrows). (c) Spherical carbon onion with 
external graphitic layers and closed quasi-spherical internal shells. Reprinted with permission from reference 
56
.Copyright (2014) American Chemical Society. 
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1.4.2 Arcing Graphite Underwater 
In 2001 Sano and co-workers described a non-vacuum method to synthetize large-scale carbon nano-onions 
by an arc discharge between two graphite electrodes submerged in deionized water57,58. In this method, two 
electrodes of high purity were electrically arced under water by applying a bias potential of 16-17 V between 
them and maintain a constant current of 30 A. Carbon nano-onions obtained thereby exhibit diameters of 25-
30nm and 10-15 shells around a core found to be consistent with that of the C60 molecule – see Figure 4. 
Therefore, carbon nano-onions with a hollow core surrounded by multilayered sp2 carbon shells prepared 
from arcing graphite underwater are considerably larger than carbon nano onions obtained from 
nanodiamonds59. The nano-onions were obtained in the form of floating powder on the water surface, while 
the rest of the product, containing a mixture of graphitic nanotubes and nanoparticles was found to be at the 
bottom of the water tank. This process gives a material of high purity through a natural segregation from the 
other carbon structures. Although it may be presumed that the density of carbon nano-onions is less than 
that of water, this is not the case. It was found that the particles were floating on water despite of their 
density (1.64 g/cm3) being higher than that of water. Therefore, the floating carbon onions on the water 
surface are presumed to be due to the formation mechanism based on the formation of large van der Waals 
crystals.  
 
 
 
Figure 4. Scheme of the apparatus used for the arc discharge synthesis of CNOs in water and the HRTEM 
image of the resulting product collected as the floating powder on the top of the water surface. Reprinted 
with permission from reference57. Copyright (2002), AIP Publishing LLC. 
 
Basically, subsequent to the formation of onions, they cluster into larger van der Waals crystals59. These 
clusters readily float to the top of the water surface remaining separated at the surface of the water even 
after vigorous dispersion through ultrasonication. In this arc-in-water system, onions are naturally 
agglomerated and float, being separated from the other large products that settle on the bottom of the 
beaker.  
Sano and co-workers proposed that during an arching underwater process a plasma zone between 
electrodes exists and the temperature between them can reach up to 4000K (the sublimation temperature of 
carbon) and that a gas bubble due to the vaporization of the surrounding liquid is generated59. The main gas 
arc plasma 
carbon 
onions 
deionized 
water 
other 
carbon  
structures 
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components are CO and H2 produced by the reaction of C atomic vapor and H2O at the gas-liquid interface 
as �� + � �ଶ� �� → ���� + � �ଶ 
 
The formation mechanism of carbon nano-onions in that case involves the graphitization of a liquid carbon 
drop. The sharp temperature gradient from the hot plasma region to the gas-water interface is fundamental 
to cause a rapid solidification of the vaporized carbon. The temperature at the hot plasma is estimated to be 
approximately 4000 K (the melting and boiling points of graphite are 3823 K and 4203K, respectively), while 
the temperature at the gas-water interface is the boiling point of water, 373 K. Remarkably, at high 
temperature, carbon from graphite electrode vaporizes and condenses when in contact with the surrounding 
cold aqueous environment. The generated temperature gradients induce an important range of conditions for 
the formation of graphitic nanoparticles; this fact leads to wide size and shape distributions (Figure 5). For 
the condition of arc-discharge, the elimination of the energetic dangling bonds during the cooling of quasi-
liquid carbon is suggested to be the driving force to induce curvature and closure leading to the formation of 
CNOs. 
  
 
Figure 5. Representation of the formation mechanism of onions by arch discharge in water. The formation of 
elongated nanoparticles in zone (I) and in zone (II) is also shown schematically. Reprinted with permission 
from reference57. Copyright (2002), AIP Publishing LLC. 
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1.4.3 Pulse Laser Ablation  
The recent developments of laser technologies offer unique opportunities for carbon nanostructures 
fabrication. The conditions for carbon nano-onion formation, using a laser vaporization technique in a laser 
ablation chamber, were investigated by Dorobantu et al60. They reported a laser-assisted technique for the 
synthesis of high-quality CNOs by ablating pure graphite targets. This synthetic process requires a 
specialized equipment. Basically, the laser ablation chamber consists of a quartz tube mounted inside a tube 
furnace. It is important to keep the temperature of the furnace constant at 900°C during the entire experiment 
and the quartz tube is O-ring sealed to ensure pressure control from 10-3 Torr up to atmospheric pressure. 
The essential parameters applied for obtaining CNOs was a laser wavelength of 248 nm, 25 ns pulse length 
and 10 Hz repetition rate. In addition, the pressure inside the reactor was fixed at 7 Torr, while the argon flow 
was kept at about 300 L/h. The plume resulting from the laser irradiation of the graphite target was 20-30 
mm long and the ablation products condensed on a water-cooled cold finger (Figure 6). 
 
 
 
 
 
Figure 6. Scheme of the laser ablation chamber apparatus. Chamber schematics: 1-quartz laser window; 2-
quartz tube; 3-electrical oven; 4-target; 5-graphite transfer rod; 6-cold finger; 7-vacuum gauge. Reprinted 
with permission from reference60. Copyright © 2014, Allerton Press, Inc. 
 
 
HRTEM analysis of the collected deposits indicate that the diameter of the observed CNOs, formed by 10-20 
shells with a  hollow core (less than 5 nm), are typically in the range of 10 to 25 nm. The graphitic interlayer 
distance was estimated to be 0.35 nm and the interatomic distance in between the carbon atoms was found 
to be 0.24 nm as evidenced by the insets in Figure 7. In addition, no amorphous carbon was detected inside 
the concentric shell structure, thus it has to be underlined that pure carbon nano-onions have been obtained.  
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Figure 7. HRTEM images of the graphitic interlayer distance (a) and the interatomic distance (b) of CNOs. 
The results of the measurements are presented in the inset. Reprinted with permission from 
reference60.Copyright © 2014, Allerton Press, Inc. 
  
1.4.4 Radio-frequency plasma-enhanced Chemical Vapor Deposition (CVD) 
 
After the discovery of carbon nano-onions, Chen and co-workers reported the synthesis of CNOs by radio-
frequency plasma-enhanced chemical vapor deposition (CVD)61. This method allows for the synthesis of 
large quantities of carbon nano-onions by the deposition of methane over the surface of a Cobalt catalyst. 
The radio-frequency plasma-enhanced CVD process is somehow similar to the classical pyrolytic CVD 
process used for the growth of carbon fibers or carbon nanotubes, but the key difference is focused on the 
gas decomposition principle. Although, the pyrolytic CVD techniques use conventional Fe, Co, Ni and their 
alloys as catalysts, up to now, these methods have not produced any carbon onions. This method might not 
be suitable for the formation of pentagonal carbon rings, which are indispensable for curvature of the 
graphite sheet. In the case of radio-frequency plasma-enhanced CVD, initially the hydrocarbon is adsorbed 
at the surfaces of the catalytic particles and in the meantime, the process of glow discharge leads to CH4 
decomposition, resulting in the formation of carbon rings, which tend to nucleate on the surfaces of the 
catalyst. Furthermore, in the presence of atomic hydrogen in the plasma, free carbon valences on the ends 
of carbon layers can be stabilized by the formation of C-H bonds. Notably, the formation mechanism of 
CNOs described in this paragraph is absolutely different from the others discussed so far. The low 
temperatures required in the radio-frequency plasma-enhanced CVD underline the fact that CNOs can be 
fabricated without the help of high energy levels. Furthermore, the formation of many cages in successive 
stages from the core to the surface is essential to carbon nano-onion formation. The nucleus is a dome 
formed by one part of a C60 molecule and only the growth of this dome by addition of hexagons and 
pentagons leads to the formation of a first cage. This first cage is the substrate on which further layers may 
nucleate and grow into a second, third, etc. spherical cage as shown in Figure 8. With the increase of cage 
surface area, the new secondary surface may involve pentagons, hexagons and heptagons which deposit 
with various degrees of epitaxial coherence, resulting in formation of wavy carbon sheets. The product 
a b 
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obtained by this method is pure and can be easily separated from the catalytic particles. In addition, the 
average size of these carbon nano-onions ranges from a few to several tens of nanometers61. 
 
 
Figure 8. Scheme of the formation mechanism of onions by radio-frequency plasma-enanced chemical vapor 
deposition. The formation of onions is based on the formation of many cages in successive stages from the 
core to the surface. (a) the nucleus is a dome formed by one cap of a C60 molecule; (b) the nucleus grow into 
a cage by the addition of hexagons and pentagons; (c) a second cage is nucleated on the first cage as 
substrate.61 
 
It is important to underline that the core of carbon nano-onions fabricated by CVD can be either filled with 
metal, or remain completely empty. In the method described above, the catalyst is not encapsulated by 
carbon layers because the rings tend to nucleate on the surfaces of the catalyst. This is in agreement with 
the formation mechanism previously reported. However, modifications of this method lead to a different 
formation mechanism that results in the encapsulation of the catalyst in the shells. Li and co-workers have 
reported a novel method for the synthesis of CNOs via catalytic decomposition of methane over a Nickel 
catalyst supported on aluminum at 600°C62. The carbon nano-onions obtained consist of several concentric 
carbon layers with sizes ranging from 5 to 50 nm covering a nickel particle. When the nickel particle has a 
quasi-spherical structure, the graphite layers roll around the spherical particle and form a similar spherical 
carbon onion-like structure. When the nickel particle is a polyhedron the result is a polyhedral carbon onion-
like construct (Figure 9). According to this, the growth of CNOs suggests a different formation mechanism 
where the CNOs form directly from the gas phase and the Ni particles act as catalyst inducing curvature in 
graphite layers, remaining trapped in the carbon shells.  
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Figure 9. HRTEM images of onions synthetized by chemical vapor deposition using a Ni/Al catalyst. The 
images show that the shape of the carbon onions depends on the shape of the nickel particles. (a) quasi-
spherical nickel particle leads to quasi-spherical carbon onions; (b) polyhedron nickel particle results in 
polyhedral carbon onions. Reprinted with permission from reference 62. 
 
1.4.5 Other synthetic methods for CNOs fabrication 
Other methods for the synthesis of carbon nano onions include catalytic synthesis using counterflow 
diffusion flames63, heavy shocking of polycrystalline silicon carbide powder, and assembly of aromatic 
molecules such as polymers64. These methods lead to carbon nano-onions with diameters around 60-80 nm. 
In 2005, Liu and co-workers reported the synthesis of CNOs via thermal reduction of glycerin with 
magnesium65. In this method, glycerin and magnesium were heated at 650°C during 12 hours resulting in the 
formation of carbon nano-onions with diameters ranging from 60 to 90 nm. The reaction can be expressed 
as the following equation: 
 ͵� �� + ���ଷ� �8� �ଷ ���→ ��͵� ��� + �͵��� + �Ͷ� �ଶ 
 
Temperature plays an important role in the reaction, in fact under different other temperature conditions no 
CNOs have been observed.  
Another research hotspot in the last years has been the fabrications of doped carbon materials with excellent 
physicochemical properties by using annealing treatment, CVD deposition and plasma etching. Chemical 
doping in carbon materials using heteroatoms (e.g. N, S, O and P) is a useful technique to modulate the 
intrinsic electronic characteristic, surface and local chemical features of the materials. In contrast to 
graphene, carbon nanotubes (CNTs) and carbon fibers (CNFs), carbon nano-onions (CNOs) have specific p 
and π electronic structures due to their high curvature. According to this, Lin and colleagues reported a 
systematic study on the preparation of boron-doped CNOs via a high temperature thermal treatment (1500-
2400°C) starting from nanodiamonds in a graphite furnace66 – see Figure 10.  
 
a b 
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Figure 10. Schematic illustration for the fabrication of various Boron-doped carbon nano-onion samples (B-
OLC) from ultra- disperse diamonds (UDD). Adapted from reference [66] with permission from The Royal 
Society of Chemistry. 
 
The boron atom can be incorporated into carbon matrix because it has a comparable atomic size and three 
valence electrons for binding with carbon atoms. The formed B-C bond is longer than C-C bond (ca. 0.5%),  
leading to chemical disorder of the graphite layers, and to a p-type (or hole) doped carbon material. The 
results indicate that the incorporation of boron in CNOs can effectively change their electronic structure and 
properties. These novel  boron doped CNO materials exhibit a higher catalytic activity than pristine CNOs for 
the oxygen reduction reaction (ORR), a very important pathway in energy conversion, corrosion and 
biosensing. 
Among all the methods published in literature for the synthesis of CNOs, annealing of nanodiamonds and arc 
discharge under water of graphite electrodes offer reasonable amounts of pure CNOs although their sizes 
differ considerably. Current research has therefore been directed towards the selective synthesis of small 
CNOs with regular size. It is noteworthy that fullerene reactivity is partially dictated by the degree of surface 
strain: the higher the curvature, the greater the reactivity. Accordingly, small CNOs show an enhanced 
reactivity rather than large CNOs. This was demonstred by Echegoyen et al. who studied the differences 
between carbon nano-onions obtained from annealing of nanodiamonds characterized by a smaller radii and 
consequently higher curvature and arcing graphite under water67. The different behaviour of these CNOs is 
described in the next paragraph.  
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1.3 Properties and characterization of CNO 
Various methods for the synthesis of carbon nano-onions have been reported as described in the previous 
paragraph. Interestingly, the physicochemical properties of CNOs strictly depend on their synthetic pathways 
and different synthetic methods lead to CNOs of different size, shape and curvature, which are responsible 
for differences in the CNO’s reactivity. The structure of the CNOs, the number of graphene layers and the 
distance between them, as well as the presence of defects, determine the physicochemical properties. 
Moreover, the structural and electrochemical characteristics of the nanostructures are important for their 
consequent functionalization and further application. As already stated in the previous chapter, since Ugarte 
increased the current in the electron microscopy for the first time and observed CNOs, two main preparative 
methods have been described in the literature. Kuznetov et al.5 reported the production of pure CNOs in high 
yields by annealing carbon nanodiamond particles at temperatures above 1200°C and more recently, Sano 
et al.57 described a method of producing CNOs that involves arching between two graphite electrodes under 
water. Remarkably, the carbon nano-onions obtained by both methodologies are rather different. The 
annealing of the ultradispersed nanodiamond particles (5 nm in average diameter) under vacuum produces 
mainly small CNOs with 6-8 shells and diamters of about 5nm. On the other hand, the arching of graphite 
under water leads to the formation of large CNOs with diameters in the range of 15-25 nm, what corresponds 
to 20-30 shells. Moreover, although the CNOs from both samples show interlayer distances of 0.34 nm, 
which corresponds to the distance between graphene sheets, it has been reported that CNOs obtained from 
nanodiamonds contain more defects than the CNOs obtained from arching68. According to this, a different 
behavior of the carbon nano-onions in terms of reactivity and subsequent functionalization is notable. In the 
following chapter, the analysis of the physical properties of CNOs with techniques such as NMR, Raman, 
TGA, EELS, and powder X-ray diffraction will be depicted. Briefly, thermogravimetric analyses of CNOs 
reveals a high thermal stability in air, even higher than that of C60. Electron energy loss sptroscopy (EELS) 
studies suggests the presence of π electrons. High-resolution magic-angle spinning (HR-MAS) solid-state 
NMR spectroscopy clearly show one peak positioned at 110 or 120 ppm. Such peaks are characteristic of 
sp2 bonds and are usually observed for CNOs and graphite, respectively and are attributed to sp2 carbon. 
The difference in the  peak position may be related to the curvature of the onion shells causing changes in 
the angle of the carbon-carbon bonds68. The presence of a large number of sp2-hybridized carbon atoms, as 
observed in the NMR spectra, should render them susceptible to addition reactions. Furthermore, the Raman 
spectroscopic studies indicate that the CNOs obtained by thermal annealing (N-CNOs) have a larger number 
of surface defects than the CNOs obtained by arching (A-CNOs). Therefore, the earlier are expected to be 
more susceptible to reactions occurring at the defect sites on the surface than the latter. The N-CNOs with a 
higher degree of disorder along with the higher curvature of the surface are more reactive than the A-CNOs, 
even though the N-CNOs are thermodynamically more stable. 
 
1.3.1 Raman Spectroscopy 
Raman spectroscopy is a useful technique for exploring the structural properties and the behavior of various 
forms of carbon. In the case of carbon nano-onions, two broad peaks at about 1350 and 1580 cm-1 can be 
detected on the spectrum55. The first Raman features, centered at 1350 cm-1, are attributed to the D band, 
which indicates the vibration of carbon atoms with dangling bonds. It is correlated with the disorder induced 
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in the structure due to the presence of sp3 carbons. The second observed Raman features at around 1580 
cm-1 are associated with the G band, which is attributed to the CNO´s sp2 carbon network. This is the only 
band present in the Raman spectrum of single crystals of graphite. In addition, the intensity of the G band is 
related to the disorder within the carbon sp2 sheets. The intensity ratio of D to G band (ID/IG) indicates the 
degree of the crystalline perfection. For instance, the absence of the D peak in highly oriented pyrolytic 
graphite (HOPG) implies perfect graphene planes. Thus, a very weak D peak and a strong G peak from 
carbon nano-onions indicate that only slight imperfections are present in the graphene planes of the onions.  
 
 
 
 
Figure 11. Raman spectra of CNOs obtained from annealing of nanodiamonds increasing the temperature 
from 1500 to 2200°C. Reprinted with permission from reference [55]. Copyright (2001), AIP Publishing LLC. 
 
The band at about 1580 cm-1 corresponds to the E2g mode in the graphite structure of carbon (G band). It 
can be observed that the ID/IG decreases with increasing annealing temperatures (Figure 11). Furthermore, 
depending on the different properties of the CNOs, the Raman spectra of the CNOs obtained from annealing 
and from arching are slightly different, although both sources exhibit D and G bands. The D band appears at 
around 1313 cm-1 and the G band at 1581 cm-1 for the A-CNOs, while the corresponding bands appear at 
1307 and 1593 cm-1 for N-CNOs respectively. Moreover, the observed Raman features in the range of 2500-
3200 cm-1 are attributed to sp3 and sp carbon networks. Interestingly, the D/G ratio is 0.8 and 1.4 for A-CNOs 
and N-CNOs, respectively. This indicates that the outermost graphene sheet in the small N-CNOs contains 
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more defects than in the large A-CNOs. This is also confirmed from the full width at half maximum of the G 
band, which is broader for the N-CNOs than for the A-CNOs. Raman and TGA studies indicate that the 
structure of the N-CNOs is more defective and more thermodynamically stable than the structure of the A-
CNOs. This is an example of defects leading to stability, presumably for entropic reasons69. Remarkably, the 
functionalization on the surface of the nanostructures correlates with the composition and the structure of the 
material. After oxidation, the Raman spectra of CNOs obtained from annealing of nanodiamonds shows a 
significant increase of the D/G ratio indicating an increase in the number of surface defects. In contrast, the 
oxidation on CNOs obtained from arching graphite under water, which are larger in diameter require more 
aggressive conditions such as the treatment with a 1:1 mixture of HNO3 and H2SO4 to increase the surface 
defects. 
 
1.3.2 Thermochemistry 
The formation of CNOs from nanodiamonds at high temperatures is related to the transformation of the (111) 
diamond planes to the (001) graphite planes. Accordingly, X-ray powder diffraction spectra confirms that the 
interlayer spacing of 0.21 nm, consistent with the d value of the (111) lattice plane of diamond with a cubic 
structure becomes of 0.34 nm close to the (001) planes of graphite after the annealing process68. 
Interestingly, the layers are formed when bending and closure of the graphitic sheets takes place by the 
formation of pentagons in the carbon network. The thermodynamic driving force of the transformation of 
nanodiamond to CNOs was attributed to a decrease of the surface energy due to the elimination of the 
surface dangling bonds in nanodiamond during heat treatment. However, the change in local carbon 
geometry from sp3 to sp2, and other factors may also contribute. Costa and co-workers investigated the 
enthalpies of formation of CNOs at 25°C by high-temperature oxidation calorimetry69. It was found that CNOs 
are more stable than their fullerene counterparts. Furthermore, the stability of CNOs increases with surface 
area and functional groups. CNOs with oxygen containing functional groups can be considered partially 
oxidized, and therefore release less heat during complete oxidation to CO2 and H2O. Therefore, such CNOs 
have a higher stability when being compared to CNOs free of functional groups. Additionally, not only the 
different synthetic pathways correlate with a difference in thermal stability, but also the cooling process after 
the formation of CNOs seems to play an important role. In air, N-CNOs show remarkably higher stability with 
a decomposition temperature around 700°C. In contrast, the larger A-CNOs show lower thermal stability and 
undergo decomposition at 500°C. The enhanced stability of the N-CNOs may be attributed to the fact that 
they were heated for 1 h (1650°C) and then subsequently cooled very slowly. The slow cooling process may 
allow for structural reorganization to a thermodynamically more stable structure. In contrast, the A-CNOs 
were rapidly cooled as they were produced in the surrounding solvent medium (water)68. 
 
1.3.3 Textural properties and porosity  
Although the original annealing procedure described by Kuznetsov et al. involved heating the nanodiamond 
particles under high vacuum69, recently Echegoyen and co-workers noticed that pure samples of onions with 
very high yield could also be obtained by using a slightly positive pressure of helium. Additionally, after 
annealing in an inert atmosphere, a second annealing was performed at 450°C in an air atmosphere to 
remove amorphous carbon after formation of the CNOs. The resulting CNOs are spherical-shell structures 
with six to eight graphitic layers and diameters of a few nanometers. These CNOs are very similar to the 
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CNOs obtained by the standard procedure proposed by Kuznetov, but the new procedure does not require 
the use of high-vacuum systems. To study the influence of the synthetic conditions on the resulting carbon 
nano-onion structure, modifications in the atmosphere and temperature conditions were performed. 
Basically, nanodiamonds were annealed at 1650 or 1750°C for 1 h under a He atmosphere and then the 
resulting CNOs were annealed at 450 or 750°C under an atmosphere of N2, CO2 or air. In agreement with 
gas adsorption measurements, it was proven that annealing under different atmosphere altered the CNOs 
textural properties. The Brunauer-Emmett-Teller (BET) static nitrogen adsorption technique is a powerful tool 
to measure and analyze micro and mesoporus structures, the pore volumes as well as the specific surface 
area of nanostructures. Basically, annealing of CNOs at 1750°C and further additional annealing in air 
atmosphere led to more micropores and the total micropore area significantly increased (Table 1). Thus, 
during thermal annealing, the sp3-to-sp2 conversion results in a decrease in density and an increase in pore 
volume and specific surface areas that occurs along with a loss of surface functional groups and volatile 
impurities. 
 
Taďle ϭ. Textural paraŵeters of CNOs aĐĐordiŶg to the NϮ 
adsorptioŶ/desorptioŶ isotherŵs 
Saŵple SBET
[a]
 
[ŵϮg-ϭ] 
MiĐropore 
Area 
[ŵϮg-ϭ][ď] 
Pore voluŵe 
Vp [Đŵ
ϯg-ϭ][Đ] 
Pore size 
[Ŷŵ] 
CNOs;ϭϲϱϬͿ-NϮ ϯϴϱ ϯϳ.ϵ ϭ.Ϭϰ ϭϬ.ϳϴ 
CNOs;ϭϳϱϬͿ-NϮ ϰϰϮ ϭϬϳ.Ϯ ϭ.ϱϲ ϭϭ.ϭϬ 
CNOs;ϭϲϱϬͿ-AIR ϰϴϴ ϭϭϲ.ϯ ϭ.ϱϲ ϭϮ.ϳϵ 
CNOs;ϭϳϱϬͿ-AIR ϱϴϭ ϰϭϴ.ϱ ϭ.ϴϲ ϭϮ.ϳϵ 
CNOs;ϭϳϱϬͿ-COϮ ϯϵϵ ϮϬ.ϯ ϭ.ϭϵ ϭϭ.ϵϲ 
[a] SBET: BET speĐifiĐ surfaĐe area. [ď] Based oŶ the t-Plot ŵethod. [Đ] SiŶgle-poiŶt adsorptioŶ, 
total pore voluŵe of the pores. 
 
 
Table 1. Textural parameters of CNOs prepared under different atmosphere and temperature conditions 
according to the N2 adsorption/desorption isotherms.70  
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1.3.4 Electronic properties of carbon nano-onions 
A powerful tool for studying the electronic state of materials and nanostructures is the Electron energy-loss 
spectroscopy (EELS). Especially, the energy-loss near-edge structure (ELNES) in the core-loss spectrum is 
directly correlated to the density of the unoccupied conduction band states. The shape of the ELNES thus 
contains useful information about the nearest neighbor environment of atoms in covalent bonding. Chhowalla 
and co-workers studied the dielectric characteristics of carbon onions and polycrystalline graphite by 
measuring the low loss features in the electon energy loss spectra (EELS)71. The low loss EELS spectra for 
graphite and carbon onions are shown in Figure 12. The broad peaks at higher energies represent the 
plasmon energy from collective excitation of both σ and π valence electrons. However, the more important 
result is the position of the low energy peaks that arise from the collective plasmon excitation of the π 
electrons. The π plasmon for the carbon onions is centered at 5.7 eV (4.6 µm-1) compared to 6.6 eV for 
graphite. The origin of the absorption feature at 4.6 µm-1 in carbon onions can be attributed to the collective 
excitations of π plasmons. Samples annealed in air show a constant absorption peak at 4.6 µm-1 with a 
variable with ranging from 1.2-1.6 µm-1. The substantial decrease in the widths for samples annealed for 
longer time is attributed to the elimination of amorphous carbon.  
 
 
 
 
 
 
Figure 12. (a) Low loss region of EELS for (i) polycrystalline graphite and (ii) carbon onions. (b) Enlarged π-
plasmon energy region. The π-plasmon of (iii) graphite is centered at 6.6 eV while the maximum of the (iv) 
carbon onion π-plasmon is located at 5.7eV. Reprinted with permission from reference [71]. Copyright 
(2003), American Physical Society. 
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Tomita and co-workers studied the structure and the electronic properties of carbon onions depending on the 
annealing temperature72. HRTEM observation demonstrated that diamond nanoparticles are transformed 
into spherical carbon onions by the annealing at 1700°C, and finally into polyhedral onions above 1900°C.  
 
 
 
Figure 13. EELS spectra in low-loss region of 5 nm nanocrystalline diamonds (spectrum A), spherical carbon 
onions (spectrum B) and polyhedral carbon onions (spectrum C). Reprinted with permission from reference 
[72]. Copyright © 1999 Elsevier Science B.V. All rights reserved. 
 
EELS studies suggested that the spherical onion consists of small domains of graphitic sp2 sheets with 
dangling bond defects in the peripheries suggesting the presence of π electrons. Interestingly, in spherical 
onions, π electrons are localized in the small domains and do not act as conduction electrons. On the other 
hand, in polyhedral onions, the further graphitization decreases the number of dangling bonds and leads to 
the delocalization of π electrons that act now as conduction electrons. Therefore, the core-loss spectrum 
results revealed that a number of sp3 bonds are contained in spherical carbon onions. It is plausible, that 
during the junction of (001) graphite planes with each other, a number of sp3 bonds remain in the spherical 
onion as interlayer bridges which link the (001) graphite planes. De Vita et al. theoretically performed the 
first-principles molecular dynamics simulations of a microscopic surface-induced diamond-to-graphite 
transition. Their simulation implied that, at an advanced state of the transition, there is an intermediate 
disordered state, where sp3 and sp2 bonds coexist; sp3 bonds are located at the periphery of graphitic sp2 
sheets. In the transformation process from the diamond nanoparticle to the polyhedral onion, the spherical 
onion is an intermediate state as shown in Figure 13. Electron energy-loss spectroscopy (EELS) study 
indeed pointed out that the spherical onion contains a number of sp3 bonds in the structure72. Sp3 bonds at 
21 
 
the peripheries of graphitic sp2 sheets are seen to act as defects and may induce dangling bonds in the 
onions. That leads to imperfectly closed graphitic shells with a number of defects such as dangling bonds. 
Moreover, graphitization proceeds with increasing annealing temperature, and spherical onions are 
transformed into polyhedral ones. Tomita and co-workers suggested that the π electrons in spherical onions 
are localized in small domains of sp2 graphitic sheets and do not act as conduction electrons. On the 
contrary, polyhedral onions have ordered graphitic structure, and thus π electrons in them act as conduction 
electrons. Thus, spherical onions consists of small domains of the graphitic sp2 sheets with dangling bond 
defects in the peripheries. π electrons in spherical onions are thus localized in the small domains and do not 
act as conduction electrons. In the polyhedral onions, the graphitization proceeds further, resulting in the 
decrease in the number of dangling bonds and the localization of π electrons. As a result of the decrease in 
the number of defects, π electrons in polyhedral onions are delocalized and π electrons act as conduction 
electrons55.  
 
1.3.5 Electrochemistry 
It is well known that the electrochemical behavior of carbon nanostructures, especially their capacitance, is 
strictly dependent on the nature of the CNO surface.73 The localized surface electrons, which are due to 
surface structural or chemical defects as well as the existence of localized π electrons on the interfacial 
graphite layers play an important role. Electrochemical studies indicate pseudorectangular cathodic and 
anodic profiles, that are typical for double-layer. No changes of the current were observed after prolonged 
potential cycling between -100 and + 500 mV (vs. Ag/AgCl). Therefore, the high degree of reversibility 
indicates that there are no chemical processes or other changes occurring between charge and discharge 
cycles. The rectangular cyclic voltammograms shapes observed for all the samples over a wide range of 
voltage scan rates (5, 10, 20, 50, 75 and 100 mVs-1) indicate a fast charge transport within the electrodes 
and electrical double layer capacitance (Figure 14). The voltammogram’s shape remained almost 
undistorted upon increase of the scan rate, indicating excellent wetting and easy transport of ions within the 
films. Furthermore, the effect of the sweep rate on the CNOs’ voltammograms was also studied.73 These 
results indicate that the charge-discharge processes of the electrical double layer are highly reversible and 
kinetically facile. The difference between the observed capacitive current behavior for the different CNO 
samples is likely the result of more porous structures and more defects on the surface of the samples 
prepared under air and CO2 atmospheres. Analysis of the specific capacitances demonstrated that the 
second modification slightly changes the electrochemical properties of the CNO films. Basically, it was found 
that annealing under air improved the penetration of the supporting electrolyte into the films and thus 
improved the electrochemical properties.73 
Moreover, Echegoyen, Plonska-Brzezinska and co-workers studied the voltammetric behavior of CNOs 
functionalized with carboxylic groups74. It was reported that the functionalization of CNOs with carboxylic 
groups leads to a less porous and more uniform nanostructures in comparison to layers of unmodified 
material. Consequently, a difference in capacitance of functionalized and non-modified nano-onions can be 
detected. A lot of attention has been paid to the capacitive properties of thin films of carbon nanostructures 
due to their porous structures and large surface areas. These materials exhibit properties of typical double-
layer capacitors, in which energy storage arises mainly from the separation of electronic and ionic charges at 
the interface between the electrode material and the electrolyte in solution. Thus, the chemistry of the 
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functional groups on the carbon nanostructures and the number of defects strongly affect the capacitive 
properties of the films. Moreover, the electronic properties on the CNO surface with carboxylic groups are 
responsible for a slower charge transfer process at negative potentials. Indeed, oxidaized CNOs are 
electrochemically active at negative potentials due to carboxylic group reduction74. 
 
 
Figure 14. (A) Cyclic voltammograms of (1) CNOs(1650)-AIR, (2) CNOs(1750)-AIR, (3) CNOs(1650)-N2, (4) 
CNOs(1750)-N2, (5) CNOs(1650)-N2 in 0.1 mol L-1 NaCl. The sweep rate is 5 mV s-1. (B) Dependence of 
the capacitive current on the sweep rate. Reprinted with permission from reference[75]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
1.4 CNOs – Toxicological aspects 
In the last few years, our group intensively explored the toxicological aspects of CNOs for biological 
applications. Giordani’s results shown that a carefully designed functionalization strategy is crucial to 
modulate the inflammatory response. The size of the nanostructure also seems to play a key role. Most 
studies concerned with inflammatory properties of carbon nanotubes were carried out using raw non-
functionalized nanotubes. However, this raw materials are generally impure and contain amounts of 
carbonaceous impurities, metal catalyst residues and microbial contaminants that are highly probable 
responsible of a varaiety of deleterious effects previously attribuited to CNTs such as granulomatous 
inflammation, release of cytosolic enzymes and pulmonary fibrosis. In 2013, Giordani et el. reported a 
comprehensive in vitro and in vivo analysis of the inflammatory potential induced by purified and 
functionalized CNOs. Pristine carbon nano-onions (p-CNOs) were synthetized by thermal annealing of d-
NDs followed by air annealing to ensure high-purity. Successively, they were functionalized, as confirmed by 
Raman and FT-IR spectroscopies, following the one-pot Tour reaction previously reported76,77 and then 
coupled with a fluoresceinamine by amide reaction in order to allow for the In vitro visualization. To evaluate 
the ability of macrophages (Macs) to internalize SWCNTs and CNOs, immortalized bone-marrow derived 
mouse macrophages (iBMM) and mouse bone-marrow-derived dendritic cells (BMDCs) were incubated in 
the presence of the fluorescein-labeled nanoparticles. The results showed the internalization of carbon 
nanoparticles (NPs). We also studied the ability of p-CNOs to induce activation and maturation of dendritic 
cells (DCs); the results showed no distinguishable effect on the expression of the different cell surface 
markers tested, no induced secretion of the inflammatory cytokines along with a negligible alteration of the 
secretion of the inflammatory cytokines. They further demonstrated the ability of these NPs to promote the 
release of the inflammatory cytokines IL-1 ß by BMDCs in the presence of TLR ligands and to induce the 
activation of the NLRP3 inflammasome. CNOs exhibited a weaker inflammatory potential compared to 
SWCNTs, both in vitro and in vivo. CNOs were taken up by antigen-presenting cells to a greater extent and 
were more efficiently targeted to draining lymph nodes. They also investigated the impact of the chemical 
functionalization on the inflammatory properties, showing that the functionalization significantly reduces the 
release of IL-1 ß both in vitro and in vivo78. With the aim of developing an efficient nanoprobe suitable for 
both imaging and targeting, the Giordani group reported the multiple covalent functionalization of CNOs with 
fluorescein and folic acid to simultaneously image and target cancer cells.79 Nanomaterials decorated with 
folic acid showed high specificity due to the ability to bind the receptors highly overexpressed by cancer 
cells. p-CNOs were modified by diazoniumchemistry to yield benz-CNOs bearing carboxylic acid groups and 
to produce silyl-CNOs, which display alkyne functionalities on the surface. After the deprotection of the silyl 
group from the phenylacetylene, multi-functionalized CNOs (benz-alkyne/CNOs), which contain benzoic acid 
and phenylacetylene groups, were produced. The success of the double step functionalization procedure 
was confirmed by XPS, Raman spectroscopy as well as by FT-IR spectroscopy. The preparation of the 
CNOs bearing both targeting and imaging agents was accomplished by two consecutive synthetic 
procedures from benzalkyne/CNO derivatives. The folic acid derivative (FA-PEG) was introduced by the 
condensation reaction of a primary amine with the benzoic acid unit on the CNOs to produce FA-CNOs and 
then the attachment of fluorescein derivative (FITC-PEG) was accomplished by a copper catalysed azide– 
alkyne Huisgen cycloaddition (CuAAC) onto the alkyne functionalities, producing the dual functionalized FA-
FITC/CNOs derivatives.  
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To investigate the possible effects induced by the different CNOs conjugates, HeLa (epithelial cervix 
adenocarcinoma) and KB cells (human epidermoid carcinoma cells), were incubated with different 
concentrations of benz-CNOs, FA-FITC/CNOs and FITC-CNOs derivatives; low cytotoxicity was exerted in 
both cell lines. The localization of FA-FITC/CNOs and FITC-CNOs in HeLa and KB cells, were studied by 
confocal microscopy. No apoptotic effect was observed in HeLa cells, after incubation with FA-FITC/CNOs 
for 24 h. The fluorescent nanoparticles were efficiently internalized and localized into lysosomal 
compartments, as demonstrated from the intense yellow co-localization signals. For comparison, FITCCNOs 
conjugates were also internalized by HeLa cells, but to a lower extend. In order to understand the 
mechanism for the cellular internalization of CNOs, correlative light electron microscopy (CLEM) analyses 
were performed in HeLa cells, confirming an endocytosis pathway for the uptake. TEM analysis of the 
subcellular regions revealed the presence of large aggregates inside late-endosome/lysosome vesicles 
(Figure 15). Confocal images of KB cells confirmed the internalization of FA-FITC/CNOs and the localization 
in vesicles; furthermore, the presence of free folic acid in solution results in minimal internalization of the FA-
FITC/CNOs as a consequence of the competition for the folate receptors on the cell membranes. These 
evidences suggested an uptake based on a folate mediated endocytosis pathway. In comparison, KB cells 
incubated with FITC-CNOs showed a low green signal, which became more intense after a prolonged 
exposition. This evidence was also observed for the HeLa cells, suggesting a non-specific adsorption of 
FITC-CNOs on the cell membrane after long time of incubation.79  
 
 
 
Figure 15. Correlative light electron microscopy analysis of HeLa cells doped with 10 ȝg mL-1 of FA-
FITC/CNOs for 12 h at 37 °C. A) Low magnification TEM reconstruction of two cells doped with FA-
FITC/CNOs. B) Superimposed fluorescence and TEM reconstruction of the same cells shown in A (imaged 
in a different section). The co-localization of FA-FITC/CNOs (green fluorescence) within lysosomes stained 
with Lysotracker (red) results in yellow fluorescence. C) Higher magnification TEM image of the boxed area 
in B. Note, the two endosomes containing FA-FITC/CNOs. D–G) Higher magnification images of the boxed 
areas from C imaged, respectively, in defocused TEM (D, F) and in high angular annular dark field (HAADF) 
scanning TEM (E, G). The nuclei are labeled with ‘‘n”. Scale barsμ A, B) 4 mm, C) 2.5 mm, D–G) 0.5 mm. 
Reprinted with permission from [79]. Copyright 2015 John Wiley and Sons. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
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They also investigated the capabilities of boron dipyrromethene (BODIPY) functionalized CNOs as imaging 
agent in human breast cancer cells (MCF-7).80 After the incubation with benz- and BODIPY-CNOs at 
different concentration, cellular viability tests were performed and no cytotoxic effects were observed up to 
72 h. Furthermore, confocal microscopy showed that BODIPY-CNOs were efficiently internalized by the cells 
and located predominantly in the lysosomes, as confirmed by the yellow co-localization signals (Figure 16)  
 
 
 
Figure 16. BODIPY functionalized CNOs (BODIPY-CNOs): structure (A) and confocal images of MCF-7 cells 
incubated for 48 h with 10 lg/mL BODIPY-CNOs (B). Adapted with permission from [80]. Copyright 2014 The 
Royal Society of Chemistry. 
 
Once the In vitro studies on different cell lines was evaluated, long term effects on more complex vertebrate 
systems were consequently assessed. In 2015 the ecotoxicological effects of CNOs were investigated by 
using the fresh-water polyp Hydra vulgaris as model organism81. The eco-toxicological effects of pristine and 
functionalized CNOs on the morphology, reproductive and regenerative capabilities of freshwater polyp 
Hydra vulgaris were investigated. p-CNOs were decorated with different functionalities, including benzoic 
acid (benz-CNO), pyridine (py-CNO) and methylpyridinium (py+-CNO). In vivo uptake and biodistribution 
studies were conducted after exposing Hydra vulgaris to both pristine and modified CNOs at different 
concentrations. All CNO types were efficiently internalized, with aggregates visible in the body, head and 
tentacles of animals as small dark spots (Figure 17); furthermore, by dissociating treated animals into single 
cell suspensions, CNO nanoparticles were found to be located within the cytoplasm. Finally, more 
interestingly, no behavioral or morphological alterations were observed. The long-term effects on the 
regenerative and reproductive capabilities of polyps treated with CNOs were estimated. No significant 
difference in the regenerative potential and the growth rates of treated and polyps were observed in 
comparison to the controls, suggesting that CNOs did not affect the regeneration efficiency along with the 
absence of toxic effects over a long time scale. Finally, the effects of CNO exposure on apoptosis were 
studied after macerating CNO-treated Hydra into a single-cell suspension; moreover, the nuclear 
morphology was monitored by fluorescence microscopy. All CNOs showed no significant adverse effects, 
except for a slightly increase of the apoptosis rate of Hydra cells treated with benz-CNOs81. 
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Figure 17. Toxicological studies of CNOs on the development and the reproductive capability of Hydra 
vulgaris polyp. (a) Chemical functionalization of CNOs with benzoic acid, pyridine and pyridinium moieties; 
(b,c) Structural anatomy of Hydra vulgaris. Scale bar, 500 ȝm. In vivo uptake and biodistribution of CNOs in 
tentacles (d) and body columns (e). Representative single cells obtained by polyps treated with pyridine-
CNOs (f) Adapted with permission from [81]. 
 
Recently, the Giordani group reported the first study on the biological impact of CNOs on vertebrates82, 
investigating the possible toxic effects induced by functionalized CNOs on zebrafish (Danio Rerio) during the 
development. Zebrafish embryos and larvae were exposed at different concentrations of benz-CNOs and 
BODIPY-CNOs, and several toxicological aspects were investigated. Their results showed that CNOs 
derivatives did not affect the survival and hatching rates of treated zebrafish embryo/larvae up to 10 ȝg mL-1, 
whereas a significant difference compared with the negative control (p < 0.01) was observed at higher 
concentration (50 and 100 ȝg mL-1); however, according to the OECD methodology, CNOs conjugates are 
evaluated as a nontoxic nanomaterial. The heart beat rate and frequency of movements in zebrafish larvae 
at 72 hpf were found to be comparable with that of the control group. Moreover, CNOs did not exert 
significant adverse effects on the zebrafish organogenesis. In contrast with the results reported for zebrafish 
treated with other CNMs83,84 CNOs showed a good biocompatibility in this small vertebrate. The in vivo 
biodistribution of BODIPY-CNOs inside the zebrafish larvae was studied by means of inverted selective 
plane illumination microscopy (iSPIM) (Figure 18). The results showed a homogeneous distribution of the 
CNOs in the whole zebrafish larvae body82. 
 
  
27 
 
 
 
 
Figure 18. Maximum intensity projections of the superior part (a) and tail (b) of treated larvae (100 ȝ g mL -1of 
BODIPY-CNOs. Exposure timeμ 200 ms, step sizeμ 0.7 ȝ m. Scale bars, 100 ȝ m. E, eye; YS, yolk sac; T, 
tail; F, finfold. Reprinted with permission from [82]. 
 
The published results let us believe that especially highly surface functionalized, small diameter CNOs are 
promising materials for biological and medicinal applications based on a high biocompatibility. The surface 
modification with different functional groups and the further conjugation with other functional molecules such 
as fluorophores, revealed an enhancement of water solubility and biocompatibility along with an enhanced 
cell penetration capability. Furthermore, in vitro and in vivo experiments demonstrated particular and 
promising features such as low cytotoxicity and weak inflammatory potential, confirming the ability of CNOs 
as imaging and targeting agents. The effects on living systems and, especially, on the human health are of 
utmost importance in the perspective of biological and biomedical applications and many efforts have yet to 
be done for a real use of a CNO-based platform in nanomedicine. However, the highly promising properties 
showed until now are expected to open novel avenues for the development of safe, non-toxic and effective 
nanomedicine technologies where CNOs could act as shuttle for the delivery of biomedically relevant drugs. 
 
 
1.5 Nanotechnology in biomedicine 
Nanotechnology has demonstrated great potential to improve cancer treatments by affecting the ways in 
which cancer is diagnosed, prevented, and treated.85,86,87,88 In particular, targeted drug delivery using 
nanoscale carriers holds great promise to substantially improve therapeutic indices (the ratio between the 
toxic dose and the therapeutic dose of a drug) of incorporated drug molecules; in fact, a number of them are 
currently under advanced-stage clinical trials or are being used in clinical settings.89 However, the 
physicochemical properties of the nanoparticles (chemical compositions, sizes, shapes, structures, 
morphologies, and surface properties) need to be finely tuned to develop an effective NP system and to 
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understand the interactions that occur between the nanomaterials and biological systems at each stage of 
the drug delivery process (Figure 19). 
 
 
Figure 19. A summary of nanoparticles that have been explored as carriers for drug delivery in cancer 
therapy, together with illustrations of biophysicochemical properties. Reprinted with permission from [89].  
 
1.5.1 Size and Shape 
The size and shape, as well as the uniformity, are two important parameters of a drug-delivery system based 
on nanoparticles, as they determine the in vivo distribution, toxicity, and targeting ability.90 Additionally, they 
can influence drug loading, drug release, and in vitro and in vivo stability. For example, smaller particles 
have a greater risk of aggregation during storage and incubation in vitro, but typically have a longer 
circulation half-life in vivo. The degradation of polymer nanoparticles can be strongly affected by their size as 
a result of water availability and removal of degradation products. Many studies have demonstrated that 
nanoparticles have a number of advantages over their micrometer-sized counterparts with sizes in the range 
of 0.1–100 mm for drug-delivery applications.91 Generally, nanoparticles have relatively higher intracellular 
uptake and broader availability to a range of biological targets owing to their small sizes and increased 
mobility.  
1.5.2 Surface Properties 
In addition to both size and shape, the surface characteristics of nanoparticles represent another critical 
parameter in determining their drug-loading efficiency and release profile, circulation half-life, tumor 
targeting, and clearance from the body. Ideally, the nanoparticles should have a hydrophilic surface to resist 
the adsorption of plasma proteins and thus escape the uptake by macrophages.92 This can be achieved in 
two ways: coating the surface of nanoparticles with a hydrophilic polymer such as PEG, or directly fabricating 
nanoparticles from block copolymers containing both hydrophilic and hydrophobic segments. Studies by 
Elsabahy and Wooley suggested that the surface chemistry of nanoparticles can greatly impact their toxicity, 
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immunogenicity, and biodistribution; excess positive charges tend to result in rapid opsonization and 
clearance.93  
 
1.5.3 Surface Charges 
The zeta potential of a nanoparticle is commonly used to characterize its surface charge. This variable 
reflects the electrostatic potential of a particle and is influenced by the composition of the particle as well as 
the medium in which the nanoparticle is suspended. Nanoparticles with a zeta potential above 30 mV (either 
positive or negative) have been shown to be stable in suspensions, as repulsion forces originating from the 
surface charges can prevent the particles from aggregation. Additionally, the inner surface of blood vessels 
and the surfaces of cells contain various types of negatively charged species, which repel negatively 
charged nanoparticles. When the surface charge of nanoparticles becomes higher (either positive or 
negative), they will become more easily scavenged by macrophages, resulting in greater clearance by the 
MPS. Therefore, control over the surface charge can help minimize the nonspecific interactions between 
nanoparticles and the MPS, preventing the loss of nanoparticles in undesired locations.94 Complete 
exclusion of nonspecific interactions, however, is currently unattainable. 
 
1.5.4 PEGylation 
In order to increase the tumor targeting efficiency, it is necessary to prolong the circulation of nanoparticles 
in the bloodstream by minimizing opsonization. The most commonly used approach to achieve this goal is to 
coat the surface of nanoparticles with a hydrophilic brush made of PEG chains.90 Studies have shown that 
the conformation of PEG on the nanoparticles surface is of the utmost importance in repelling opsonins. 
While PEG coatings with a brush-like configuration reduce phagocytosis and complement activation, those in 
a mushroom-like configuration are potent complement activators to induce phagocytosis.92 Since the initial 
use of PEG in extending the circulation half-life of a protein,95 PEGylation has been widely adopted to protect 
nanoparticles such as liposomes,96 polymer nanoparticles and micelles97 from premature clearance during 
circulation. The PEG chains form a hydrated shell that allows the nanoparticle to evade opsonization and 
subsequent phagocytosis.98 However, this protective shell can interfere with the interactions between a 
nanoparticle and the target cell.99 For example, PEGylated liposomal doxorubicin showed a prolonged 
plasma half-life, which is believed to correlate with better therapeutic efficacy. However, the formulation 
resulted in lower tumor accumulation than the same liposomes with no PEG coating, indicating a 
counterproductive effect of PEGylation.100  
 
1.5.5 Polysaccharides 
As a major class of natural polymers, polysaccharides have been widely used in drug delivery and tissue 
engineering because of their good biocompatibility, availability, and easy modification.101 As a result of their 
capability to avoid the complement system and opsonization, some polysaccharides, such as dextran and 
heparin, have also been recognized as stealth-coating materials. Some studies have shown that the 
polysaccharides, such as chitosan and hyaluronic acid, even display certain ligand activities of their own. 
Nanoparticles coated with these polysaccharides show more efficient cellular uptake than other 
nanoparticles because of specific interactions with various receptors on the surface of target cells.102 
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Therefore, polysaccharides have gained increasing interest in the development of nanomedicine as an 
effective surface modification strategy. Nanoparticles incorporating polysaccharides can be prepared using 
many different methods, which have been extensively reviewed.103 Polysaccharides can be applied as 
surface coatings on nanoparticles through electrostatic interactions or directly incorporated into the 
nanoparticles during synthesis. Alternatively, hydrophilic polysaccharides can be grafted to hydrophobic 
molecules, such as cholesterol, and then used to form nanoparticles through self-assembly, which can also 
encapsulate hydrophobic drugs in the core. Furthermore, nanoparticles can be prepared through conjugation 
of polysaccharides to synthetic polymers.  
 
1.5.6 Conjugation with Targeting Ligands 
Many techniques and tools are currently available to armor nanoparticles for active targeting of cancerous 
cells. Traditionally, monoclonal antibodies have been used to target epitopes on the surface of cells, but the 
extensive screening of peptide and aptamer libraries has greatly expanded the repertoire of ligands available 
for targeted delivery.85 The currently used targeting ligands include antibodies, antibody fragments, peptides 
(e.g., RGD for avb3 integrin), aptamers (e.g., those for prostate-specific membrane antigen and VEGF), 
oligosaccharides, and even small molecules (folate and SV-119), as long as they can specifically recognize 
and bind to an overexpressed target on the cell surface. Here we only provide a brief discussion on these 
ligands: 
1) Monoclonal antibodies (MAbs) are macromolecules widely used as targeting ligands because of their 
immediate availability and their high affinity and specificity for molecular targets. These ligands usually 
possess a molecular weight of approximately 150 kDa and exhibit high binding affinities. To date, MAbs have 
been conjugated to essentially all different types of nanoparticles, such as SPIONs,103 QDs,104 liposome,105 
and Au nanocages,106 to give them site-specific targeting ability. However, the bulky size and redundant 
constant region may cause some major issues in the use of MAbs as targeting ligands because of their 
immunogenicity and size increase (i.e., the overall size of nanoparticles will dramatically increase). The use 
of antibody fragments, affibodies, and peptides may help overcome this shortcoming. 
2) Single-chain variable fragments (scFv) are fusion proteins of the variable regions of the heavy and light 
chains of an antibody (VH and VL) connected with a short linker peptide of 10–25 amino acids. The 
molecular weight of an scFv is about 27 kDa. By engineering the MAbs to cut down the redundant parts of 
the scFv, the size and immunogenicity of the original antibody can be largely reduced. 
3) Affibodies are small, stable Z-domain scaffolds consisting of 58 amino acids and derived from the IgG 
binding domain of staphylococcal protein A. The binding pocket is composed of 13 amino acids and is able 
to bind to a variety of targets, depending on the randomization of the amino acids. In contrast with IgGs, the 
small size (6–15 kDa) of affibodies enables penetration into tumor tissue. Affibodies possess a high receptor 
affinity, which mimics the active portion of the Fab region of the corresponding antibody. Their short plasma 
half-life makes them good candidates as tumor imaging probes, but less ideal for tumor targeting, where long 
circulation half-life is required.107 
4) Peptides represent a viable targeting moiety with several advantageous characteristics, including low 
molecular weight (ca. 1 kDa), tissue penetration capability, lack of immunogenicity, ease of production, and 
relative flexibility in chemical conjugation processes.107 Various peptides that can recognize cancer-specific 
epitopes overexpressed on tumor cells and vasculature have been used as targeting moieties for drugs and 
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drug carriers. For example, RGD peptides showed a high affinity in binding toward integrin, which are 
typically overexpressed by the endothelium during tumor angiogenesis. By conjugating RGD to the surface 
of SPIONs, the nanoparticles showed superior targeting affinity and specificity.108 One possible disadvantage 
is that peptides sometimes exhibit a lower binding affinity to receptors as compared to MAbs, but this can be 
compensated by increasing the coverage density of peptides. 
5) Aptamers are short, single-stranded, synthetic nucleic acid oligomers, DNA or RNA, that can form 
complex threedimensional structures with a capability to bind to surface markers with high affinity and 
specificity.109 Advantages of aptamers include availability, ease of chemical synthesis, low molecular weight, 
and lack of immunogenicity. Many publications have reported the conjugation of aptamers to polymer 
nanoparticles as targeting ligands.109 
6) Endogenous ligands, such as folic acid, epidermal growth factor (EGF), and transferrin, are attractive for 
tumor targeting because they can bind to their respective receptors with low immunogenicity and high 
affinity. Several protocols have been reported to conjugate folic acid, EGF,110 and transferrin111 to various 
types of nanoparticles. In summary, the choice of a targeting ligand revolves around numerous 
considerations, including availability, easiness of production, diversity, affinity and protocols for conjugation 
and immunogenicity.  
 
1.5.7 Drug Loading 
Theoretically, a successful drug-delivery system based on nanoparticles should have a high drug-loading 
capacity to minimize the quantity of materials needed for administration. Loading of drug molecules into the 
nanoparticles can be achieved in different ways such as chemical surface functionalization, incorporation at 
the time of nanoparticle formation or absorption (as well as adsorption) of the drug after the formation of 
nanoparticles by incubating them with a highly concentrated drug solution. The efficiency of drug loading 
onto a nanoparticle is determined by the properties of both the drug molecules and the carrier material. The 
properties of the material include its molecular weight, polymer composition, drug–polymer interaction, and 
the functional groups (e.g., carboxy or ester) at both ends of each polymer chain.112 A macromolecule or 
protein has the greatest loading efficiency when the drug loading is performed at or near its isoelectric point, 
which gives it the minimum solubility and maximum absorption. For small molecules, the use of electrostatic 
interactions between the drug and matrix material is an effective way to increase the drug-loading 
efficiency.113 
 
1.6 Conclusion 
A number of such delivery systems have been approved for cancer therapy in the clinics, with many more 
currently under clinical trials or preclinical evaluations (see Table 2 for a list). Nanoparticle-based 
therapeutics are poised to significantly improve the treatment outcomes for oncological diseases, promising 
to reshape the landscape of the pharmaceutical industry.114 
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Table 2. Delivery systems approved for cancer therapy in clinics. 
 
Trade name Formulation Drug Company Application Phase of 
developmen
t 
Abraxane 
 
 
albumin-bound 
nanoparticle 
paclitaxel Abraxis Bioscience, 
Inc. 
metastatic 
breast cancer115 
approved 
Caelyx  
 
 
PEGylated 
liposome 
doxorubicin Schering-Plough metastatic 
breast and 
ovarian cancer, 
Kaposi 
sarcoma116 
approved 
DaunoXom
e  
liposome daunorubicin  Galen Ltd Kaposi 
sarcoma117 
approved 
DepoCyt  liposome cytarabine Pacira 
Pharmaceuticals, 
Inc. 
lymphoma118 approved 
Doxil 
Kaposi  
liposome doxorubicin
  
 
Sequus 
Pharmaceuticals, 
Inc. 
sarcoma119 approved 
Genexol-PM  
 
polymeric 
micellar 
nanoparticle 
paclitaxel Samyang 
Biopharmaceuticals 
breast cancer120 approved 
Marqibo  liposome vincristine 
sulfate 
Talon Therapeutics, 
Inc. 
lymphoblastic 
leukemia121 
approved 
Myocet  liposome doxorubicin Zeneus Pharma Ltd metastatic 
breast cancer122 
approved 
Oncaspar  PEGylated 
asparaginase 
Enzon 
Pharmaceutical
s, 
Inc. 
 acute 
lymphoblastic 
leukemia123 
approved 
Zinostatin  
 
 
stimalamer 
poly(styrene-co-
maleic 
acid)-
conjugated 
neocarzinostati
n 
neocarzinostati
n 
Astellas Pharma, 
Inc. 
hepatocellular 
carcinoma124 
approved 
CYT-6091  
 
 
 
gold 
nanoparticle 
tumor necrosis 
factor a 
Cytimmune 
Sciences, 
Inc. 
pancreatic 
cancer, 
melanoma, 
softtissue 
sarcoma, 
ovarian, and 
breast 
cancer125 
phase I/II 
Docetaxel-
PNP  
polymeric 
nanoparticle 
docetaxel Samyang 
Biopharmaceuticals 
advanced solid 
malignancies126 
phase I 
TKM-
080301  
lipid 
nanoparticle 
siRNA National Institutes of 
Health Clinical 
Center 
liver cancer127 phase I 
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The use of nanoprobes as imaging agents is a very promising new development for obtaining detailed 
images of living systems. The combination of drug delivery features with imaging techniques allows the 
researchers to follow the distribution of the drug inside the organism and gives further hints for the 
optimization of disease treatment. 
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2. CNO for biomedical imaging 
 
2.1 Introduction 
The recognition and labelling of biologically and environmentally important species has emerged as a 
significant goal in the field of biomedicine in recent years.1,2,3 Fluorogenic methods in conjunction with 
suitable probes are preferable approaches for the measurement of analytes because fluorimetry is rapidly 
performed, is nondestructive, is highly sensitive, is suitable for high-throughput screening applications, and 
can afford real information on the localization and quantity of the targets of interest. To date, various 
fluorophores with different excitation and emission wavelengths have been employed, such as coumarin, 
pyrene, 1,8-naphthalimide, xanthenes, squaraine, cyanine, boron dipyrromethene difluoride (BODIPY), 
nitrobenzofurazan.4 Among the fluorophores developed, xanthenes, including rhodamines and fluoresceins, 
are highly favorable because of their excellent photophysical properties, such as high extinction coefficients, 
excellent quantum yields, great photostability in water, and relatively long emission wavelengths. As a typical 
xanthene dye, fluorescein was first synthesized by von Bayer in 1871 with resorcinol and phthalic anhydride 
via Friedel_Crafts acylation/cyclodehydration. Some of the advantageous features of the fluorescein 
fluorophores are good water solubility, visible excitation and emission (an absorption maximum at 494 nm 
and emission maximum of 521 nm in water), and maximum brightness at physiological pH.5 However, 
fluorescein derivates are nonfluorescent when they exist in the lactone form. On the other hand the ring 
opened form can induce color changes and fluorescence enhancements. Interests in designing and 
synthesizing new fluorescein derivatives are still enormous to meet needs in the recognition and sensing of 
biologically and environmentally important chemical species in biology. In literature, fluorescein based 
sensors as nontoxic fluorescent dyes are reported to be extensive used as fluorescent indicators and tags, 
pH probes of intercellular fluids, protein sensors and ions detectors  in cell biology and neurology.1 Because 
of the good physicochemical properties of the fluorescein we used it in order to develop a fluorescent 
labelled CNOs in order to study the cytotoxicity and the localization of the CNO within cells. The investigation 
of novel nano-platforms capable of carrying therapeutic agents and with recognition capabilities for specific 
targeting and optical outputs for imaging is of major interest in the treatment of cancer 6 and of other types of 
infections, such as HIV.7 As discussed in the previous chapter, CNOs have great promise for use as effective 
biomarkers for cell imaging due to their excellent properties such as low cytotoxicity, high photostability, 
absence of quenching, and photobleaching in cells if functionalized properly. However, reports discussing 
fluorescence labelled CNOs as materials for biological imaging are rare. In the first year of my PhD, a highly 
fluorescent imaging probe based on carbon nano-onions (CNOs) for biological imaging have been 
developed and characterized. Different strategies for CNOs functionalization have been investigated and a 
versatile and robust strategy for the preparation of highly surface modified CNOs for biomedical imaging was 
deepen explored. The results reveal a critical correlation between the surface functionalization and the 
dispersion of the modified CNOs in physiological conditions. In addition, because the development of 
imaging probes based on carbon nanomaterials for biomedical studies requires the understanding of their 
biological response as well as the efficient and safety exposition of the nanomaterial to the cell compartment 
where is designed to operate, the biocompatibility and the cytotoxicity were systematically investigated in 
HeLa Cells. 
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2.2 Experimental 
2.2.1 Highly surface functionalized carbon nano-onions for bright light bioimaging 
One of the major drawbacks for the potential applications of CNMs is their poor solubility in common 
solvents. In order to improve the solubility of these nanomaterials in different solvents, surface modification 
of CNMs with different functional groups has been developed by either covalent or noncovalent synthetic 
methods, as already discussed in chapter 1. A well-established procedure for the surface grafting of CNOs is 
the radical addition based on the in situ generated diazonium salts. However, other surface chemistries 
should be investigated because they could results favorable for specific applications. In the first instance, two 
different synthetic strategy for the surface functionalization of CNOs were compared: the Tour reaction and 
the oxidation of the surface with nitric acid. If with the Tour reaction, benzoic acid functionalities were 
introduced by reacting p-CNOs with 4-aminobenzoic acid and sodium nitrite in an acidified DMF/water 
mixture (Figure 1), with the oxidation, carboxylic acid functionalities were introduced by heating p-CNOs 
under reflux in 3 N HNO3 for 48 h (Figure 2). The number of functionalities introduced by oxidation were 
significantly higher. The high degree of surface functionalization of the ox-CNOs in comparison to previously 
reported chemical modification of CNOs, such as the grafting of the CNO surface with benzoic acid groups 
by radical addition procedure, was observed by TGA performed in air. The thermal decomposition of the 
benzoic acid groups was revealed, followed by the decomposition of the CNOs core. The comparison of the 
TGA weight loss curves (Figure 1) of p-CNO with that of benz-CNO reveals a decrease in the decomposition 
temperature from 655 °C to 648 °C. The coverage of benzoic acid groups on the surface of the benz-CNO 
was calculated from the TGA weight loss at 450 °C and around 50 benzoic functionalities per CNO were 
estimated. In comparison, the modification of the CNOs by the chemical oxidation procedure shows a 
decrease in the decomposition temperature from 655 °C to 626 °C yielding to 210 carboxylic functionalities 
per CNO (Figure 2). Moreover, the higher surface coverage of carboxylic acid groups also results in an 
enhancement of the dispersibility of CNOs in water.  
 
2.2.2 Synthesis of p-CNO, benz-CNO and ox-CNO 
The synthesis of p-CNOs (6–8 shells) was performed by annealing nanodiamond powder (Molto, 5 nm 
average particle size) under a positive pressure of helium at 1650 °C in a tubular furnace. In order to obtain  
benz-CNO, NaNO2 (1.47 g, 21.3 mmol) was dissolved in 20 mL deionized water and cooled to 0 °C. This 
solution was added at once to a solution of 4-aminobenzoic acid (2.88 g, 21.0 mmol) in 30 mL DMF at 0 °C. 
Conc. HCl (200 ȝL) was added and the mixture was stirred for 30 min at 0 °C. p-CNOs (31 mg) were 
dispersed in 20 mL DMF by ultrasonication for 20 min and the dispersion was added to the reaction mixture, 
which was stirred at 0 °C for 4 h and at RT for additional 3 days. Following this, the CNOs were separated 
from the reaction mixture by centrifugation (30 min, 2100g) and purified by subsequent re-dispersion – 
centrifugation steps in water, DMF, and methanol. After drying at 60 °C overnight, 25 mg of benz-CNOs were 
recovered (Figure 1). The oxidation was performed directly on the sp2 carbon present on the p-CNOs 
surface, leading to the creation of hybridized sp3 carbon atoms. 40 mg of pristine CNOs were dispersed in 30 
mL of a solution of nitric acid (3M) and stirred under reflux for 48 h. After cooling to room temperature, the 
CNOs were filtered off on a nylon filter membrane (pore size 0.2 ȝm) and washed with water, methanol and 
acetone. 38 mg of ox-CNO were recovered as black powder after drying over night at RT (Figure 2). 
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Figure 1. Synthetic procedure for the covalent functionalization of benz-CNO. Thermogravimetric analysis of 
p-CNO (black) and  benz-CNO (blue) and the corresponding weight loss derivatives are reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Synthetic procedure for the covalent functionalization of ox-CNO. Thermogravimetric analysis of p-
CNO (black) and  ox-CNO (red) and the corresponding weight loss derivatives are reported.  
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2.2.3 Synthesis of fluo-CNO 
Once obtained a highly surface functionalized CNOs decorated with carboxylic acid groups, these 
functionalities were derivatized by amide coupling with fluoresceinamine in order to obtain an efficient 
imaging agent. A dispersion of ox-CNO (15 mg) was prepared by ultrasonication (20 min at 37 kHz) in a 
mixture (30 mL) of dry THF and DMF (2:1). The mixture was deoxygenated under N2 and 50 mg (0.41 mmol) 
of DMAP, 50 mg (0.43 mmol) of NHS and 80 mg (0.42 mmol) of EDC-HCl were added. The reaction mixture 
was briefly sonicated and after the addition of 40 mg (0.12 mmol) of fluoresceinamine (isomer I) heated 
under reflux for 4 days under N2. After cooling to RT, the CNOs were redispersed in DMF, filtered off (nylon 
membrane, pore size 0.2 ȝm) and washed with THF and acetone. 12 mg of fluo-CNO were recovered as 
black powder after drying under air for one day.  
 
 
Scheme 1. Synthetic procedure for preparation of fluorescein decorated CNOs. 
 
After reaction, the fluo-CNOs were isolated and washed with plenty of THF and acetone in order to 
completely remove the fluorescein physically adsorbed on the surface of the fluo-CNOs. The successful 
surface modification of the p-CNO with carboxylic acid groups to yield ox-CNO and the coupling with 
fluorescein to obtain fluo-CNO, was characterized by a variety of techniques, including thermogravimetric 
analysis (TGA), Fourier transform infrared (FTIR), Raman, absorption and fluorescence spectroscopies, 
dynamic light scattering (DLS) and Zeta potential measurements. 
 
 
2.3 Results and discussion 
2.3.1 Thermo Gravimetric Analysis (TGA) 
TGA performed in air reveals a decrease in the decomposition temperature from 655 °C to 617 °C for p-CNO 
and ox-CNO respectively (Figure 3). The coverage of carboxylic acid groups on the surface of the ox-CNO 
was calculated from the TGA weight loss at 450 °C and around 210 carboxylic functionalities per CNO were 
estimated. The attachment of fluoresceinamine on the ox-CNO to yield fluo-CNO results in a further 
decrease of the decomposition temperature to 578 °C, as resulted from the TGA curve. The number of 
fluorescein molecules per CNO was calculated form the weight loss at 450 °C of the fluo-CNO and are 
approx. 28 units per unit. The higher surface coverage of carboxylic acid groups as already mention, along 
with the presence of the fluorophore, results in an enhancement of the capability of the CNO constructs to be 
dispersable in water.  
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Figure 3. Thermogravimetric analysis and the corresponding weight loss derivatives of p-CNO (blue), ox-
CNO (red) and fluo-CNO (green). All experiments were run in air with a temperature rate of 10 °C min-1. 
 
2.3.2 Fourier-transform infrared spectroscopy (FTIR) 
The chemical modification of p-CNO was confirmed by solid-state ATR FT-IR spectroscopy which displays 
the characteristic stretching and vibration bands of the carboxylic acid groups in the case of ox-CNO and the 
fluorescein functionalities for the fluo-CNOs. The FTIR spectrum of ox-CNO shows a peak at around 1680 
cm-1 corresponding to the stretching vibrations of C=O (Figure 4). A significant change of the FTIR spectra 
was observed after coupling of fluorescein amine on the surface modified CNO, and new bands 
corresponding to the vibrations of the fluorescein moiety are seen in the spectrum of fluo-CNO. 
 
Figure 4. ATR-FTIR spectra of p-CNO (blue), ox-CNO (red) and fluo-CNO (green). Inset: ATR-FTIR spectra 
of fluoresceinamine. Each ATR-FTIR spectrum was accumulated from 256 scans with normal resolution 
using germanium crystals.  
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2.3.3 Raman Spectroscopy 
Raman spectra of p-CNO, ox-CNO and fluo-CNO are shown in Figure 5. ox-CNO display a little lowering of 
the D-band (1320 cm-1) compared to the G-band (1580 cm-1), suggesting purification of the pristine CNOs 
from carbonaceous material upon nitric acid treatment. As expected the amidation of the carboxyl moiety 
leading to fluo-CNO did not alter significantly the ratio between the  D and G bands.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Raman spectra of p-CNO (blue), ox-CNO (red) and fluo-CNO (green). The Raman spectra were 
normalized for the G-band at 1580 cm-1. 
 
2.3.4 Fluorescence Spetroscopy 
The emission properties of the fluorescein labeled CNOs were tested under different conditions. Upon 
photoexcitation at 490 nm of a dispersion of fluo-CNO in DMSO, an intense emission band was observed 
with a maximum at 544 nm (Figure 6). The fluorescence spectra of dispersions of fluo-CNO in phosphate 
buffer and cell culture medium give rise to an emission centered at around 518 nm, which is slightly shifted in 
comparison to the emission of free fluorescein in PBS (Ȝem= 513 nm). The difference in the wavelength of 
maximum emission between free fluorescein and fluo-CNO implies a different environment surrounding the 
fluorophores anchored on the surface of the CNOs. Another aspect relates to the photostability of the 
fluorescein anchored on the fluo-CNO. We found that a dispersion of fluo-CNO in phosphate buffer retains 
the photophysical properties upon two weeks storage at 4 °C.  
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Figure 6. Absorption and Emission spectra (Ȝexc = 490 nm) of fluo-CNO dispersed in DMSO (solid line), 
phosphate buffer 0.01 M (dotted line) and cell culture medium (dashed line). The fluo-CNO samples were 
dispersed at concentration of 10 ȝg mL-1. The fluorescence spectra of the cell culture medium was 
subtracted to the spectra of fluo-CNO. 
 
2.3.5 Dinamic Light Scattering (DLS) and ζ-potential measurements 
In order to examine the behavior of the CNOs under physiological conditions DLS and zeta-potential 
measurements were performed not only in DMSO but also in phosphate buffer 0.01 M and cell culture 
medium (DMEM with 10% FBS, 2% Penstrep and 1% glutamine). The dispersion of ox-CNO or fluo-CNO 
was carried out at an initial concentration of 500 µg/mL by sonication of the sample for 30 min in DMSO, 
phosphate buffer 0.01M (pH 7.4) and cell medium, followed by dilution of the samples to achieve final 
concentrations of 50, 20, 10, 5 and 1 µg/mL. Although previously reported benz-CNOs displayed a significant 
tendency to agglomerate with time, ox-CNO reveal an effective hydrodynamic diameter in DMSO and in 
phosphate buffer of 115 ± 1 nm and 105 ± 1 nm respectively at a final concentration of 10 µg/mL. These 
values of diameters does not change significantly with the time as well as the concentration of ox-CNO, 
suggesting the low tendency of these dispersions to form large agglomerates even at relatively high 
concentrations. Under similar conditions hydrodynamic diameters of 171 ± 8 nm and 179 ± 33 nm were 
measured for the fluo-CNO dispersed in DMSO and in phosphate buffer. The dispersion of the particles in 
cell medium has a dramatic effect on the behaviour of the ox-CNO with an average hydrodynamic diameter 
of 828 ± 110 nm. An average diameter of 225 ± 36 nm was measured for a dispersion of fluo-CNO in cell 
medium. The huge difference described is probably due to the protein corona mechanism which is often 
present with nanoparticles tested in physiological condition. The concept of the nanoparticle–protein corona 
of course is important in shaping the surface properties, charges, resistance to aggregation and 
hydrodynamic size of nanoparticles and requires further investigations. 
Z-potential measurements of ox-CNO and fluo-CNO samples were performed in phosphate buffer 0.01M at 
pH 7.4 and Cell Medium. Under these conditions the zeta-potentials for the ox-CNO was -41 ± 1 mV, 
independently on the CNO concentrations used. A change in the zeta-potential was observed after 
functionalization of the CNOs with fluorescein, indicating that the carboxy functionalities have a significant 
effect on the charging capacity of each particle. For comparison, the zeta-potential of a dispersion of p-CNO 
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in phosphate buffer 0.01 M was -18 ± 2 mV. The dispersion of ox-CNO and fluo-CNO samples in cell 
medium resulted respectively in a decrease of the zeta-potential values to -23 ± 1 mV and -20 ± 2 mV (Table 
1). 
 
Table 1. Effective hydrodynamic diameter obtained from dynamic light scattering (DLS) measurements and 
Zeta-potential of ox-CNO and fluo-CNO.   
 
 
 
The results clearly show that CNOs might encounter biological interfaces after suspension in a tissue culture 
or biological medium. In a given medium, the most important nanoparticle characteristics that determine the 
surface properties are the material’s chemical composition, surface functionalization, shape and angle of 
curvature, porosity, hydrophobicity or hydrophilicity. Other quantifiable properties, such as effective surface 
charge (zeta potential), particle aggregation, state of dispersion, stability/biodegradability are determined by 
the characteristics of the suspending media, including the ionic strength, pH, temperature and the presence 
of large organic molecules (for example proteins). The interface between carbon nanomaterials and 
biological systems for sure comprises a dynamic series of interactions between nanomaterial surfaces and 
biological surfaces but the biophysicochemical interactions and the relationships between structure and 
activity determined by nanomaterial in cells (membrane surfaces, endosomal compartments, organelles and 
cytoplasm)  require a deeper understanding. 
 
2.3.6 Cell studies 
Because the cytocompatibility of functionalized nanomaterials is a fundamental consideration when 
investigating their use as bioimaging agents, Dr. Marco Frasconi, Senior Post Doc in NACM group at iit, 
tested these probes based on fluorescently functionalized CNOs in HeLa cells for in-vitro imaging. The 
cytotoxicity of ox-CNO and fluo-CNO samples dispersed in cell medium was tested at different 
concentrations (1, 2, 5 and 10 ȝg mL-1) in HeLa cells (Figure 7 and 8). The obtained percentage viability at 
different administration time did not result in significant cytotoxicity of the differently functionalized CNOs. 
The viability of the HeLa cells treated with ox-CNO and fluo-CNO was found to be higher than 80% for an 
incubation time of 24 h at 37 °C at all concentration of CNOs tested. Confocal live cell imaging was 
performed in order to explore the ability of the fluorescein labelled CNOs to be internalized by cells and to 
localize their presence in cellular compartments. HeLa cells grown in subconfluent monolayer on a glass 
slide were treated with a dispersion of fluo-CNO in DMEM at concentrations of 1, 5 and 10 µg mL−1. After 24 
h of incubation at 37 °C, the cells were carefully rinsed with fresh media to remove the excess of CNOs and 
treated with Hoechst 33342, for live nuclear staining. 
 
Sample
Effective Hydrodynamic Diameter
(nm)
Zeta-Potential
(mV)
DMSO PBS 0.01M Cell Medium PBS 0.01M Cell Medium
ox-CNO 115 ± 1 105 ± 1 828 ± 110 -41 ± 1 -23 ± 1
fluo-CNO 171 ± 8 179 ± 33 225 ± 36 -38 ± 1 -20 ± 2
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Figure 7. Cellular viability of HeLa cells after exposure to 1, 2, 5 and 10 µg mL−1 ox-CNO. The viability was 
evaluated for the samples of CNOs against a non-treated control. 
 
 
 
 
 
Figure 8. Cellular viability of HeLa cells after exposure to 1, 2, 5 and 10 µg mL−1 fluo-CNO. The viability was 
evaluated for the samples of CNOs against a non-treated control. 
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2.3.8 Cellular Uptake 
 
 
 
 
Figure 9. Confocal image of HeLa cells after incubation for 24 h with 1 (A), 5 (B), 10 (C) µg ml−1 of fluo-CNO. 
Nuclei were stained with Hoechst 33342 (blue). 
 
The cellular uptake characteristics of the fluo-CNO in the concentration range investigated are shown in 
Figure 9. The green fluorescence signal detected in the cells clearly indicates that fluo-CNOs were 
internalized by cells. Cells treated with 1 µg mL−1 fluo-CNO display a point-like distribution of the 
fluorescence signal in the perinuclear region (Figure 9 A). In agreement with previous studies on the cellular 
uptake of CNOs functionalized with fluorophores, the localization of the fluo-CNO in living cells within the 
cytoplasmatic compartment is likely due to intravesicle storage of the CNOs as a consequence of the cell 
internalization of fluo-CNO by an endocytosis pathway. For higher concentrations of fluo-CNO, 5 and 10 µg 
mL−1 (Figures 9 B and C), the cells display a widely spread green emission from the fluorescein coupled onto 
the CNOs, indicating an efficient cellular internalization of the fluo-CNO. The high biocompatibility and 
minimal systemic toxicity of these fluorescent CNOs along with an efficient cellular uptake in the perinuclear 
region as demonstrated by using confocal live cell imaging encourage the use of these fluorescent 
nanomaterials in biomedical applications and the further investigation of these materials as biosensors for 
cancer cells. 
 
2.4 Conclusion 
A fluorescent probe based on carbon nano-onions (CNOs) for biological imaging has been synthetized and 
fully characterized. We have demonstrated a versatile strategy for the preparation of highly surface modified 
CNOs by oxidation of the defects on the CNOs surface and a chemical functionalization of the carboxyl 
groups by amide coupling with fluoresceinamine. The modification of CNOs by chemical oxidation of the 
defects on the outer shell of these carbon nanoparticles results in an extensive surface functionalization with 
carboxyl groups that translate in excellent dispersability in water and high emission properties. These are 
key features in the field of biomedical applications. Moreover, we have systematically investigated the 
importance of surface functionalization in physiological conditions. The high biocompatibility and minimal 
systemic toxicity of these fluorescent CNOs along with an efficient cellular uptake, make these functionalized 
CNOs suitable candidates as fluorescent probes for bioimaging studies and hold promise as multifunctional 
A B C
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nanomaterial for theranostic applications. In summary, in comparison to the previously reported chemical 
modification of CNOs through the well-known Tour reaction which introduced benzoic acid groups by radical 
addition on CNO surface, the new functionalization based on oxidation provide better emission properties 
and dispersability in physiological condition due to the excellent loading achieved. The results reveal also a 
high biocompatibility and minimal cytotoxicity along with an efficient cellular uptake which render this carbon 
nano-material a good candidate for in vivo optical imaging. According to that, the second stage of my 
research project has been focused on introducing targeting ligands to CNOs. Attachment of sugar moieties 
to carbon nanomaterials is a very attractive technique not only because of improvements in water solubility 
but also because play an important role in many cell-cell interactions. Therefore, CNOs conjugated with 
specific targeting peptides might facilitate the delivery of functional CNOs to site of interest within cells. 
Moreover, through the optimization of chemical modifications with small molecules and biomolecules, these 
highly surface functionalized CNOs are expected to emerge as ideal platform for the preparation of 
sophisticated multi-functional smart materials capable of imaging, recognition, targeting, and drug delivery, a 
work currently in the focus of my research activities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
2.5 Efficient covalent ligation methodology of Isoquinolines 
onto Carbon Nano-onions (CNOs) 
 
2.5.1 Introduction 
The emission of fluorescence labelled CNMs is largely dependent on the chemical and photophysical nature 
of the implemented fluorophores. In addition, the linkage between the fluorophores and CNMs can play an 
important role, since it influences largely the interaction between the building blocks. In most cases, the 
emission intensity of a fluorophore bound to a CNMs lower than that of the free dye in solution. In the 
corresponding section of this review article, several examples will be presented where this effect is observed. 
Typically, the remaining fluorescence signal is intense enough for cellular imaging. The reduced 
fluorescence intensity can be led back to a high intrinsic absorption of the CNMs, especially when taking into 
account that most CNMs show plasmonic absorption over the whole spectral range. On the other hand, the 
quenching of the fluorophores photo-excited states by the CNM is observed. This can be due to different 
kinds of electronic interactions, involving energy or electron transfer events from the photo-excited 
chromophore to the CNM or vice versa. Amongst many examples in the literature, typical CNM based 
systems showing photo-induced electron transfer consist of CNTs in combination with phthalocyanines,8,9 
porphyrins,10 and also boron azadipyrromethenes.11 Many of these CNT–dye-conjugates were successfully 
probed in antenna systems for solar cell application. For imaging, this fluorescence quenching is obviously a 
large drawback, which was overcome by developing synthetic strategies to electronically separate the 
fluorophore from the CNM. This can be accomplished, for example, by the introduction of molecular spacers, 
biomolecules or coatings between the fluorophore and the CNM. 
We study this feature in collaboration with Prof. Riva’s group. They have synthetized a library of furo[2,3-
c]isoquinolines bearing a linker of different length and an amino group Boc protected (See Figure 10). 
Various examples illustrating this concept will be discussed in the next paragraph of this chapter. 
 
 
 
 
Figure 10. Library of Isochinolines employed for the conjugation with ox-CNOs. 
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In 2000, Cushman et al.12 synthesized and evaluated a series of indenoisoquinolines as topoisomerase I 
(top1) inhibitors and as cytotoxic agents in human cancer cell cultures. The synthesis relied on the 
condensation of substituted Schiff bases with homophthalic anhydrides to produce cis-3-aryl-4-
carboxyisoquinolones that were cyclized to indenoisoquinolines in the presence of thionyl chloride. Both top1 
inhibitory activity and cytotoxicity has been found maximized in a single compound (See Figure 11), which 
have been proved to be a very potent top1 inhibitor.  
 
 
 
 
 
 
 
 
 
Figure 11. Indeno[1,2-c]isoquinoline hydrochloride: cytotoxic topoisomerase I inhibitor. 
 
Structurally related indenoisoquinolines would hopefully lead to novel anticancer agents that act through top1 
inhibition. In 2015, Carta et al.13 reported the synthesis of a small library of 3-ethylpyrrolo[3,2-f]quinoline 
derivatives to identify a novel class of dyes for use in biological studies. According to the spectroscopic 
analyses performed to evaluate the fluorimetric parameters of quantum yield and brightness, 7-methyl- and 
6,7-dimethylpyrroloquinolin(9)one derivatives were found to be the best blue luminescent dyes for biological 
applications. To enhance the luminescence profiles and to obtain probes that could be conjugated to 
functional groups of supramolecular drug delivery systems, these compounds were further modified at 
position 3 to obtain 3-heptanoic acid and 3-aminohexylpyrroloquinolin(9)one methylated derivatives. The 
most brilliant 6,7-dimethyl-3-aminohexylpyrroloquinolinone hydrochloride was conjugated to pullulan, a 
biocompatible polysaccharide used to produce colloidal systems for drug delivery. Comparative studies 
showed that this compound can be properly exploited as a blue fluorescent label in biological investigations, 
namely cell trafficking and pharmacokinetics/biodistribution studies. These molecules possess higher 
fluorescence efficiency than commercial dyes in biological media, making them suitable alternatives to 
commercially available products in current use.  
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Recently, Prof. Riva’s group have developed an efficient synthesis of a rather unexplored heterotricyclic 
scaffold of furo[2,3-c]isoquinolines through a two-step procedure from simple or readily available starting 
materials (Figure 12).14  
 
 
Figure12. Synthesis of furo[2,3-c]isoquinolines by two-step procedure. Reprinted with permission of 
reference [14]. 
 
This approach is characterized by an Ugi multicomponent reaction furnishing the substrate for a Pd-
catalyzed insertion-alkynylation-cycloisomerization cascade to provide the final compounds in moderate to 
high yield. All the furo[2,3-c]isoquinolines synthetized with this method display pronounced blue 
luminescence in solution or in the solid state. Furthermore, the photophysical characterization by absorption 
and emission spectroscopy reveals that the emission wavelength, Stokes shift, and fluorescence intensity is 
largely dependent on the donor substitution pattern on the isoquinoline part of the tricyclic core and also to a 
minor extent by the 4-aryl substituent on the furomoiety. Studies to explore the functionalization and 
modulate the photophysical properties of this novel tricyclic luminophore system are currently underway. 
 
2.5.2 Experimental 
2.5.2.1 Deprotection of Blue Emissive Isoquinolines 
In collaboration with Prof. Riva’s group (UniGe), a higly riproducibile ligation methodology for covalent 
modification of CNOs with blue emissive isoquinolines14,15 has been developed. Following the Boc 
deprotection with TFA in CH2Cl2 1:1 (v/v) affording the isoquinoline with the deprotected linker containing a 
free amine (Scheme 2), the coupling between the fluorophore and the carboxylic acids groups on the surface 
of the CNOs to furnish the target isoquinoline-CNO was investigated.  
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Scheme 2. Boc deprotection of three isoquinolines bearing linker differing in length. 
 
2.5.2.2 Characterization of Isoquinoline 1.1 
 
1H NMR (600 MHz, CDCl3) δ 9.53 (d, J = 8.5 Hz, 1H), 8.21 (t, J = 5.7 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.60 
– 7.47 (m, 8H), 7.31 – 7.28 (m, 3H), 7.26 – 7.21 (m, 3H), 7.16 (d, J = 7.2 Hz, 2H), 6.80 (s, 2H), 4.11 (s, 2H), 
4.05 (s, 2H), 3.71 (d, J = 6.4 Hz, 2H), 3.26 (s, 2H), 2.91 (t, J = 7.1 Hz, 2H), 2.15 (s, 2H). 13C NMR (151 MHz, 
CDCl3) δ 166.74 (s), 156.7λ (s), 154.λ3 (s), 154.62 (s), 142.4λ (s), 137.33 (s), 133.18 (s), 132.38 (s), 132.21 
(s), 130.54 (s), 130.35 (s), 130.10 (s), 129.24 (s), 128.82 (dd, J = 23.0, 14.6 Hz), 127.06 (s), 126.64 (s), 
125.19 (s), 122.81 (s), 119.79 (s), 116.78 (s), 114.89 (s), 77.45 (s), 77.24 (s), 77.03 (s), 66.46 (s), 41.62 (s), 
39.32 (s), 35.19 (s), 33.01 (s), 29.93 (s), 26.89 (s), 1.35 – 0.91 (m). HRMS (APCI+) m/z calcd for C36H34N3O3 
[M + H]+ 556.261863, found 556.259468. 
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2.5.2.3 Characterization of Isoquinoline 2.1 
 
1H NMR (600 MHz, CDCl3) δ λ.54 (d, J = 6.1 Hz, 1H), 8.16 (s, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.60 – 7.44 (m, 
6H), 7.33 – 7.26 (m, 3H), 7.26 – 7.19 (m, 3H), 7.13 (d, J = 25.3 Hz, 2H), 6.79 (s, 2H), 4.19 – 4.01 (m, 4H), 
3.76 – 3.61 (m, 2H), 3.30 (s, 2H), 2.87 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 166.33 (s), 156.17 (s), 154.61 
(s), 154.43 (s), 142.42 (s), 137.16 (s), 132.95 (s), 132.41 (s), 132.22 (s), 130.34 (s), 130.02 (d, J = 18.0 Hz), 
129.01 (s), 128.86 – 128.58 (m), 128.44 (s), 126.84 (s), 126.38 (s), 124.99 (s), 122.53 (s), 119.57 (s), 116.45 
(s), 114.73 (s), 77.24 (s), 77.03 (s), 76.82 (s), 63.63 (s), 41.30 (s), 35.06 (s), 32.79 (s), 29.72 (s), 14.17 (d, J 
= 9.4 Hz). HRMS (APCI+) m/z calcd for C35H32N3O3[M + H]+ 542.244610, found 542.243818. 
 
 
2.5.2.4 Characterization of Isoquinoline 3.1 
 
1H NMR (600 MHz, CDCl3) δ λ.52 (s, 1H), 8.22 (s, 1H), 7.78 (d, J = 7.λ Hz, 2H), 7.63 – 7.45 (m, 6H), 7.34 – 
7.11 (m, 8H), 6.84 (s, 2H), 4.13 (s, 4H), 3.62 (d, J = 135.5 Hz, 6H), 3.18 (s, 2H), 2.92 (s, 2H). 13C NMR (151 
MHz, CDCl3) δ 157.08 (s), 154.65 (s), 154.41 (s), 142.5λ (s), 137.14 (s), 132.λλ (s), 132.17 (s), 131.87 (s), 
130.33 (s), 130.19 (s), 129.95 (s), 129.04 (s), 128.69 (d, J = 13.6 Hz), 128.49 (s), 126.86 (s), 126.43 (s), 
124.99 (s), 122.58 (s), 119.62 (s), 116.52 (s), 115.05 (s), 77.25 (s), 77.04 (s), 76.83 (s), 70.12 (s), 67.31 (s), 
66.59 (s), 41.34 (s), 34.93 (s), 32.81 (s), 29.72 (s), 1.04 (s). HRMS (APCI+) m/z calcd for C37H36N3O4 [M + 
H]+ 586.272722, found 586.270033. 
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The coupling of blue emissive isoquinolines onto CNOs have been obtained by using a reaction involving the 
amide bond formation between the amino groups of the isoquinolines and the carboxylic acids groups on the 
surface of the CNOs. The modification of CNOs by chemical oxidation of the defects on the outer shell of 
these carbon nanoparticles results in an extensive surface functionalization with carboxyl groups. The 
functionalized CNOs display high emission properties due to the presence of high surface coverage of 
carboxylic acid groups and the good functionalization provided. 
 
2.5.2.5 Synthesis of 1-CNO 
A dispersion of ox-CNO (10 mg) was prepared by ultrasonication (20 min at 37 kHz) in a mixture (30 mL) of 
dry THF and DMF (2:1). The mixture was deoxygenated under N2 and 20 mg (0.20 mmol) of DMAP, 20 mg 
(0.21 mmol) of N-Hydroxysulfosuccinimide (sulfo-NHS) and 35 mg (0.22 mmol) of EDC-HCl were added. The 
reaction mixture was briefly sonicated and after the addition of 20 mg of isoquinoline 1.1 heated under reflux 
for 4 days under N2. After cooling to RT, the CNOs were redispersed in DMF, filtered off on a nylon 
membrane (pore size 0.2 ȝm) and washed with THF, DMSO and acetone in order to completely remove the 
isoquinoline physically adsorbed on the surface of the CNOs. The resulting material was re-dispersed in 
DMSO, filtered again and centrifuged to wash out any non-covalently bound species. 12 mg of 1-CNO were 
recovered as black powder after drying under air for one day (Scheme 3). 
 
2.5.2.6 Synthesis of 2-CNO 
A dispersion of ox-CNO (15 mg) was prepared by ultrasonication (20 min at 37 kHz) in a mixture (30 mL) of 
dry THF and DMF (2:1). The mixture was deoxygenated under N2 and 20 mg (0.20 mmol) of DMAP, 20 mg 
(0.21 mmol) of N-Hydroxysulfosuccinimide (sulfo-NHS) and 35 mg (0.22 mmol) of EDC-HCl were added. The 
reaction mixture was briefly sonicated and after the addition of 20 mg of isoquinoline 2.1 heated under reflux 
for 4 days under N2. After cooling to RT, the CNOs were redispersed in DMF, filtered off on a nylon 
membrane (pore size 0.2 ȝm) and washed with THF, DMSO and acetone in order to completely remove the 
isoquinoline physically adsorbed on the surface of the CNOs. The resulting material was re-dispersed in 
DMSO, filtered again and centrifuged to wash out any non-covalently bound species. 14 mg of 2-CNO were 
recovered as black powder after drying under air for one day (Scheme 3). 
 
2.5.2.7 Synthesis of 3-CNO 
A dispersion of ox-CNO (15 mg) was prepared by ultrasonication (20 min at 37 kHz) in a mixture (30 mL) of 
dry THF and DMF (2:1). The mixture was deoxygenated under N2 and 20 mg (0.20 mmol) of DMAP, 20 mg 
(0.21 mmol) of N-Hydroxysulfosuccinimide (sulfo-NHS) and 35 mg (0.22 mmol) of EDC-HCl were added. The 
reaction mixture was briefly sonicated and after the addition of 20 mg of isoquinoline 3.1 heated under reflux 
for 4 days under N2. After cooling to RT, the CNOs were redispersed in DMF, filtered off on a nylon 
membrane (pore size 0.2 ȝm) and washed with THF, DMSO and acetone in order to completely remove the 
isoquinoline physically adsorbed on the surface of the CNOs. The resulting material was re-dispersed in 
DMSO, filtered again and centrifuged to wash out any non-covalently bound species. 12 mg of 3-CNO were 
recovered as black powder after drying under air for one day (Scheme 3). 
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The successful surface modification of the p-CNO with carboxylic acid groups to yield ox-CNO and the 
coupling with isoquinolines to obtain blue emissive CNOs, was confirmed by absorption and emission 
studies, thermogravimetric analysis and dynamic light scattering measurements. 
 
 
 
Scheme 3. Synthetic procedure for preparation of isoquinolines decorated ox-CNOs.  
 
2.5.3 Results and Discussion 
2.5.3.1 Blue Emissive Isoquinolines-CNOs Characterization 
The high degree of surface functionalization of 1-CNO, 2-CNO and 3-CNO in comparison to the ox-CNO, 
was observed by TGA analysis. TGA performed in air shows thermal decomposition of surface organics at 
401 °C, 380 °C and 392 °C for 1-CNO, 2-CNO and 3-CNO respectively followed by the decomposition of the 
CNO core at around 551 °C (Figure 14, top section). In order to calculate the average number of functional 
groups per onion, it has been assumed based on TEM observations, that CNOs contain, on average, six 
shells and that the core is a C60 fullerene. The number of carbon atoms in each shell is estimated as: 60 x n2, 
where n is the number of shells that we are considering. The outer 6th shell contains 2160 carbon atoms and 
the total number of carbon atoms in the onion is 5460. Therefore, the average mass of onions is 5460 x 12= 
65520 g mol-1. Calculating the mass of the functional groups attached to the CNO is possible to estimate the 
number of functionalities per onion. According to that, 79, 63 and 123 functionalities have been estimated for 
1-CNO, 2-CNO and 3-CNO respectively. 
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The emission properties of the isoquinoline labelled CNOs were tested in DMSO. Upon photoexcitation at 
350 nm of a dispersion of 1-CNO, 2-CNO and 3-CNO in DMSO, an intense emission band was observed 
with a maximum at 400 nm, 408 nm and 398 nm for 1-CNO, 2-CNO and 3-CNO respectively (Figure 14, 
bottom section). The concentration of isoquinoline 1 in a 10 ȝgmL-1 dispersion of 1-CNO in DMSO was 
determined to be about 1.13 x 10-6 M by absorption (Figure 14, middle section). A concentration of 4.65 x 10-
5
 M and 6.83 x 10-7 M was estimated for 2-CNO and 3-CNO respectively (Figure 14, middle section). The 
isoquinolines loading onto carbon-nanoonion is in comparison with the functionalization previously carried on 
with green and red emitting dyes.16,17 Moreover, from the fluorescence spectra, it is notable a quenching of 
20% for 1-CNO, 15% for 2-CNO and 20% for 3-CNO in comparison with the free blue emissive dye at the 
same absorption supporting the value obtained with the UV-spectroscopy.  
The size of the clusters formed were investigated by dynamic light scattering (DLS) in DMSO at a 
concentration of 10 ȝgmL-1. DLS is driven by collisions with the solvent molecules present, which are in 
constant movement due to their thermal energy. According to that, this measurement depends on the size of 
the particle core, the surface structures, particle concentration, and the type of ions in the medium. After 20 
min sonication ox-CNO revealed an effective hydrodynamic diameter in DMSO of 277 ± 1 nm. On the other 
hand 1-CNO, 2-CNO and 3-CNO revealed a hydrodynamic diameter in DMSO of 390 ± 1 nm, 546 ± 5 nm 
and 332 ± 2 nm respectively, suggesting a good surface functionalization along with a better dispersion in 
solution and a lower size for particles bearing an extra oxygen in the linker (Figure 13). 
 
 
 
 
 
 
 
 
 
 
Figure 13. Effective hydrodynamic diameter obtained from dynamic light scattering (DLS) measurements of 
1-CNO, 2-CNO and 3-CNO in DMSO at a concentration of 10 ȝg mL-1. 
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Figure 14. Characterization of the functionalized 1-CNO, 2-CNO and 3-CNO. (Top section) 
Thermogravimetric analysis of ox-CNO (blue), and 1-CNO, 2-CNO and 3-CNO (red). All experiments were 
run in air with a temperature rate of 10 °Cmin−1. (Middle section) Absorption spectra of 1-CNO, 2-CNO and 
3-CNO (solid line) and free isoquinoline 1, 2 and 3 (dotted line) in DMSO at a concentration of 10 ȝgmL-1. 
(Bottom section) Emission spectra (Ȝexc = 350 nm) of 1-CNO, 2-CNO and 3-CNO (solid line) and free 
isoquinoline 1, 2 and 3 (dotted line) in DMSO at a concentration of 10 ȝgmL-1.  
 
2.5.4 Conclusion 
In summary, we have demonstrated a versatile strategy for the preparation of highly surface modified CNOs 
by oxidation of the defects on the surface of CNOs and chemical functionalization of the carboxyl groups by 
amide coupling with isoquinolines which were never reacted before with CNOs. The intrinsic electronic, 
magnetic and optical properties of CNOs along with their high surface-to-volume ratio, chemical versatility 
and ease of manipulation, as well as their performance as a chemically robust platform render these 
functionalized CNOs valuable candidate for blue high emissive materials. Unfortunately, due to their low 
solubility in biological medium, they result unsuitable for biological applications. Despite that, the substitution 
pattern on the core of the isoquinoline with high polar functional groups such as sulfonamides, amines or 
carboxylic acid groups, often used in drugs to improve their solubility, could improve significantly their 
physico-chemical properties. This is a work currently in the focus of my group’s research.  
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3. CNO as vaccine carrier 
 
3.1 Introduction 
The modification of nanomaterials with biologically active substrates such as glycopeptides, glycoproteins 
and antibodies offers a fascinating platform technology for developing targeted nanotherapeutics and 
vaccine candidates. In the second step, the development of a general synthetic strategy for CNO 
modification using cysteine as a ligation site for peptide and protein conjugation has been investigated 
(Figure 1). The ‘proof of concept’ has been demonstrated using a model synthetic glycopeptide substrate 
(prepared in collaboration with Prof. Scanlan) and reproduced using the native bovine serum albumin protein 
(BSA).  
 
Figure 1. Schematic representation of the bioconjugations investigated. 
 
In order to visualize the CNOs in vitro and to monitor the localization pattern of the glycopeptide modified 
CNOs, a fluorescently labelled glycopepide for the preliminary studies was synthetized. Given the numerous 
biological applications associated with synthetic glycopeptides, the ability to transfer these compounds into 
the cells using nano-platforms offers fascinating prospects for the development of these compounds as 
nano-therapeutics. Therefore, the application of maleimide functionalised CNOs as general carrier 
substrates for cysteine containing glycopeptides and proteins might offer an extremely innovative platform 
technology. As a medical nanoplatform, the design of multifunctional carbon nanomaterials for targeted 
bioimaging and drug delivery, in which carbon nano-onions may act as a carrier has been developed to 
strengthen the delivery of functional onions to sites of clinical interest. 
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3.1.1 Nanovaccinology 
Vaccines have a tremendous global impact on human health, from the near-eradication of several 
contagious diseases to the annual prevention of recurrent epidemics in a variety of vulnerable populations. 
However, most vaccines in use today were developed using techniques pioneered more than 100 years ago 
and do not reflect the full potential of the field. With the introduction of emerging biotechnologies such as 
genetic engineering, rapid advances have been made in the design, synthesis, and application of modern 
vaccines against a myriad of preventable diseases. Recently, nanotechnology has been applied to address 
the clear biomimicry challenge inherent to the next generation of more potent and sophisticated adjuvants. 
Although early adjuvants, such as aluminum hydroxide, have been successful in stimulating the immune 
response, the advent of nanoscale antigen delivery platforms has catalyzed the transition from these simple 
immunoactive chemical agents to adjuvants that can engage and direct immune responses more akin to the 
methods employed by pathogens themselves.1,2,3,4,5,6,7 Vaccine adjuvants are an essential component of 
vaccine design, helping to generate immunity to pathogen antigens in the absence of infection. Recent 
advances in nanoscale engineering have created a new class of particulate bionanotechnology that uses 
biomimicry to better integrate adjuvant and antigen. These pathogen-like particles, or PLPs, can come from 
a variety of sources, ranging from fully synthetic platforms to biologically derived, self-assembling systems. 
By employing molecularly engineered targeting and stimulation of key immune cells, recent studies utilizing 
PLPs as vaccine delivery platforms have shown great promise against high-impact, unsolved vaccine targets 
ranging from bacterial and viral pathogens to cancer and addiction.3,8 
 
 
Figure 2. Immunostimulation routes of synthetic nanovaccine carriers. 
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Soluble antigens, independent of some larger delivery vector, suffer from reduced uptake by APCs and poor 
immunogenicity. These fundamental flaws have led to the development of particle-based vaccine carriers 
that can more closely mimic the physiochemical characteristics of natural pathogens, enhancing antigen 
delivery to the immune system9. PLP carriers can be formulated using nanoparticles created from 
biocompatible polymers, such as polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA), liposomes, 
and even simple lipid emulsions.8 Antigens are then either encapsulated by, or integrated onto the surface 
of, these particles. Particle-based delivery is a promising technology due to its ability to target APCs such as 
dendritic cells (DCs) and stimulate antigen uptake, simultaneously deliver antigens and co-stimulatory 
signals, and generate strong and distinct immune responses (Figure 2). Furthermore, each of these 
characteristics may be finely tuned to the specific needs of the vaccine by varying the physiochemical 
attributes of the particle. 
Nanovaccinology has applications in both prophylactic and therapeutic approaches and can be used to 
either increase antigen processing or presentation and/or as an immunostimulatory adjuvant.10,11 This 
approach offers many advantages over traditional vaccine design; it has the potential to overcome the 
limitations associated with conventional vaccines (weak immunogenicity, intrinsic in vivo instability, toxicity 
and the requirement of multiple administrations).12 The enhanced humoral and cellular immune response 
that is elicited by nano based vaccines is due to the smaller size – which increases uptake by phagocytic 
cells, the gut-associated lymphoid tissue, and the mucosa-associated lymphoid tissue. This subsequently 
leads to enhanced antigen recognition and presentation.12 Surface modification of these nanocarriers with 
targeting moieties (peptides, carbohydrates, or antibodies) can facilitate specific and selective immune 
responses by targeting specific receptors on the surface of various immune cells.13,14 An additional benefit of 
incorporating nanoparticles in vaccine formulations is accomplishing slow and sustained release of antigens 
or adjuvants. 10,12 Nanovaccines can also eliminate the requirement for cold-chain transport or storage as the 
formulation can be lyophilized, thereby prolonging shelf-life over an increased range of temperatures (from 
0°C to 4°C). Another major advantage of using nanoparticles in vaccine delivery is that the sizes of these 
particles are approximately the same as viruses and bacteria, which the immune system readily identifies. 
Distinct populations of APCs may be targeted simply by modulating particle size. Smaller particles (20–200 
nm) are able to more easily target DCs residing in lymph nodes by exploiting interstitial circulation to access 
the lymphatic system, whereas larger particles (0.5–2 mm) remain at the injection site and are taken up by 
peripheral DCs and tissue-resident macrophages.15 
 
 
3.2 Experimental 
3.2.1 Covalent Immobilization of Glycopeptides and Proteins onto Carbon Nano-
onions (CNOs) 
The functionalization of carbon-nanonions with biologically active peptide requires three consecutive steps: 
the synthesis of glycopeptide conjugated fluorophore, the surface functionalization of CNO and the 
conjugation of the fluorophore-glycopeptide on the activated CNO. Because the coupling reaction between 
the amino group of the fluorophore and the carboxylic group of the C-terminus cysteine residue of the 
glycopeptide is a crucial step in the chemical synthesis, a test reaction using N-acetyl L-cysteine and 
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benzylamine to mimic the larger  substrate has been investigated (Scheme 1). It has been extremely useful 
to optimize the ligation chemistry before testing it on the final substrates. The DIC/HOBt coupling ligation has 
been performed and has been found to be very efficient with cysteine moieties. Indeed, reactions carried out 
on different scales have been tested giving an average isolated yield of 67%. The reaction consists of two 
consecutive steps. Firstly, the activation of the carboxylic acid moiety with diisopropylcarbodiimide (DIC) 
plays a key role. It gives the urea as byproduct which is water soluble and can be removed by aqueous 
extraction. Secondly, the formation of the amide bond occurs. Hydroxybenzotriazole (HOBt) that acts as the 
catalyst, forms an OBt esters which reacts with the primary amine giving the amide bond. Furthermore, an 
excess of N,N- Diisopropylethylamine (DIPEA) was added. This compound is a good base and a poor 
nucleophile and it is commonly used to improve the reaction yield.  
 
 
 
 
 
Scheme 1. N-acetyl L-cysteine and benzylamine reaction. 
 
3.2.2 Synthesis of Benzyl- N-acetyl L-cysteine 
 
 
 
 
 
To N-Acetyl L-cysteine (50 mg, 0.31 mmol) in 60% dry DCM (30 mL), was added HOBt (45.9 mg, 0.34 mmol) 
and DIC (43.0 mg, 0.34 mmol) and the reaction was stirred at 0 °C for 1 h. The reaction was brought to rt  
and benzylamine (33.2 mg, 0.31 mmol) in 40% DMF (20 mL) and DIPEA (160.3 mg, 1.24 mmol) was added 
and stirred for 16 hours. The solvent was removed in vacuo and purification by flash chromatography 
(gradient elution from  DCM to 3% methanol in DCM) afforded the final compound as a white solid in 68% 
yield. δH (400 MHz, MeOD) 7.29-7.23 (m, 5H, 5 x Ar-H), 4.48 (dd, 1H, J = 7.1 and 5.8, H-3), 4.39 (s, 2H, Ar-
CH2), 2.87 (dd, 1H, J = 13.9 and 5.9, HH-10), 2.79 (dd, 1H, J = 13.9 and 7.1, HH-10), 2.01 (s, 3H, CH3); δC 
(101 MHz, MeOD) 173.5 (C=O), 172.3 (C=O), 139.7 (C6), 129.5 (2 x Ar-H), 128.5 (2 x Ar-H), 128.2 (C9), 
57.3 (C3), 44.1 (C5), 26.8 (C10), 22.5 (C1); HRMS (ES−) m/z calcd for C12H16N2O2S [M − H]−  252.0932, 
found 251.0862. 
 
3.2.3 Synthesis of functionalized fluorescein 
Once the peptide coupling reaction has been optimised on the model substrate, the ligation between the 
peptide and the fluorophore was carried out (Scheme 3). It is anticipated that the ligation reaction to form the 
target, fluorescently labelled glycopeptide has been carried out once the synthesis of the fluorophore linker 
has been performed. Following the Boc deprotection with HCl affording the fluorescein with the deprotected 
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linker containing a free amine (Scheme 2), the coupling between the fluorophore and the glycopeptide to 
furnish the target fluorescently labelled glycopeptide was investigated.  
 
 
 
 
Scheme 2. Synthesis of functionalized fluorescein. 
 
Synthesis of functionalized fluorescein. To a solution of Boc monoprotected 2,2’-
(ethylenedioxy)bis(ethylamine) (166 mg, 0.67 mmol), in dry DCM (30 mL) was added FITC (200 mg, 0.51 
mmol) in dry DMF (20 mL) and  TEA (250 ȝL, 1.53 mmol) . The reaction mixture was stirred at room 
temperature, in the dark, for ca. 18 h. After reaction completion, the solvent was evaporated under reduced 
pressure and the crude product dissolved in MeOH (10 mL), and HCl 4 N in dioxane (5 mL) was added. The 
mixture was stirred at room temperature in the dark for 1 h, monitoring the reaction by TLC. The solvent was 
evaporated under reduced pressure and purification by flash chromatography (gradient elution in 
ethylacetate to methanol in ethylacetate) afforded the final product in 78% yield.1 (orange solid). 1H NMR 
(400 MHz, methanol-d4) δ 8.17 (s, 1H, Ar-H), 7.67 (d, J = 7.7 Hz, 1H, Ar-H), 7.01 (d, J = 8.2 Hz, 1H, Ar-H), 
6.82 (d, J = 8.9 Hz, 2H, Ar-H), 6.70 (s, 2H, Ar-H ), 6.58 (d, J = 8.8 Hz, 2H, Ar-H), 3.58 (s, J = 23.3 Hz, 2H, 
CH2NHCS), 3.53 – 3.43 (m, 8H, CH2O), 2.91 (s, 2H, CH2NH2). 13C NMR (101 MHz, methanol-d4): δ 181.9 
(C=S), 168.7 (C=O), 164.8, 155.7, 142.0 (C-Ar), 130.8, 129.2, 126.9, 115.6, 113.16, 102.4 (CH-Ar), 70.3, 
69.1, 66.8 (CH2OCH2), 44.1 (CH2)NHSNH, 39.5 (CH2NH2); HRMS (ES-) m/z calcd for C27H27N3O7S [M - H]- 
537.1570, found 536.1497. 
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3.2.4 Synthesis of fluorescein-functionalized glycopeptide 
The ligation reaction between the glycopeptide and the functionalized-fluorescein was investigated using the 
reaction conditions optimized for the model system previously described (Scheme 1). DIC/HOBt mediated 
coupling conditions were employed for the reaction. The ligation reaction was successful and the target 
compound was isolated and fully characterized by 1H-NMR and 13C-NMR. The yield for the ligation reaction 
was  78%. The proposed synthetic route for the preparation of a fluorescently labelled glycopeptide, suitable 
for CNO conjugation is outlined in Scheme 3. The DIC coupling reaction was compatible with the cysteine 
moiety of the glycopeptide and formation of the desired amide conjugate proceed in high yield (74%). 
 
Scheme 3. Synthesis of fluorescein-functionalized glycopeptide. 
Synthesis of fluorescein-functionalized glycopeptide. To a solution of 2 (50 mg, 0.06 mmol) in DMF (10 mL), 
was added HOBt (9.5 mg, 0.07 mmol) and DIC (7ȝL, 0.07 mmol) and the reaction was stirred at 0 °C for 1 h. 
The reaction was brought to room temperature and glycopeptide 1 (323 mg, 0.06 mmol) and DIPEA (160.3 
mg, 1.24 mmol) in a mixture DMF:MeOH (10:1) was added and stirred for 16 h. The solvent was removed in 
vacuo and purification by flash chromatography (gradient elution in ethylacetate to methanol in 
dichloromethane) afforded the final compound as a yellow solid in 74% yield. IR 3305.44 (OH), 2925.25 
(NH), 2853.96 (SH), 1747.76, 1658.09 (C=O), 1452.39 (SCH2), 1368.44 (C=S), 1225.24 (CH Alkyl), 1058.05 
(COC), 900.01, 850.68 (CH-Ar). 1H NMR (400 MHz, MeOD) δ 8.13 (s, 1H, Ar-H), 7.76 (s, 1H, Ar-H), 7.13 (d, 
J = 8.2 Hz, 1H, Ar-H), 6.66 (dd, J = 13.8, 5.3 Hz, 4H, Ar-H), 6.52 (dd, J = 8.7, 2.3  Hz, 2H, ArCH), 5.35 (s, J = 
3.0 Hz, 1H, H4), 5.17 – 4.98 (m, 4H, H-1,H-2,H-3,H-5), 4.60 (s, 2H, CH2OCH3), 4.09 (m, J = 7.2 Hz, 4H, 
CHCH3, CHCH3, CH2NO), 3.84 (d, J = 27.4 Hz, 2H, OCH2CH2), 3.75 – 3.60 (m, 8H, OCH2), 3.60 – 3.48 (m, 
2H, CH2NS), 3.37 (s, 1H, CHCH2SH), 3.10 (s, 1H, CHCH2S), 2.90 (s, 2H, CHCH2SH), 2.86 – 2.72 (m, 2H, 
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CHCH2S), 2.58 (m, 2H, OCH2CH2), 2.11, 2.02, 1.99, 1.91 (s, 12H, COCH3), 1.42 (s, 12H, C(CH3)3, CHCH3), 
1.31 (s, 3H, CHCH3). 13C NMR (101 MHz, MeOD/CH3COOH-d) δ 179.67 (C=S), 173.1, 172.2, 170,3, 169.3, 
168.92, 168.82, 168.33, 168.18, 167.98, 167.44 (C=O), 158.16, 150.94, 146,51, 139.11, 128.50, 127.12, 
125.66, 122.59, 116.22, 110.41 (Ar-C), 108.23 (C1), 100.33, 99.06 (Ar-C), 77.55 (C(CH3)3, 69.12 (C3), 68.53 
(C5), 68.29 (C2), 68.09, 67.35 (OCH2), 67.27 (OCH2), 66.02 (C4), 65.62 (CHCH2S), 64.45 (C6), 61.58 
(CHCH2SH), 59.36 (CHCH3), 55.13 (CHCH3), 42.19 (CH2NS), 39.90 (CH2NO), 37.23 (SCH2CH), 29.92 
(SCH2CH2), 27.41 (OCH2CH2), 26.18 (CHCH2SH), 25.41 (C(CH3)3), 22.03, 22.03, 22.03, 20.49 (C(O)CH3), 
19.39, 17.77 (CHCH3). [α]D26 = (deg cm3 g-1 dm-1) = 117° (c = 0.000145, MeOH). HRMS (MALDI) m/z calcd 
for C61H79N7O23NaS3 [M + Na]+ 1396.4287, found 1396.4326. 
3.2.5 Synthesis of Maleimido-PEG conjugate 
Once the maleimide-PEG linker had been synthetized and fully characterized (Scheme 4), the conjugation 
with the fluorescent labelled glycopeptide was ready to be carried out. The maleimide group reacts 
specifically with sulfhydryl groups when the pH of the reaction mixture is between pH 6.5 and 7.5; the result 
is formation of a stable thioether linkage that is not reversible (i.e., the bond cannot be cleaved with reducing 
agents). Under more alkaline conditions (pH >8.5), the reaction favors primary amines and also increases 
the rate of hydrolysis of the maleimide group to a non-reactive maleamic acid. Maleimides do not react with 
tyrosines, histidines or methionines. Significantly, the synthetic methodology appeared to be highly 
reproducible. 
 
 
 
Scheme 4. Synthesis of Maleimido-PEG conjugate. 
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Synthesis of maleimido-PEG conjugate. To a solution of 4,7,10-trioxa-1,13-tridecanediamine (10 g, 0.045 
mol) in CH2Cl2 (40 ml) in an ice bath, a solution of Boc2O (5 g, 0.023 mol) in CH2Cl2 (40 ml) was added 
dropwise over a period of 3 h. The reaction mixture was stirred overnight at room temperature. The solvent 
was removed under reduced pressure and after mixing the residue with H2O (40 ml) the precipitate formed 
was filtered on celite. The filtrated H2O was extracted with CH2Cl2 (20 mL per 5), the organic phase was 
washed with H2O (40 ml), brine (40 ml) and dried over Na2SO4. The evaporation of the solvent afforded the 
Boc-monoprotected compound as a colorless oil (83%). Benzoic acid (1.90 g, 0.016 mol) were dispersed in 
200 ml CH2Cl2 containing Boc-monoprotected PEG (5 g, 0.016 mol). After that, DMAP (1.95 g, 0.016 mol) 
and EDC HCl ( 3.07 g, 0.016 mol) were added and the reaction mixture was stirred under reflux at 45°C for 
24 h. The solvent was evaporated under reduced pressure and once the residue was dispersed in  CH2Cl2, it 
was washed with Na2HCO3 (20 mL per 4), HCl 1M (20 mL per 4), H2O (40 mL), brine (40 mL) and dried over 
Na2SO4. The evaporation of the solvent afforded the compound as a colorless oil (80%). The obtained 
compound was dissolved in 4M HCl in dioxane (5mL) and the mixture was stirred at room temperature in the 
dark for ca. 1 h monitoring by TLC. The solvent was evaporated under reduced pressure and the product 
was dried under vacuum overnight (100%). To that compound (4.66 g, 0.014 mol) a solution of maleic 
anhydride (1.41 g, 0.014 mol) in 15mL of glacial AcOH were added under vigourous stirring. The solution 
was stirred for 12h under nitrogen at R.T. The solvent was evaporated under reduced pressure and the 
product was dried under vacuum overnight. The crude was dispersed in 10 mL of H2O and heated under 
reflux for 1 hour.2 The evaporation of the solvent afforded the compound as a white oil (90%). 1H NMR (400 
MHz, MeOD) δ 7.83 – 7.78 (d, 2H), 7.56 – 7.48 (t, 1H), 7.45 (t, J = 7.4 Hz, 2H), 6.29 (s, 2H), 3.66 – 3.57 (m, 
10H), 3.47 (t, J = 7.0 Hz, 2H), 3.30 (t, J = 3.2, 1.5 Hz, 2H), 3.14 – 3.02 (t, 2H), 1.96 – 1.83 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 168.45, 167.78 (C=O), 133.82, 132.72, 131.67, 128.54, 127.37 (C-Ar), 70.15, 69.93, 
69.74, 69.65, 69.41, 39.84 (OCH2), 38.05, 29.09 (CH2N), 26.33, 26.33 (OCH2CH2). HRMS (APCI+) m/z calcd 
for C21H29N2O6 [M + H]+ 405.201818, found 405.202013. 
 
At this stage the Michael addition reaction involving the thiol as a nucelophoile was ready to be performed. 
These steps are essential in order to improve and optimize the reaction conditions that will take place on the 
CNOs surface and also to furnish two different references compound presenting a Cys moiety. According to 
this, a short polyethylene glycol (PEG) chain functioning as both a linker and a hydrophilic group bearing a 
maleimide functionality was synthetized and used as a thiol reacting unit (Scheme 4).  
 
3.2.6 Reduction of organic disulfide bonds with TCEP 
Thiols are prone to oxidative dimerization with the formation of disulfide bonds. Cysteine residues thus form 
cystine bridges, which stabilize protein tertiary structures. Disulfides do not react with maleimides. Therefore, 
it is necessary to reduce disulfides prior to the conjugation and exclude oxygen from the reaction. 
Tris(carboxyethyl)phosphine (TCEP) has been reported to be a very effective reagent for cleaving disulfide 
bonds in aqueous solution.17 It is water-soluble and stable in both acidic and alkaline solutions and it has 
been applied to the cleavage of disulfide linkage patterns in peptides with tightly clustered cystines.18,19 
TCEP is a potent, versatile, odorless, thiol-free reducing agent with broad application to protein and other 
research involving reduction of disulfide bonds. The  compound is readily soluble and very stable in many 
aqueous solutions. It reduces disulfide bonds as effectively as dithiothreitol (DTT), but unlike DTT and other 
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thiol-containing reducing agents, TCEP does not have to be removed before certain sulfhydryl-reactive 
cross-linking reactions. The ability and virtues of trialkylphosphine compounds to reduce protein disulfide 
bonds have been known for many years.1,2 Phosphines are stable in aqueous solution, selectively reduce 
disulfide bonds, and are essentially nonreactive toward other functional groups commonly found in proteins. 
TCEP selectively and completely reduces even the most stable water-soluble alkyl disulfides over a wide pH 
range. Reductions frequently require less than 5 minutes at room temperature. TCEP is non-volatile, 
odorless, and unlike most other reducing agents, is resistant to air oxidation. Compared to DTT, TCEP is 
more stable, more effective, and able to reduce disulfide bonds at lower pHs.5. Once the synthetic 
glycopeptide has been prepared and fully characterised, it will be conjugated to CNOs suitably modified with 
reactive maleimide groups. The ligation reaction between the primary thiol and the maleimide Michael 
acceptor is extremely mild and can be carried out at room temperature and in buffered aqueous solution with 
sensitive substrates such as proteins and antibodies. 
 
3.2.7 Mal-CNO synthesis 
Once the main biologically active building bloks were synthetized and fully characterized, a chemoselective 
ligation methodology for covalent modification of CNOs with both synthetic and naturally occurring, cysteine 
containing biomolecules has been explored. The synthesis of the maleimido decorated CNOs is outlined in 
Scheme 5. Pristine CNOs (p-CNO) were prepared by annealing nanodiamonds of 5 nm average particle size 
in a tubular furnace at 1650 °C, according to the previously reported procedure.21  
 
 
 
Scheme 5. Synthetic procedure for preparation of maleimido decorated CNOs. 
 
 
Ox-CNOs were prepared from raw CNO material (p-CNO) through thermal annealing and subsequent 
oxidation by reflux heating in 3 N HNO3. The carboxylic groups of ox-CNOs (80 mg) were amidated with 
4,7,10-Trioxa-1,13-tridecanediamine (15 mL) in dry DMF (15 mL) by water-soluble EDC HCl (152 mg, 0.79 
mmol), NHS (50 mg, 0.43 mmol) and DMAP (50 mg, 0.41 mmol) stirring the ox-CNOs under reflux at 140°C 
for 4 days. After the complexation, the CNOs were filtered off on a nylon filter membrane (pore size 0.2 ȝm) 
and washed with water, methanol and acetone. 163 mg PEG-CNO were recovered as black powder after 
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drying over night at RT. 20 mg of PEG-CNOs were solubilized in dry DMF (5mL) and 120 mg of maleic 
anhydride were added. The solution was sonicated for 20 min, heated at 75 °C for 2 h and let it stirred at 
room temperature for 16 h. The reaction was filtered on nylon filter 0.2 µm and washed with DMF and THF to 
get rid of the unreacted compounds. The surface chemical composition at the different stages of the CNOs 
functionalization was probed by TGA analysis (Figure 8A). For each surface modification step, a variation in 
weight loss of combustible organics is clearly observed. Further confirmation of surface composition was 
achieved using ATR-FTIR analysis where clear evidence of COOH stretching was observed at 1750 cm -1 for 
ox-CNO and at 1172 cm for CO stretch of the PEG groups. Evidence for the introduction of the maleimido 
moiety was provided by NMR analysis of the Mal-CNO that showed a strong signal for the maleimide C-H at 
5.97 ppm.  
 
3.2.8 Gly-CNO synthesis 
With the Mal-CNO in hand, the ligation of a synthetic cysteine containing glycopeptide onto the CNOs has 
been investigated. The structure of the glycopeptide was based on our previously reported ala-cys-ala-cys 
tetrapeptide core.22 The glycopeptide was prepared through a sequential native chemical ligation, thiol-ene 
click (NCL-TEC) approach. A protected galactose reside was S-linked onto the peptide backbone using a 
thiol-ene ligation reaction between a cysteine residue and a modified glycan displaying a terminal alkene 
residue at the anomeric position. A second cysteine residue was subsequently introduced through native 
chemical ligation to provide a reactive moiety for subsequent maleimido coupling. The glycopeptide was 
modified at the C-terminus with a short, fluorescein labelled PEG-group to furnish the fluorescently labelled 
glycopeptide. The coupling reaction was carried out using DIC/HOBt mediated conditions which are 
compatible with the sulfhydryl group. The glycopeptide was purified by column chromatography and fully 
characterized by NMR and mass spec analysis prior to maleimido coupling. With the fluorescent 
glycopeptide in hand, the Michael addition reaction between the CNOs bearing maleimido moieties and the 
fluorescent glycopeptide was investigated (Scheme 6). Importantly, the glycopeptide was first treated with a 
phosphine reducing agent to reduce unreactive disulfides.  
 
 
Scheme 6. Ligation reaction between synthetic glycopeptide 3 and Mal-CNO. 
 
At this stage, Mal-CNO was treated at pH 7.4 with the fluorescent glycopeptide. 10 mg of Mal-CNO were 
dispersed in dry DMF (4mL) and 20 mg of fluorescently labelled glycopeptide were added. The reaction was 
stirred for 16 h at room temperature in the dark. The modified CNOs were filtered off on a nylon filter 
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membrane (pore size 0.2 ȝm) and washed with MeOH and Acetone. The resulting material was re-dispersed 
in MeOH, filtered again and centrifuged in MeOH to wash out any non-covalently bound species (Scheme 6). 
 
3.2.9 BSA-CNO synthesis 
As discussed in the introduction, covalent modification of nanomaterials with proteins represents an effective 
method for modifying biocompatibility. In order to investigate the maleimide mediated ligation methodology 
for covalent protein modification, we investigated the ligation reaction of Mal-CNO with the BSA-FITC. Mal-
CNO was treated with BSA-FITC for 16 h at pH 7.4 in buffer. On completion of the ligation reaction, the 
solution was filtered on nylon and washed with MeOH and acetone. The BSA-CNO was re-dispersed in 
MeOH, filtered again and centrifuged three times in MeOH to wash out the unbound species (Scheme 7).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Ligation reaction between BSA-FITC and Mal-CNO. 
 
At this stage, Mal-CNO was treated at pH 7.4 with the fluorescent BSA. 10 mg of Mal-CNO were dispersed in 
dry DMF (4mL) and 20 mg of BSA were added. The reaction was stirred for 16 h at room temperature in the 
dark. The modified CNOs were filtered off on a nylon filter membrane (pore size 0.2 ȝm) and washed with 
MeOH and Acetone. The resulting material was re-dispersed in MeOH, filtered again and centrifuged in 
MeOH to wash out any non-covalently bound species (Scheme 7). 
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3.3 Results and Discussion 
3.3.1 Absorption and Emission Spectroscopy 
Once the fluorescent labelled glycopeptide 3 had been synthetized and fully characterized, emission and 
absorption studies have been performed and the molar extinction coefficient estimated. The fluorescent 
labelled glycopeptide 3 have been dissolved in DMSO at 3.63 x 10-4 M and diluted to a final concentration of 
3.63 x 10-6 M, 7.27 x 10-6 M, 7.27 x 10-6 M, 1.09 x 10-5 M, 1.45 x 10-5 M and 3.63 x 10-5 M. Upon 
photoexcitation at 520 nm of a dispersion of fluorescent labelled glycopeptide 3 in DMSO, an intense 
emission band was observed with a maximum centered at 542 nm (Figure 3, top). Because the graph shows 
that the maximum of fluorescence above a concentration of 10 ȝg mL-1 reaches a steady state probably due 
to intramolecular interactions and the tendency of aggregation of the glycopeptide, lower concentrations of 
the fluorescent labelled glycopeptide 3 have been prepared. According to this, the fluorescent labelled 
glycopeptide 3 have been dissolved in DMSO at 3.63 x 10-4 M and diluted to a final concentration of 7.27 x 
10-7 M, 1.45 x 10-6 M, 2.91 x 10-6 M, 3.63 x 10-6 M, 4.36 x 10-6 M, 5.81 x 10-6 M, 7.27 x 10-6 M. Interestingly, 
the fluorescent labelled glycopeptide 3 shows a linear correlation for all the concentrations used for both 
absorption and emission studies (Figure 3, bottom). Furthermore, absorbance and fluorescence studies have 
been studied in DMEM white in order to evaluate the physio-chemical properties of the molecule in biological 
environment. Upon photoexcitation at 490 nm of the fluorescent labelled glycopeptide 3 in DMEM, an intense 
emission band was observed with a maximum at 516 nm and a linear correlation for all the concentrations 
used was still found. 
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3.3.2 Absorption studies of the fluorescent glycopeptide 3   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Absorption studies of fluorescent labelled glycopeptide 3 at a concentration of 5, 10, 15, 20 and 50 
ȝg mL-1 in DMSO (top) and 1,2,4,5,6,8 and 10 ȝg mL-1 in DMSO (bottom). 
Figure 4. Absorption studies of fluorescent labelled glycopeptide 3 at a concentration of 1, 2, 5, 6 and 10 ȝg 
mL-1 in DMEM phenol red free. 
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3.3.3 Emission studies of the fluorescent glycopeptide 3  
 
Figure 5. Emission studies of fluorescent labelled glycopeptide 3 at a concentration of 5, 10, 15, 20 and 50 
ȝg mL-1 in DMSO (top) and 1,2,4,5,6,8 and 10 ȝg mL-1 in DMSO (bottom). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Emission studies of fluorescent labelled glycopeptide 3 at a concentration of 1, 5, 6, 8 and 10 ȝg 
mL-1 in DMEM phenol red free. 
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3.3.4 (FT-IR)  
FT-IR spectroscopy shows the characteristic stretching and vibration bands of the fluorescent labelled 
glycopeptide (Figure 7). In particular, the OH at 3305 cm-1, amide A (mainly –NH stretching vibrations) at 
2966 cm-1, amide I (mainly C=O stretching vibrations) at 1640 cm-1, and amide II (the coupling of bending 
vibrate of N-H and stretching vibrate of C-N) bands at 1559 cm-1. 
Figure 7. FTIR spectroscopy of synthetic glycopeptide 3. 
 
3.3.5 Confocal Microscopy  
A preliminary cell-uptake study was carried out using the MCF-7 cell line (human breast adenocarcinoma). In 
order to explore the ability of the synthetic glycopeptide to enter MCF-7 cells, confocal live cell imaging was 
carried on. MCF-7 cells grown in subconfluent monolayer on a glass slide were treated with a dispersion of 
fluorescently labelled glycopeptide in DMEM at concentrations 20 µg mL−1. After 24 h of incubation at 37 °C, 
the cells were carefully rinsed with fresh media to remove the excess of fluorescent glycopeptide and treated 
with Hoechst 33342, for live nuclear staining and WGA 594 for red plasma membrane labelling. The cellular 
uptake characteristics of the fluorescent glycopeptide are shown in Figure 8.Confocal imaging revealed that 
the synthetic glycopeptide was efficiently uptaken by MCF-7 cells with the distinct spot-like regions in the 
cytosol indicative of lysosomal localization following cellular uptake (Figure 8). Furthermore, sequential 
optical sections (Z-stacks), 1 ȝm thickness, from the basal-to-apical surfaces of the cells were acquired to 
study the cellular internalization and distribution. Although the glycopeptide could undergo endocytosis in the 
absence of the nano-particle, the ability to deliver the covalently bound substrates into cancer cells offers 
fascinating prospects for controlled release and immunotherapy applications. 
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Figure 8. Confocal images of MCF-7 cells incubated with fluorescein-functionalized glycopeptide 3 at a mass 
concentration of 20 µg mL-1 for 24 h. Nuclei are stained with Hoechst 33342 (blue), the presence of 
glycopeptide 3 is indicated by the green fluorescence signal. Hoechst 33342 (A), Green FITC signal (B), 
WGA 594 (C) merged images (D). Scale bars A-H= 25 µm. 
 
3.3.6 Glycopeptide-CNO conjugate characterization 
Evidence for the successful covalent modification of Mal-CNO with the fluorescent glycopeptide was 
provided by NMR, ATR-FTIR, TGA, UV-spectroscopy and emission analysis. In the HR-MAS NMR spectrum 
of the conjugate, peaks corresponding to the methyl groups of the alanine residues, Boc protecting group, 
acetyl group, PEG and FITC moieties are clearly visible. FTIR analysis of the Gly-CNO sample shows the 
characteristic vibration bands of broad O-H centred at (3285 cm-1), N-H (2940 cm-1), S-H (2861 cm-1), C=O 
and amides (1720, 1639, 1536 cm-1), C=S (1368 cm-1), COC (1056 cm-1), (Figure 9,C). TGA performed in air 
shows thermal decomposition of surface organics at 330°C and at 430°C respectively, followed by the 
decomposition of the CNOs core at 510°C (Figure 9, A). The emission properties of the Gly-CNOs were 
investigated under physiological conditions. Upon photoexcitation at 490 nm in biological medium (DMEM) 
without phenol red, an intense emission band was observed with a maximum centered at 518 nm (Figure 9, 
D). The result is in comparison with the emission of the free glycopeptide (Ȝem = 516 nm) suggesting a similar 
mico-environment surrounding the fluorophores once the biomolecules are anchored on the surface of the 
CNOs. The concentration of glycopeptide in a 10 ȝg mL-1 dispersion of Gly-CNO was determined to be about 
4.6 x 10-6 M by absorption (Figure 9, B).  
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Figure 9. Characterization of the functionalized Gly-CNO. (A) Thermogravimetric analysis of p-CNO (black), 
ox-CNO (blue), PEG-CNO (red) and Gly-CNO (green). All experiments were run in air with a temperature 
rate of 10 °C min−1. (B) Absorption spectra of Gly-CNO (solid line) and fluorescent labelled glycopeptide 3 
(dotted line) in DMEM phenol red free at a concentration of 10 ȝg mL-1. (C) ATR-FTIR spectra of Gly-CNO 
using germanium crystals and 256 scans. (D) Emission spectra (Ȝexc = 490 nm) of fluorescent labelled 
glycopeptide 3 (dotted line) and Gly-CNO (solid line) in DMEM at a concentration of 10 ȝg mL-1.  
 
The kinetic of aggregation and the size of the clusters formed were investigated by dynamic light scattering 
(DLS). DLS measurements were performed on the CNO samples dispersed in water. The hydrodynamic 
diameter was found to be 236 ± 4 and 325 ± 6 respectively for PEG-CNOs and Gly-CNOs at a concentration 
of 5 µg mL-1 (Figure 10). Furthermore, Z-potential measurements of PEG-CNO and Gly-CNO samples were 
performed in phosphate buffer 0.01 M at pH 7.4. Under these conditions the zeta potentials for the PEG-
CNO was found to be −28.1 mV ± 1 mV, independently of the concentration used. Interestingly, after the 
glycopeptide ligation, the Z-potential has been found to be -36 ± 1 mV for Gly-CNOs indicating that the 
biomolecules have a significant effect on the colloidal stability of the nanoparticles (Figure 10). Indeed, 
nanoparticles with Zeta Potential values above 25mV (either positive or negative) have high degrees of 
stability. The repulsion forces originating from the Gly-CNO surface charges prevent the particles from 
aggregations whereas nanoparticles with a low zeta potential value could aggregate due to Van Der Waal 
inter-particle attractions.23  
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Figure 10. DLS of PEG-CNO (red) and Gly-CNO (green) at a concentration of  5 µg ml-1 in  water (left) and 
Z-potential measurement of PEG-CNO (red) and Gly-CNO (green) at a concentration of  10 µg ml-1 in 
phosphate buffer 0.01 M at pH 7.4 (right). 
 
3.3.7 BSA-CNO conjugate characterization 
Evidence for the successful covalent modification of Mal-CNO with BSA-FITC was provided by ATR-FTIR, 
TGA, UV-spectroscopy and emission analysis. Strong stretching vibrations were recorded for BSA-CNO. The 
main peaks show the stretching vibration of OH at 3293 cm-1, amide A (mainly –NH stretching vibrations) at 
2937 cm-1, amide I (mainly C=O stretching vibrations) at 1636 cm-1, and amide II (the coupling of bending 
vibrate of N-H and stretching vibrate of C-N) bands at 1573 cm-1. TGA performed in air displays the thermal 
decomposition of surface-bound organics at 280 °C and at 440 °C, followed by the decomposition of the 
CNOs core at 720 °C (Figure 11, A). Furthermore, upon photoexcitation at 490 nm in biological medium 
(DMEM) without phenol red, an intense emission band was observed with a maximum at 518 nm (Figure 11, 
D). The result is in comparison with the emission of the free BSA-FITC (Ȝem = 518 nm) suggesting a similar 
micro-environment surrounding the fluorophores once the biomolecules are anchored on the surface of the 
CNOs. The results are in close agreement with the Gly-CNO discussed above. The concentration of the BSA 
in a 10 ȝg mL-1 dispersion of BSA-CNO was determined to be about 1.7 x 10-4 M. 
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Figure 11. Characterization of the functionalized BSA-CNO. (A) Thermogravimetric analysis of p-CNO 
(black), ox-CNO (blue), PEG-CNO (red) and BSA-CNO (green). All experiments were run in air with a 
temperature rate of 10 °C min−1. (B) Absorption spectra of BSA-CNO (solid line) and BSA-FITC (dotted line) 
in DMEM phenol red free at a concentration of 10 ȝg mL-1. (C) ATR-FTIR spectra of BSA-CNO using 
germanium crystals and 256 scans. (D) Emission spectra (Ȝexc = 490 nm) of BSA-FITC (dotted line) and 
BSA-CNO (solid line) in DMEM at a concentration of 10 ȝg mL-1. 
 
The hydrodynamic diameter was found to be 236 ± 4 and 705 ± 70 nm for PEG-CNOs and BSA-CNOs 
respectively at a concentration of 5 µg mL-1 (Figure 12). Because the DLS measures the scattered intensity 
over a range of scattering angles for a given time, it is notable that when the density of the protein is high, 
the strong influence of bioconjugate interactions becomes important. Despite that, after the bioconjugation 
the Z-potential has been found to be -35 ± 2 (Figure 12). These observations are consistent with the results 
demonstrated for Gly-CNO. 
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Figure 12. DLS of PEG-CNO (red) and BSA-CNO (green) at a concentration of 5 µg ml-1 in water (left) and Z-
potential measurement of PEG-CNO (red) and Gly-CNO (green) at a concentration of 10 µg ml-1 in 
phosphate buffer 0.01 M at pH 7.4 (right). 
 
3.3.8 Absorption and Emission Spectroscopy 
Absorption and emission studies have been performed on both Gly-CNO and BSA-CNO in DMEM. CNO 
samples have been dissolved in DMEM at 0.5 mg mL-1 and diluted to a final concentration of 5, 10, 15, 20 
and 50 ȝg mL-1. Upon a photoexcitation at 490 nm of a dispersion of Gly-CNO in DMEM, an intense 
emission band was observed with a maximum at 514 nm (Figure 14). Similarly, upon a photoexcitation at 
490 nm of a dispersion of BSA-CNO in DMEM, an intense emission band was observed with a maximum at 
516 nm (Figure 15). Interestingly, for both samples has been observed a linear correlation for all the 
concentrations used suggesting a good stability of the nano-carriers in biological media. Figure 13 shows a 
UV-visible spectrum for ox-CNO in DMEM-phenol red free as a comparison. 
 
 
Figure 13. Absorption spectra of ox-CNO at 5, 10, 20 and 50 ȝg mL-1 in DMEM-phenol red free. 
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3.3.9 Absorption and emission studies of Gly-CNO  
  
 
 
 
 
 
Figure 14. Absorption (top) and Emission spectra (Ȝexc = 490 nm) of Gly-CNO at 5, 10, 15, 20 and 50 ȝg 
mL-1 in DMEM-phenol red free. 
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3.3.10 Absorption and emission studies of BSA-CNO  
 
 
 
 
 
Figure 15. Absorption (top) and Emission spectra (Ȝexc = 490 nm) of BSA-CNO at 5, 10, 15, 20 and 50 ȝg 
mL-1 in DMEM-phenol red free. 
 
 
300 400 500 600 700
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
Ab
so
rb
an
ce
 
In
te
ns
ity
 [a
.
u
.]
Wavelength [nm]
 5 mg mL-1
 10 mg mL-1
 15 mg mL-1
 20 mg mL-1
 50 mg mL-1
0 10 20 30 40 50
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Ab
so
rb
an
ce
 
In
te
ns
ity
 @
 4
95
 n
m
Concentration [mg mL-1]
500 550 600 650 700 750
0
200000
400000
600000
800000
1000000
Fl
uo
re
sc
en
ce
 
In
te
ns
ity
 [a
.
u
.]
Wavelength [nm]
 5 mg mL-1
 10 mg mL-1
 15 mg mL-1
 20 mg mL-1
 50 mg mL-1
0 10 20 30 40 50
200000
400000
600000
800000
1000000
Fl
uo
re
sc
en
ce
 
In
te
ns
ity
 @
 5
18
 n
m
Concentration [mg mL-1]
82 
 
3.3.11 Cell Studies: Toxicity 
The cytocompatibility of the functionalized CNOs is a key consideration for their biomedical application. The 
cytotoxicity of the different CNO conjugates, ox-CNO, Gly-CNO and BSA-CNO, were tested on MCF-7 
(human breast adenocarcinoma cell line) cells. The cells were treated with a suspension of the CNO at two 
different concentrations (10 and 20 ȝg ml-1) and the metabolic activity was assessed at three different 
incubation times (24, 48 and 72 h), (Figure 16). The viability of the MCF-7 cells was evaluated by 
PrestoBlueTM Cell Viability Reagent. The data showed no significant differences in the cell metabolic activity 
between the ox-CNOs and those covalently modified with biomolecules. The viability of MCF-7 cells treated 
with Gly-CNO at both 10 and 20 µg mL-1 was found to be more than 80% at all three timepoints. Data for the 
BSA-CNO conjugate presented very similar results, albeit with reduced viability observed at the lower 
concentration. It is well known that modification of nanomaterials with proteins can offer improved 
biocompatibility over the bare carbon nanomaterial. What is particularly noteworthy in our findings is that the 
small glycopeptide conjugate appears to offer an improved biocompatibility that is comparable to that of the 
larger BSA protein, suggesting a key role for small synthetic peptides and glycopetides in the development of 
nano-therapeutics. The results obtained are in good agreement with the previous biological studies made 
with other carbon nano-materials, in particular CNTs. Muzi and colleagues have demonstrated a high 
sensitivity to pristine SWCNTs in different cell lines and an attenuated behavior when the CNTs were coated 
with different types of blood protein, including BSA.24 Holt and collaborators showed not only how BSA 
stabilized SWCNTs but also how it could be readily taken up by different cell lines without apparent acute 
lethal effects.25,26 
 
 
 
  
 
Figure 16. Cellular viability of MCF-7 cells after exposure to  ox-CNO, Gly-CNO and BSA-CNO at a 
concentration of 10 µg ml−1 and 20 µg ml−1 for 24, 48 and 72 h. The viability was evaluated for the samples 
of CNOs against a non-treated control. 
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3.3.12 Cell Studies: Cellular Uptake 
Uptake is an important consideration in the design of nanotherapeutics, because this will have a direct 
influence on the therapeutic load, and hence the appropriate dose, entering the cells. Variations in the 
physical properties of the nanoparticles, as well as differences in the cellular membrane characteristics, can 
affect the efficacy of the uptake process.27 Accordingly, nanoparticle size is a major determinant of cellular 
uptake with approximately 50 nm in diameter being optimum for non-phagocytic cells.27 Various ligands 
(proteins or peptides) can be used to enhance cellular uptake. For example, the HIV-derived TAT peptide is 
a well-recognized cell penetrating peptide, which can be used to facilitate cellular entry.28,29 The surface 
charge of the nanoparticle has influence on whether or not it can cross the negatively charged cell 
membrane,9 whereby increasing the overall surface charge of the nanoparticle can result in increased uptake 
across cellular membranes.27 Mechanisms of cellular internalization of nanoparticles include phagocytosis, 
macropinocytosis, caveolar-mediated endocytosis, or clathrin-mediated endocytosis.8 The size of the 
nanoparticle also determines the mechanism by which nanoparticles enter the cells and where it 
subsequently localizes intracellularly.3 It has recently been demonstrated that the shape of nanoparticles is 
also a determining factor of the mechanism of uptake.30,31,32,33,34 Therefore, knowledge of both of these 
aspects is invaluable in the engineering of nanoparticles targeted to specific microenvironments. Moreover, 
there is a strong relationship between the mode of particle uptake and the size of the particles themselves. 
Particles with small diameters (<200 nm) are taken up primarily via receptor-mediated endocytosis, while 
particles with larger diameters (>500 nm) are traditionally taken up by phagocytosis or micropinocytosis. 
 
A preliminary cell-uptake study was carried out using the MCF-7 cell line. In order to explore the ability of the 
nano-conjugates to enter MCF-7 cells we performed confocal live cell imaging. MCF-7 cells were incubated 
for 24 h at 37 °C in the presence of 20 ȝg mL-1 of fluorescently labelled glycopeptide 3 and Gly-CNO. 
Confocal imaging revealed that both Gly-CNO and compound 3 were efficiently uptaken by MCF-7 cells with 
the distinct spot-like regions in the cytosol indicative of lysosomal localization following cellular uptake 
(Figure 17). Although the glycopeptide could undergo endocytosis in the absence of the nano-particle, the 
ability to deliver the covalently bound substrates into cancer cells offers facinating prospects for controled 
release and imunnotherapy applications. Given the numerous biological applications associated with 
synthetic glycopeptides, the ability to transfer these compounds into the cells using nano-platforms offers 
fascinating prospects for the development of these compounds as nanotherapeutics. 
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Figure 17: Confocal images of MCF-7 cells incubated with fluorescent labelled synthetic glycopeptide 3 (top 
panel) and Gly-CNO (bottom panel) at a concentration of 20 µg mL-1 for 24 h. Nuclei are stained with 
Hoechst 33342 (blue), the presence of synthetic glycopeptide 3 and Gly-CNO is indicated by the green 
fluorescence signal. Hoechst 33342 (A), Green FITC signal (B), WGA 594 (C) merged images (D). Scale 
bars A-H= 25 µm. 
 
3.4 Conclusion 
In summary, we have developed a versatile ligation approach for the covalent modification of CNOs 
employing chemoselective cysteine addition onto CNO bound maleimide residues. Both synthetic 
glycopepides and native BSA protein were found to be compatible with these conditions. Covalently modified 
CNOs have been chemically and physically characterized by HR-MAS, infrared and fluorescence 
spectroscopy, FTIR, TGA, dynamic light scattering (DLS) and zeta potential measurements. The high 
biocompatibility and the efficient cellular uptake of these nanomaterials together with their high fluorescence 
reveal great promises for the development of new architectures for targeted imaging nanotherapeutics and 
antigen delivery devices. Of particular interest is the finding that a small glycopeptide conjugate appears to 
offer comparable biocompatibility to that of the larger BSA protein. This finding offers fascinating prospects 
for the development of biocompatible nano-materials, decorated with highly-defined synthetic peptides and 
glycopeptides as novel therapeutics. Furthermore, good functionalizations on the surface of CNOs could 
envisage the realization of multi stimuli-responsive and dynamic materials capable of changing their 
physicochemical behavior upon encountering specific micro-environmental signals becoming relevant for 
diagnosis, imaging and therapies of specific disease applications. 
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4. CNO for Photodynamic Therapy 
 
4.1 Introduction 
Photodynamic therapy (PDT) is a clinically approved therapeutic technique for the treatment of multiple 
diseases, mainly cancer.1 It relies on the photoexcitation of an inactive photosensitizer (PS) at a wavelength 
that matches the absorption of the PS, leading to localized generation of cytotoxic reactive oxygen species 
(ROS). ROS cause oxidative damage to nearly all types of biomolecules (proteins, lipids and nucleic acids) 
and tumor cell death. PDT has remarkably improved selectivity and fewer side effects than traditional 
anticancer therapies. The photocytotoxic effects, which are utilized in PDT, are initiated by the absorption of 
light by a photosensitizer. A molecule that has absorbed a light quantum is excited to the first or higher 
excited states (Figure 1). The higher excited states are dissipated very rapidly (picoseconds) down to the first 
excited singlet state with a lifetime of the order of nanoseconds. This excited state can be deactivated by 
release of heat (non-radiative decay), emitted as fluorescence of a wavelength equal to or longer than that of 
the excitation light (utilized for cancer diagnosis) or undergo intersystem crossing (ISC). Photochemistry may 
occur from the first excited singlet state, but usually with low probability owing to the short life-time of this 
state. ISC is usually forbidden, but macrocyclic molecules with conjugated double bond systems (π-electron 
system) are exceptions and allow for ISC to long-lived (microseconds to milliseconds) triplet states. The 
triplet state may react in two ways, either by a type I mechanism involving electron or hydrogen atom transfer 
from one molecule to the other or by a type II mechanism involving energy transfer to molecular oxygen. 
Both mechanisms may occur simultaneously and their relative importance depends on the surroundings and 
the nature of the substrate molecules. Singlet oxygen causes mainly cell membrane damage by oxidizing 
amino acids (tryptophan, cysteine, histidine, methionine and phenylalanine), unsaturated fatty acids and 
cholesterol. Additionally, guanine may also be oxidized by singlet oxygen. 
Once dioxygen is in its singlet excited state, it can be deactivated by other species to return to its ground 
state. This quenching can take place in two major ways: 
1) Physical quenching: in which the interaction leads only to deactivation of singlet oxygen with no O2 
consumption or product formation 
2) Chemical quenching: where the quencher reacts with singlet oxygen to give a new product. This active 
species could oxidize substrates that were unaffected by oxygen in its normal energy state. Oxygen is ca. 1 
V more oxidizing in its singlet excited state and is therefore significantly more electrophilic, reacting rapidly 
with unsaturated carbon/carbon bonds, neutral nucleophiles such as sulfides and amines, and as well as 
with anions. Each photosensitizer molecule can typically produce 103/105 molecules of 1O2 before being 
degraded through photobleaching by 1O2 or by some other process. 
Singlet oxygen (1O2), the lowest excited state of molecular oxygen, is a fascinating species in many ways. Its 
chemistry differs significantly from that of ground state triplet oxygen. Singlet oxygen readily reacts with a 
wide range of biological and organic materials which leads to their alteration and degradation. Arguably the 
most important way of singlet oxygen formation is the so-called photosensitizing process: A light excited 
molecule of an appropriate dye - so called photosensitizer (PS) - transfers energy to molecular oxygen giving 
rise to singlet oxygen. Singlet oxygen is involved in a rich variety of diverse biochemical processes, such as 
photosynthesis, cell signaling, immune responses or polymer degradation. 
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Figure 1. The diagram shows the electronic states following absorption of light by a photosensitizer. The blue 
arrow indicates the excitation of the photosensitizer to the excited singlet states (1PS*). The other arrows 
indicate alternative pathways for dissipation of the energy in the excited state. ISC, intersystem crossing; 
3PS, the sensitizer in the triplet state. F, fluorescence; Ph, phosphorescence. 
 
4.1.1 Carbon Nanomaterials for Photodynamic Therapy 
Fullerenes such as C60 and C70 have been used as photosensitizers with a high efficiency of generating 
reactive oxygen species,2 allowing for efficient photodynamic therapy using fullerenes without the need to 
load additional photosensitizing molecules. Ground state, singlet fullerene can be photoexcited to a short-
lived triplet state, which transfers its energy to molecular oxygen in its triplet state, resulting in a series of 
reactive oxygen species including singlet oxygen and oxygen radicals. Hamblin et al. reported photodynamic 
therapy using N-methylpyrrolidinium-fullerene for the treatment of colon adenocarcinoma by intraperitoneal 
injection of the functionalized fullerene into the abdomen of the tumor-bearing mice, and found significantly 
slowed tumor growth compared to the control group.3 Besides photodynamic treatment of tumor, the same 
group also reported the use of functionalized C60 fullerene as a broad-spectrum antimicrobial 
photosensitizer, which cures fatal wound infections under white light illumination in a mouse model.4 Kim et 
al.5 reported the synthesis of chitosan/fullerene nanogel for an efficient tumor therapy. At pH 7.4, 
electrostatic interactions between the pendant carboxylic acid groups of 2,3-dimethylmaleic acid (DMA) and 
the residual free amine groups of glycol chitosan (GC) resulted in the formation of multinanogel aggregates. 
Nevertheless, dissociation of the nanogel aggregates was observed at pH 5.0, resulting in improved singlet 
oxygen generation and elevated photodynamic tumor cell ablation.5 The unique property of fullerenes in the 
efficient conversion from photons to reactive oxygen species has made fullerene derivatives competitive 
photosensitizers for PDT applications in vivo animal and even preclinical settings.6 Lee et al. reported the 
synthesis of PEGylated SWCNTs loaded with a common photosensitizing drug, Chlorin e6 (Ce6), for PDT-
based tumor treatment in mice.7 It has also been reported by Tan et al. that the nanotube−photosensitizer 
complex can act as a “smart” PDT agent with molecular specificity. In this study, SWCNTs were used to 
quench singlet oxygen generation of the photosensitizer molecules, until the photosensitizer molecules were 
released from the backbone of SWCNTs in the presence of a specific molecular target.8 Carbon nanotubes 
are known to strongly quench fluorescence of nearby molecular fluorophores and it was proposed that 
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photosensitizing molecules could be quenched in a similar fashion when in close proximity to the carbon 
nanotube surface. After conjugating an aptamer that recognized thrombin to the photosensitizer, Ce6, 
carbon nanotubes, and the aptamer-conjugated photosensitizer were mixed, leading to extremely high 
quenching of 98%. After the introduction of thrombin, a large increase in singlet oxygen generation was 
observed, indicating that the thrombin-recognizing aptamer− photosensitizer conjugate disassociated from 
the carbon nanotube and allowed recovery of photodynamic efficiency of Ce6. This approach has many 
significant benefits, namely that the generation of the cytotoxic reactive oxygen species is only produced 
after exposure to a particular target, resulting in a “smart” PDT agent that can be specifically turned on or off 
via selective molecular recognition and may have enhanced efficacy with mitigated toxicity to normal tissue.8 
By taking advantage of the ultrahigh loading of molecules through π−π stacking, nanoGO has been used to 
deliver photosensitizers in vitro at high concentrations.9 The same photosensitizer molecule as used in 
previous studies involving SWCNTs, Ce6 was used and loaded onto the PEGylated and well-dispersed 
nanoGO sheets through the supramolecular π−π stacking. The GO−PEG−Ce6 conjugate demonstrated 
excellent serum stability and elevated cytotoxicity after irradiation. While the production of singlet oxygen 
species was slightly diminished by the presence of the quenching graphene surface (10−15% of free Ce6) in 
a similar fashion as reported in the previous study with carbon nanotubes,8 many more surface defects are 
found in graphene oxide, which appears to be much less efficient at absorbing energy than carbon 
nanotubes. To this end, photodynamic therapy was still readily feasible utilizing nanoGO, evidenced by the 
large population of dead cells after incubation with GO−PEG−Ce6 conjugate and laser irradiation at 660 nm. 
 
4.1.2 Inhibited phototoxicity of a carbon nano-onion immobilized diiodo-BODIPY 
photosensitizer 
Photodynamic therapy is a non-invasive methodology for the treatment of malignant tumors and age related 
macular degeneration.10 More recently, a significant cardiovascular potential for PDT was also 
demonstrated.11 The treatment in general involves systemic administration of a photosensitizer. The 
sensitizer lingers longer in tumor tissues due to what is known as enhanced permeation and retention (EPR). 
Then, irradiation of the tumor tissues with preferably red light (due to its higher tissue permeability) excites 
the sensitizer, which should undergo an intersystem crossing before it excites dissolved ground state oxygen 
to generate highly reactive and (hence) cytotoxic singlet oxygen. While porphyrins are the most commonly 
used PDT sensitizers, there are many potential candidates for this role, most with impressive characteristics, 
such as strong absorption of red to near IR light, efficient generation of singlet oxygen, high chemical stability 
and availability in a pure, single isomeric state. Two classes of dyes recently added to the growing arsenal of 
potentially useful PDT sensitizers are Bodipy12 derivatives and perylenediimides.13 BODIPY dyes (Boron 
complexes of dipyrromethenes), have been established as suitable fluorophores for several applications due 
to their synthetic versatility, high photostability and bright fluorescence emission.14,15,16 Based on the multiple 
possibilities to synthetically modify the BODIPY fluorophore, the tuning of the excited state properties of 
BODIPY dyes towards efficient triplet photosensitizers can be realized by the introduction of iodo-
substituents on the BODIPY core.14,17 In the biomedical field, the application of BODIPY dyes as singlet 
oxygen sensitizers for the photodynamic therapy (PDT) has emerged as one significant therapeutical 
approach for cancer treatment.18,19,20 Furthermore, the photodynamic inactivation of microbes, fungi and 
viruses by iodo-substituted BODIPY derivatives was demonstrated and found to be dependent on the 
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photosensitizer dose and on the light source exposure, which can be specifically modulated to trigger the 
eradication of the bacterial strains.21 Thus, Bodipy derivatives are especially interesting as these 
chromophores are easily derivatized to suit many applications.15,22 Previously, it was shown that iodine or 
bromine substitution on the Bodipy nucleus enhanced intersystem crossing, and a few promising sensitizers 
for use in photodynamic therapy have been reported in the last few years.23 An important issue with regard 
to photodynamic therapy agents is the delivery of these molecules into the organs/tumor tissues/tissues 
cells. There are many strategies for drug targeting, but a satisfactory multifunctional delivery agent is 
nevertheless needed. In this work, we report the synthesis of a novel pyrene-BODIPY dye acting as an 
efficient photosensitizer for photodynamic therapy and combine it with a CNO based delivery vector. The 
photosensitizer as well as the pyrene-iodo-BODIPY/CNO nanohybrids were characterized by optical 
spectroscopies. Moreover, the cellular uptake by HeLa cells and the photodynamic efficiency of the dye and 
the corresponding nanohybrids was investigated. The surprising finding of suppressed photodynamic 
efficiency of BODIPY/CNO nanohybrids is described and the recovery of the phototoxicity upon disruption of 
the nanohybrids is discussed. This report represents the first approach of CNM based molecular shuttles for 
a tunable delivery of hydrophobic BODIPY photosensitizer, including in vitro studies. 
 
 
4.2 Experimental 
4.2.1 Synthesis of the pyrene-diiodoBODIPY dye 
The synthesis of the pyrene-diiodoBODIPY dyad 3 was accomplished by a Huisgen type “click” reaction of a 
propargylated diiodo-BODIPY and 1-(azidomethyl)pyrene (Scheme 1). Despite previously reported non-
iodated pyrene-BODIPY dyad,24 the “click” reaction failed in the presence of catalytic amounts of CuI and 
sodium ascorbate. However, an excess of CuI and triethylamine, without ascorbate, led to the desired 
compound 3. Following this, 3 was immobilized on the surface of pristine CNOs by ultrasonication. The 
solution was filtered and the excess of dye was removed using our established protocol leading to 3/CNO. 
Additional experiments were carried out with benzoic acid functionalized CNOs (3/benz-CNO) in order to 
study the influence of different CNO surface modifications. Benz-CNOs were prepared based on our 
previous reports.24,25 
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Scheme 1. Synthesis of diiodo-BODIPY photosensitizer 3.  
 
 
 
 
 
 
 
1.
2.
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4.2.2 Synthesis of 4-(prop-2-ynyloxy)benzaldehyde 
 
 
 
 
4-Hydroxybenzaldheyde (2.44 g, 20 mmol) and K2CO3 (3.88 g, 28 mmol) were dissolved in acetone 
(100mL). The reaction mixture was refluxed for 30 min at 76 C°, then propargyl bromide 80% in toluene 
solution (5.11 mL, 6.824 g, 57.4 mmol) was added and refluxed at 132°C. The reaction was refluxed until all 
4-hydroxybenzaldehyde consumed (TLC 1:1 Hex/EtOAc). After 1 hour, the reaction mixture was filtered 
through a pad of silica and the solvent removed under reduced pressure to provide the desired compound as 
a light brown solid (96 % yield). 1H NMR (400 MHz, CDCl3) δ λ.λ0 (s, 1H), 7.λ3 – 7.74 (m, 2H), 7.14 – 7.00 
(m, 2H), 4.78 (d, J = 2.4 Hz, 2H), 2.59 (t, J = 2.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 1λ0.7λ (s), 162.37 
(s), 131.89 (s), 130.58 (s), 115.18 (s), 114.87 (s), 77.50 (d, J = 16.2 Hz), 77.10 (s), 76.78 (s), 76.42 (s), 55.95 
(s) HRMS (ES+) m/z calcd for C10H8NaO2 [M + Na]+ 183.0422, found 183.0422 
 
4.2.3 Synthesis of 1,3,5,7-Tetramethyl-8-(4-Propargyloxyphenyl)-4,4-
difloroboradiaza-s-indacene 
 
 
 
 
 
 
 
4-(prop-2-ynyloxy)benzaldehyde (752 mg, 4.7 mmol) and 2,4-dimethylpyrrole (900 mg, 9.6 mmol) were 
dissolved in a deoxygenated solution of dichloromethane (280mL) and absolute ethanol (20mL). After 15’ the 
reaction was started by adding TFA (3 drops), and the reaction mixture was stirred at RT overnight, in the 
dark. Chloranil (1.144 g, 4.7 mmol) was added, and after stirring for 2h 30’, the solvent was removed in 
reduced pressure, and the crude mixture was dissolved in dichloromethane (150mL). DiPEA (4.9 mL, 3.635 
g - 28 mmol) was added, and 30’ later, boron trifluoride diethyl etherate (5.2 mL, 5.98g, 28.8 mmol) was 
slowly added, and the reaction mixture was left stirring for 3 hours at RT. The reaction mixture was filtered 
through a pad of silica and the solvent removed under reduced pressure. The crude was purified by column 
chromatography. (SiO2, eluted with hexane:dichloromethane 1:1 (11% yield). 1H NMR (400 MHz, CDCl3) δ 
7.24 – 7.18 (m, 2H), 7.14 – 7.08 (m, 2H), 6.02 (d, J = 18.3 Hz, 2H), 4.84 – 4.73 (m, 2H), 2.62 – 2.54 (m, 6H), 
1.59 (d, J = 15.8 Hz, 1H), 1.44 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 158.13 (s), 12λ.26 (s), 128.04 (s), 
121.18 (s), 115.64 (s), 77.33 (s), 77.01 (s), 76.69 (s), 75.86 (s), 56.03 (s), 34.60 (d, J = 14.1 Hz), 31.60 (s), 
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29.07 (s), 26.92 (s), 25.28 (s), 22.63 (d, J = 5.6 Hz), 20.68 (s), 18.75 (s), 14.53 (s), 14.10 (s), 11.42 (s). 
HRMS (ES+) m/z calcd for C22H22BF2N2NaO [M + Na]+ 401.1617, found 401.1644 
 
4.2.4 Synthesis of 2,6-Diiodo-1,3,5,7-tetramethyl-8-(4-Propargyloxyphenyl)-4,4-
difloroboradiaza-s-indacene  
 
 
1,3,5,7-Tetramethyl-8-(4-Propargyloxyphenyl)-4,4-difloroboradiaza-s-indacene (50 mg, 0.13 mmol) and I2 (83 
mg, 0.33 mmol) were dissolved in deoxygenated absolute ethanol (100 ml). Iodic acid, HIO3 (45.74 mg, 0.26 
mmol) was dissolved in a few drops of water and added into previous solution. The reaction mixture was 
stirred at 80 °C for 3 hours till all reactant was consumed. Then, saturated sodium thiosulfate solution was 
added (50 ml) and it was stirred at room temperature for additional 30 min. Then, it was extracted with CHCl3 
and water. Organic layer was dried with MgSO4 and evaporated under reduced pressure. The product was 
purified by silica gel column chromatography using CHCl3/DCM (50/50, v/v). Fraction containing the final 
compound  was collected and the solvent was removed under reduced pressure (72% yield ). 1H NMR (400 
MHz, CDCl3), 7.09 (d, J=8.8 Hz, 2H), 7.04 (d, J=8.8 Hz, 2H), 4.70 (s, 2H), 2.56 (s, 6H), 2.49 (s, 1H), 1.36 (s, 
6H). 13C NMR (101 MHz, CDCl3) 158.6, 156.7, 146.0, 141.4, 131.6, 129.1, 127.8, 116.0, 100.1, 85.8,. 76.1, 
56.1, 17.1, 16.0. HRMS (ES+) m/z calcd for C22H20BF2I2N2NaO [M + Na]+ 652.9550, found 652.9515.  
 
4.2.5 Synthesis of 1-(azidomethyl)pyrene 
 
1-(azidomethyl)pyrene. 1-(bromomethyl)pyrene (537.9 mg, 1.83 mmol) and NaN3 (616.3 mg, 9.48 mmol) 
were added to a flame dried round bottom flask under argon. 10 mL of DMF was added to the mixture. The 
reaction mixture was placed in an oil bath and heated at 120°C for 3 hours. The reaction was refluxed until 
all 1-(bromomethyl)pyrene was consumed. It was then poured into 100 mL water and extracted with CH2Cl2 
(3 x 25 mL). Combined organic extractions were dried (MgSO4) and concentrated to provide the desired 
compound as a light orange solid (87 % yield). 1H NMR (400 MHz, CDCl3) δ 8.14 – 8.07 (m, 2H), 8.04 – 7.83 
(m, 6H), 7.74 (d, J = 7.8 Hz, 1H), 4.78 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 131.56 (s), 131.15 (s), 130.63 
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(s), 129.40 (s), 128.94 (s), 128.59 (s), 128.15 (s), 127.70 (s), 127.19 (d, J = 14.3 Hz), 126.10 (s), 125.53 (d, J 
= 4.8 Hz), 124.78 (s), 124.52 (d, J = 6.6 Hz), 122.43 (s), 77.88 (s), 77.56 (s), 77.24 (s), 52.95 (s). HRMS 
(FAB): m/z calculated for C17H11N3 257.0953, measured: 257.0955. 
 
4.2.6 Synthesis of photosensitizer 3 
 
 
 
azidomethyl)pyrene (54.5 mg, 0.2 mmol), iodo-bodipy (75.6 mg, 0.2 mmol) and Na ascorbate (23.8 mg, 0.12 
mmol) were dissolved in deoxygenated DMF (20 mL), and the reaction mixture was stirred for 20 minutes at 
RT. CuI (11.4 mg, 0.06 mmol) was added and the reaction mixture was stirred overnight at 40°, in the dark. 
Subsequently, the reaction mixture was extracted with dichloromethane and H2O, then the organic phase 
was dried with MgSO4, filtered, and the solvent removed under reduced pressure (82 % yield). The crude 
was purified by column chromatography (SiO2, eluted with hexane:dichloromethane 1:1. 1H NMR (400 MHz, 
CDCl3) δ 8.32 – 7.98 (m, 9H), 7.46 – 7.33 (m, 1H), 7.11 – 6.93 (m, 4H), 6.33 (s, 2H), 5.32 (s, 2H), 5.16 (d, J 
= 11.7 Hz, 2H), 2.62 (d, J = 23.9 Hz, 6H), 1.35 (d, J = 6.8 Hz, 6H). 13C NMR (100 MHz, CDCl3) 14.4, 14.6, 
52.7, 62.1, 115.4, 116.7, 121.1, 121.9, 122.7, 125.0, 125.9, 126.1, 126.4, 126.5, 127.2, 127.8, 128.5, 129.2 
,129.4, 130.6, 131.2, 132.3, 141.5, 143.1, 155.3, 158.2, 158.7. HRMS (ESI) m/z: calcd. for C39H31BF2N5O+: 
636.2746 [M + H], found 636.2762. 
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4.2.7 Synthesis of 3/CNO Nano-hybrid 
While overall less research has been conducted on carbon nanomaterials for PDT, the synergistic effects of 
combining carbon nanotubes, graphene, and carbon dots with photosensitizers significantly boost the 
efficacy of treatment. Our group recently reported the non-covalent functionalization of carbon nano-onions 
(CNOs) with highly fluorescent pyrene-BODIPY dyads and their application for biomedical imaging, with 
promising results.24 These findings were in line with other recent works, where CNOs exhibited a prompt and 
effective uptake by different cell lines, revealing high stability, low toxicity and high efficiency.25,26,27 In a 
similar fashion to drug loading applications of carbon nanomaterials, photosensitizers could be non-
covalently loaded onto the aromatic surface of carbon nanomaterials coated in biocompatible polymers 
through π−π stacking for activation after laser excitation.  
An important issue with regard to photodynamic therapy agents is the delivery of these molecules into the 
organs/tumor tissues/tissues cells. There are many strategies for drug targeting, but a satisfactory 
multifunctional delivery agent is nevertheless needed. To achieve this goal, we chose to use a strong 
pyrene–carbon nanoonion p–p interactions. Thus, our target molecule (Scheme 6) is composed of a red 
absorbing chromophore (Bodipy), intersystem crossing promoter heavy atoms (iodines at 2 and 6 positions 
of the Bodipy core), and a pyrene substituent on the branch of the chromophore for p-stacking interactions 
with the CNO (Scheme 2). 
 
Scheme 2. Non covalent immobilization of diiodo-BODIPY photosensitizer 3 onto CNO.  
 
3 (4 mg, 0.006 mmol) and 15 mg of pristine CNOs  were dispersed in 15 mL of dry dimethylformamide (DMF) 
and sonicated in an ultrasonic bath for 30 minutes. Then, the CNOs were filtered through a nylon filter (0.2 
ȝm) and washed with THF until the THF appears colorless. Finally, the functionalized CNO nanomaterial 
was dried overnight at room temperature. 15 mg of 3/CNO hybrid were recovered from the filter as a black, 
fine powder.  
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4.2.8 Synthesis of 3/benz-CNO Nano-hybrid 
Additional experiments were carried out with CNOs bearing benzoic acid functionalities on the surface 
(3/benz-CNO) in order to study the influence of different CNO surface modifications (Scheme 3). 3 (4 mg, 
0.006 mmol) and pristine CNOs (12 mg) were dispersed in 15 mL of dry dimethylformamide (DMF) and 
sonicated in an ultrasonic bath for 60 minutes. Then, the CNOs were filtered through a nylon filter (0.2 ȝm) 
and washed with THF until the THF appears colorless (approx. 100 mL). Finally, the functionalized CNO 
nanomaterial was dried overnight at room temperature. 11 mg of 3/CNO hybrid was recovered from the filter 
as a black, fine powder.  
 
Scheme 3. Non covalent immobilization of diiodo-BODIPY photosensitizer 3 onto benz-CNO. 
 
 
4.3 Results and Discussion 
4.3.1 Absorption and Emission spectroscopy of pyrene-diiodoBODIPY dye 
The solubility of 3 in common polar organic solvents such as methanol, ethanol, isopropanol, but also in 
acetonitrile is negligible. Also in water, 3 is not soluble, while in non-polar organic solvents the solubility of 3 
is excellent. 3 was characterized by absorption and fluorescence spectroscopy. The absorption maximum of 
3 in DMSO is located at 536 nm with molar extinction coefficients of 79.9 x 103 M-1cm-1.Pyrene-centered 
absorption bands were observed at 268, 279, 316, 330 and 346 nm, with an additional broad, BODIPY-
based absorption band located in the area around 400 nm in DMSO (Figure 2). The fluorescence quantum 
yield of 3 is very low, due to the heavy-atom effect of the iodo-substituents on the BODIPY core structure, 
with values between 1% and 3% and emission maxima between 552 and 555 nm. The singlet oxygen 
quantum yield of 3 upon irradiation, measured in relation to rose bengal in benzylalcohol, was found to be 
0.37.28 
 
4.3.2 Absorption and Emission spectroscopy of 3/CNO and 3/benz-CNO 
The photophysical characterization of the two nano-hybrids clearly revealed the loading of the CNO 
nanoparticles with 3 (Figure 2). A dispersion of 3/CNO and 3/benz-CNO in DMSO showed the plasmonic 
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absorption and scattering of the CNO nanomaterial over the whole spectral area. Furthermore, distinct 
absorption peaks at 279, 329, 346 and 536 nm are related to the presence of 3 in an estimated 
concentration of 2.3 x 10-7 M for 3/CNO and 7.7 x 10-8 M for 3/benz-CNO at a mass concentration of 10 ȝg 
mL-1 (Figure 2).  
 
 
 
Figure 2. Absorption spectra of 3 (black) and of a dispersion of 3/CNO (blue, 10 ȝg mL-1) and 3/benz-CNO 
(red, 10 ȝg mL-1) in DMSO illustrating the molar extinction coefficient of 3 and the loading of the CNOs with 
dyad 3. Inset: Fluorescence spectrum of 3 upon excitation at 490 nm. 
 
4.3.3 Biological Studies of Nano-hybrid 3/CNO 
In order to evaluate the suitability of these nano-hybrids as possible drug delivery system, the cellular uptake 
and cytotoxicity of 3/CNO in vitro on HeLa cells was investigated. For the uptake studies, HeLa cells were 
incubated with dispersion of 3/CNO at a mass concentration of 10 ȝgmL-1. An efficient uptake of 3/CNO into 
the cancer cells after 24 h of incubation (Figure 3) was confirmed by observing a green fluorescence signal 
of the BODIPY dye in the cytoplasm. The 3D combined rendering clearly showed a spot-like pattern inside 
the cells, suggesting an endocytosis pathway for the 3/CNO internalization.  
 
 
 
Figure 3. Confocal images of live HeLa cells incubated for 24h with 3/CNO at a mass concentration of 10 ȝg 
mL-1. Nuclei are stained with Hoechst 33342 (blue), the presence of 3/CNO is indicated by the green 
fluorescence signal. Green BODIPY signal (A), Hoechst 33342 (B) and combined images with bright field 
(C). (D) 3D combined rendering revealing the spotty pattern of the green BODIPY fluorescence. Scale bars 
A-D= 50 µm. 
500 550 600 650 700
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For cytotoxicity studies, HeLa cells were incubated with dispersions of pristine CNO and 3/CNO at 10 and 20 
ȝg mL-1 in DMEM medium for 24h. Following the incubation, the cells were washed with PBS three times and 
illuminated with a white LED for different periods of time (5 and 15 minutes) in phenol red-free DMEM 
medium. Time-dependent phototoxicity of the treated cells was quantified by using the Presto Blue® assay. 
The cell’s metabolic activity was not affected by CNOs at any mass concentrations and illumination time 
tested (Figure 4). Moreover, in control experiments BODIPY 3 demonstrates to be cytotoxic following 
irradiation, whereas the hybrid material 3/CNO did not impair the HeLa cell’s metabolic activity. 
 
 
 
Figure 4. Cellular metabolic activity of HeLa cells incubated with different concentrations of CNO, 3/CNO and 
3 following illumination at different time points. Please note: CNOs were dispersed in PBS buffer mother 
solutions. 
 
Based on these preliminary observations, further modifications of the experimental procedure were 
instigated. The concentrations of 3/CNO were set to be 10 and 20 ȝg mL-1; final working dilutions were 
obtained by dispersing CNOs from mother solutions in either PBS or DMSO in DMEM. Illumination exposure 
time points were set to 2, 5, 10, and 15 minutes. Non-irradiated experiments were conducted as well (dark 
control, t=0). Furthermore, a 2.3 x 10-7 M solution of 3 (obtained by the dilution of a DMSO mother solution in 
DMEM, with a final DMSO concentration of 2 vol%) was used as reference, based on the estimated loading 
of 3 onto the nanohybrid. DMSO was added to all samples in order to obtain a final DMSO concentration of 2 
vol%. As shown in Figure 6, photosensitizer 3 alone revealed an impressive cytotoxicity after illumination. 
After 2 minutes, no cellular metabolic activity can be detected, while in the dark control the cell’s metabolic 
activity is not compromised by the exposure to the dye. The presence of 3/CNO, pre-dispersed in PBS, don’t 
induce an illumination time or concentration dependent reduction of HeLa metabolic activity. On the other 
hand, by exposing cells to 3/CNO, pre-dispersed in DMSO – with increasing illumination time and CNO 
concentration, HeLa metabolic activity declined remarkably. The cytotoxicity assays clearly indicated that the 
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presence of CNOs prohibited the photodynamic efficiency of the BODIPY photosensitizer 3, as long as it is 
immobilized onto the CNO surface (Figure 5).  
 
 
Figure 5. Schematic representation of the effect on the cells of the 3/CNO-nanohybrid.  
 
When the photosensitizer was partially removed from the CNO surface, PDT efficiency was partially 
restored. To evaluate this conclusion, the following aspects need to be considered. Important for any drug 
delivery system is that the drug molecule does not detach from the surface of the molecular shuttle before 
being delivered intracellularly. Upon filtration of 3/CNO dispersed in DMSO by using a syringe filter with a 0.2 
ȝm nylon membrane, the BODIPY based absorption spectrum with the characteristic pyrene and BODIPY 
centered absorption bands, but no plasmonic CNO absorption, was observed. This clearly indicated that, 
when 3/CNO was dispersed in DMSO, 3 was removed from the CNO surface, thus released in solution. 
Similar treatment of a PBS dispersion of 3/CNO did not evidence any free BODIPY 3 after the filtration 
process. These findings strongly match with the in vitro results: when 3/CNO is dispersed in PBS, an intact 
nanohybrid delivery system where the active component is immobilized on the molecular shuttle is prepared. 
On the other hand, by initially dispersing 3/CNO in DMSO, BODIPY 3 is released in solution, and the drug 
delivery system is obviously disrupted and no longer comparable to the initial intact 3/CNO delivery system. 
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Figure 6. Cell metabolic activity of HeLa cells incubated with 3/CNO and 3 at different concentrations and 
illumination times, versus different dilution methods. Please note: Different CNO mother solutions (in PBS 
buffer or DMSO) were used as indicated. 
 
4.3.4 Biological Studies of Nano-hybrid 3/benz-CNO 
The concentration of 3 in a 10 ȝgmL-1 DMSO dispersion of 3/benz-CNO was determined to be about 7.7 x 
10-8 M. This corresponds to 1/3 compared to the 3/CNO dispersion. Interestingly, also lower concentrations 
of 3 confirmed a strong photodynamic-triggered reduction of the cellular metabolic activity and again, in the 
PBS-based dispersions, 3 anchored at the whole nano-shuttle don’t not reveal a significant cytotoxicity. On 
the other hand, by dispersing the 3/benz-CNO constructs in DMSO, the free photosensitizer 3 once being 
removed from the CNO surface, showed a clear efficiency in the photodynamic killing of HeLa cells (Figure 
7A and 7B). 
Figure 7A. Cellular metabolic activity of HeLa cells incubated with different concentrations of CNO, 3/CNO 
and 3 following illumination at different time points. Please note: CNOs were dispersed in PBS buffer mother 
solutions. 
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Figure 7B. Cell metabolic activity of HeLa cells incubated with 3/benz-CNO and 3 at different concentrations 
and illumination times, versus different dilution methods. Please note: Different CNO mother solutions (in 
PBS buffer or DMSO) were used as indicated (bottom graph). 
 
4.3.5 Photobleaching studies  
1,3-diphenylisobenzofuran (DPBF) is a fluorescent molecule which possesses a highly specific reactivity 
towards singlet oxygen (1O2) forming an endoperoxide which decomposes to give 1,2-dibenzoylbenzene 
(See Figure 8). In other words, DPBF is a singlet oxygen trap which reacts with 1O2 giving cis-
dibenzoylbenzene. This reaction between DPBF and 1O2 can be followed by measuring the decrease in 
fluorescence intensity of DPBF. In 1993, Carloni et al.29 in order to check the specificity of DPBF toward free 
radicals carried out a series of experiments. DPBF was reacted with hydroxy (HO•), alkyloxy (RO•), 
alkylperoxy (ROO•), and C-centered radicals (2-cyanoisopropyl radical) in Triton-X micelles and in natural 
systems (rat liver microsomes). In all cases, the DPBF is rapidly transformed to 1,2-dibenzoylbenzene in the 
case of O-centered radicals and to the corresponding adduct in the case of 2-cyanoisopropyl radical. The 
experiments in the model systems were also carried out from the chemical point of view and the reaction 
products were isolated and identified. From the results obtained, it should be stressed that DPBF must be 
used with caution in complex biological systems for the detection of 1O2, as it also reacts with different 
radical species.29 
 
 
 
 
 
 
Figure 8. DPBF mechanism of action. 
 
The use of DPBF is of particular interest, because when the molecule is incorporated in model biological 
membranes and excited at 410 nm, it shows a fluorescence emission spectrum with a maximum at 455 mn.30 
This allows the molecule to be used in biological membranes where the presence of proteins does not 
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interfere with the DPBF fluorescence. Hence, the monitoring of DPBF fluorescence would be a simple 
method which does not require particular techniques to detect 1O2 in natural systems. 
 
Data derived from additional photobleaching experiments supported these results by describing the ability of 
BODIPY 3 to generate ROS and its release features from the CNO’s surface. BODIPY dye 3 without CNOs 
showed a high efficiency in ROS generation, indicated by the rapid photobleaching of the ROS sensor 
molecule DPBF. When BODIPY loaded CNOs were used, the photobleaching of DPBF is slowed, but still 
progresses rapidly. This reflects the above-mentioned partial removal of the dye from the CNO surface in 
organic solvents such as benzylalcohol or DMSO (in the in vitro experiments) - a disruption of the delivery 
system - and thus a certain efficiency in singlet oxygen generation (See Figure 9). Also the lower loading of 
the benz-CNO/3, compared to the CNO/3 hybrids was confirmed by this set of data (See Figure 10). 
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4.3.6 Photobleaching studies for 3/CNO 
 
 
 
 
Figure 9. Fluorescence spectra of 1,3-diphenylisobenzofuran (DPBF) in the presence of 3 (A) and 3/CNO (B) 
upon 380 nm excitation in benzylalcohol. Concentration DPBF 4.6 x 10-6 M. Emission spectra recorded at 
different time intervals between 0 and 10 min (top row) of illumination. Control experiments in the dark after 0 
and 5 min (center row), and maximum fluorescence intensities as function of illumination time (bottom row). 
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4.3.7 Photobleaching studies for 3/benz-CNO 
 
 
 
Figure 10. Fluorescence spectra of 1,3-diphenylisobenzofuran (DPBF) in the presence of 3 (A) and 3/benz-
CNO (B) upon 380 nm excitation in benzylalcohol. Concentration DPBF 4.6 x 10-6 M. Emission spectra 
recorded at different time intervals between 0 and 10 min (top row) of illumination. Control experiments in the 
dark after 0 and 5 min (center row), and maximum fluorescence intensities as function of illumination time 
(bottom row).  
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4.4 Conclusion 
In this study, a novel pyrene-BODIPY dyad was synthetized, isolated and characterized, revealing effective 
features for the application in photodynamic therapy. In vitro tests on HeLa demonstrated a ROS-triggered 
phototoxicity of the photosensitizer 3. The pyrene-diiodo-BODIPY dyad 3 was then successfully immobilized 
onto the surface of carbon nano-onions, with the CNOs acting as molecular shuttle for the hydrophobic 
photosensitizer. Live-cell confocal imaging revealed that the pyrene-diiodo-BODIPY dyad 3 was effectively 
internalized by the cells, monitoring the residual fluorescence of the BODIPY chromophore. Illumination of 
the BODIPY/CNO treated cells, however, revealed no significant, illumination time or CNO mass 
concentration dependent, reduction in cell metabolic activity. The phototoxicity of the pyrene-BODIPY dyad 
could be restored by disrupting the nanohybrids in a DMSO solution. When the nanohybrids were disrupted, 
e.g. the photosensitizer was detached from the CNO surface before exposing the cells to the nanomaterial, a 
clear photo-triggered cytotoxic effect was observed, comparable to the results for the free BODIPY 
photosensitizer 3. This indicated that the BODIPY photosensitizer 3 is deactivated by the presence of the 
CNOs, while being attached to the CNO surface. The non-covalent approach presented here paves the way 
to a systematic study of intact and disassembled non-covalent delivery systems, which is not readily feasible 
in covalent bonding approaches. It is, to our best knowledge, the first systematic approach, including in vitro 
studies, where a non-covalent BODIPY PDT photosensitizer-CNM system is evaluated. Future research 
efforts will involve a thorough photophysical elucidation of the observations herein reported, including in-
depth studies of the ongoing cellular metabolic pathways as well as of possible CNO-promoted quenching 
effects of the photoexcited BODIPY moiety. 
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5. CNOs for Photocatalysis 
 
5.1 Introduction 
Organosulfur compounds are widely present in nature and play important roles in many biological structures 
and functions.1,2 Sulfur containing functional groups such as thioether, thioester, and disulfide are found in a 
number of natural products, for example the disulfide depsipeptide FK228 (romidepsin, anticancer);3 the 
thioester depsipeptide largazole (anticancer);4 and pharmaceutical agents such as ranitidine (Zantac, 
antiulcer), NCH-31 (antitumor),5 and the cyclic tetrapeptide disulfide SCOP (HDAC inhibitor).6 Disulfide-
containing linkers are now used in  antibody−drug conjugates (ADCs), which are used as targeted cell-based 
immunotherapeutics.7 Lastly, organosulfur compounds commonly serve as useful synthetic intermediates, 
with applications in chemical biology, medicinal, and polymer chemistry. A common method to construct 
carbon−sulfur bonds is via the thiol−ene reaction, a prototypical “click reaction” that effects the anti-
Markovnikov radical addition of thiol across nonactivated carbon−carbon double bonds.8 The high efficiency 
and orthogonality of thiol−ene chemistry has led to increased utility in polymer functionalization, 
macromolecular synthesis, biological applications, and functionalization of biomaterials.9 Growing concerns 
about the environment and energy use have spurred extensive efforts to make chemical processes more 
sustainable and “green”. Examples include employing sunlight or low energy visible light to promote 
reactivity and performing synthetic transformations without the use of rare, expensive, and potentially toxic 
elements, especially in the pharmaceutical industry.10 Pioneering work by Yoon11 and Stephenson12 on 
radical thiol−ene coupling of alkenes and thiols using visible-light-absorbing ruthenium polypyridyl complex 
(Ru- (bpz)3 2+ and Ru(bpy)3Cl2) photocatalysts constitutes a striking development of chemical transformations 
promoted by low cost energy.13 However, both methodologies require the use of rare, expensive, and toxic 
metals (See Figure 1). More recently, Greaney and co-workers reported the use of the naturally abundant 
and nontoxic metal oxide TiO2 for thiol−ene coupling, but the protocol requires a nanoparticulate form of TiO2 
and the substrate scope was limited.14 It is well established that highly efficient photocatalysts can be 
prepared as composite semi-conducting materials composed of metal oxides displayed on the surface of 
carbon nanomaterials.15,16 These low-cost photocatalysts have been widely investigated for environmental 
applications including water purification.17 Carbon nanomaterial metal oxide composites (NMMO composites) 
are readily prepared through a number of methods including the simple stirring of the two materials.18 The 
carbon NMMO composite offers a synergic effect induced by the presence of carbon materials in the hybrid 
photocatalyst.19 This is mainly attributed to the decrease of electron/hole recombination, bandgap tuning and 
increase in the adsorptive active sites.20 In this chapter, an application of Carbon NMMO composites as 
highly-efficient photocatalysts for light-mediated thiol-ene ligation reactions has been investigated. 
Characterisation of the composite materials is presented and a putative mechanism for the catalytic cycle is 
depicted. Substrate scope is explored across inter and intramolecular thiol-ene ligation and intermolecular 
thiol-yne reactions. The simple catalyst preparation, high-yields, ease of purification and biocompatibility 
render this a highly attractive option for cytocompatible thiol-ene ligation reactions. 
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Figure 1. Pathway for photocatalysed thiol-ene ligation reactions, common reagents used and overview of 
catalyst described herein. 
 
5.2 Experimental 
5.2.1 General Procedure for Radical Thiol-Ene Reaction 
To a solution of an alkene (1 eq) and a thiol (1.5 eq) or thioacetic acid (4 eq) in ethylacetate (700 ȝL) was 
added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was sealed with a Teflon cap and left at room 
temperature under irradiation with UV lamp for 1 h. Upon completion of the reaction, the solution was 
concentrated in vacuo, and the residue was purified by flash column chromatograph ( gradient elution in 
Hexane to ethylacetate 7:3) to afford the final thiol-ene adducts.  
 
5.2.2 Synthesis of compound 1 
 
 
3-(acetylthio)propyl benzoate: To a solution of allyl benzoate (81.03 mg, 0.5 mmol) and thioacetic acid 
(142.71 ȝL, 2mmol) in ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was 
sealed with a Teflon cap and left at room temperature under irradiation with UV lamp for 1 h. Upon 
completion of the reaction, the solution was concentrated in vacuo, and the residue was purified by flash 
column chromatograph ( gradient elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 
90% yield. 1H NMR (400 MHz, CDCl3) δ 8.10 – 8.01 (m, 2H), 7.60 – 7.52 (m, 1H), 7.45 (ddt, J = 8.0, 6.9, 1.2 
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Hz, 2H), 4.48 – 4.27 (m, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2.35 (s, 3H), 2.16 – 1.97 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 1λ6.08, 167.04, 133.55, 130.16, 128.λ4, 63.89, 31.18, 29.40, 26.36. IR 3064, 2956, 1717, 1692, 
1453, 1270, 1114, 958, 713, 617. HRMS (ES+) m/z calcd for C12H14NaO3S [M + Na]+ 261.055404, found 
261.055586. 
5.2.3 Synthesis of compound 2 
 
 
 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-(benzoyloxy)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate: To a solution of allyl benzoate (81.0 mg, 0.5 mmol) and 1-Thio-β-D-glucose tetraacetate (273 mg, 
0.75mmol) in ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was sealed with 
a Teflon cap and left at room temperature under irradiation with UV lamp for 1 h. Upon completion of the 
reaction, the solution was concentrated in vacuo, and the residue was purified by flash column 
chromatograph ( gradient elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 72% 
yield. 1H NMR (400 MHz, CDCl3) δ 8.13 – 7.97 (m, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.44 (dd, J = 16.0, 8.5 Hz, 
2H), 5.23 (dd, J = 17.5, 8.1 Hz, 1H), 5.06 (dd, J = 19.5, 9.7 Hz, 2H), 4.51 (d, J = 10.0 Hz, 1H), 4.41 (t, J = 6.2 
Hz, 2H), 4.21 (dt, J = 18.6, 9.3 Hz, 1H), 4.17 – 4.04 (m, 1H), 3.76 – 3.62 (m, 1H), 2.85 (dtd, J = 20.3, 13.1, 
7.3 Hz, 2H), 2.14 – 2.07 (m, 2H), 2.05 (d, J = 3.0 Hz, 6H), 2.01 (d, J = 7.3 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ 170.63, 170.18, 16λ.41, 133.05, 12λ.5λ, 128.42, 83.65, 75.λ8, 73.83, 6λ.75, 68.28, 63.2λ, 62.11, 
29.09, 26.70, 20.70, 20.62, 20.59. IR 2954, 1752, 1454, 1369, 1224, 1119, 1037, 908, 713, 601. HRMS 
(ES+) m/z calcd for C24H30NaO11S [M + Na]+ 549.140020, found 549.140103. 
 
5.2.4 Synthesis of compound 3 
 
 
 
3-(benzylthio)propan-1-ol: To a solution of allyl alcohol (80.0 mg, 1.40 mmol) and benzyl mercaptan (0.16 
mL, 2.06 mmol) in ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was sealed 
with a Teflon cap and left at room temperature under irradiation with UV lamp for 1 h. Upon completion of the 
reaction, the solution was concentrated in vacuo, and the residue was purified by flash column 
chromatograph ( gradient elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 84% 
yield. 1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 10.3, 2.8 Hz, 4H), 7.26 (ddd, J = 11.8, 5.4, 2.0 Hz, 1H), 3.73 
(dd, J = 11.4, 5.3 Hz, 4H), 2.56 (t, J = 6.5 Hz, 2H), 1.83 (dq, J = 13.1, 6.5 Hz, 2H), 1.77 (s, 1H). 13C NMR 
(101 MHz, CDCl3) δ 138.35, 128.87, 128.54, 127.04, 61.74, 36.29, 31.59, 28.00. IR 3408, 2921, 1705, 1597, 
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1500, 1453, 1353, 1226, 1053, 912, 708, 560. TOF MS (EI+) m/z calcd for C10H14OS [M+] 182.0765, found 
182.0768. 
5.2.5 Synthesis of compound 4 
 
 
 
S-cyclohexyl ethanethioate: To a solution of cyclohexene (81.0 mg, 1 mmol) and thioacetic acid (0.28 mL, 
4 mmol) in ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was sealed with a 
Teflon cap and left at room temperature under irradiation with UV lamp for 1 h. Upon completion of the 
reaction, the solution was concentrated in vacuo, and the residue was purified by flash column 
chromatograph ( gradient elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 85% 
yield. 1H NMR (400 MHz, CDCl3) δ 3.57 – 3.41 (m, 1H), 2.28 (s, 3H), 1.90 (dt, J = 9.2, 4.5 Hz, 2H), 1.67 (td, J 
= 10.2, 5.0 Hz, 2H), 1.57 (ddd, J = 12.7, 7.7, 4.9 Hz, 1H), 1.50 – 1.33 (m, 4H), 1.31 – 1.19 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 1λ5.81, 42.43, 42.43, 32.λλ, 30.77, 25.λ1, 25.53. IR 2932, 2855, 1730, 1686, 1434, 
1357, 1221, 1105, 1002, 946, 590. TOF MS (EI+) m/z calcd for C8H14OS [M+] 158.0765, found 158.0771. 
 
5.2.6 Synthesis of compound 5 
 
 
 
 
(E)-2-((2-((9H-fluoren-9-yl)methoxy)-2-oxoethylidene)amino)-3-methoxy-3-oxopropyl 5-
(acetylthio)pentanoate: To a solution of (E)-2-((2-((9H-fluoren-9-yl)methoxy)-2-oxoethylidene)amino)-3-
methoxy-3-oxopropyl pent-4-enoate (81.0 mg, 0.19 mmol) and thioacetic acid (54 ȝL, 4 mmol) in 
ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The vial was sealed with a Teflon cap 
and left at room temperature under irradiation with UV lamp for 1 h. Upon completion of the reaction, the 
solution was concentrated in vacuo, and the residue was purified by flash column chromatograph ( gradient 
elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 82% yield. 1H NMR (600 MHz, 
CDCl3) δ 7.7λ (d, J = 7.6 Hz, 2H), 7.66 – 7.60 (m, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.34 (tt, J = 7.4, 1.2 Hz, 2H), 
5.70 (d, J = 8.2 Hz, 1H), 4.70 – 4.63 (m, 1H), 4.51 (dd, J = 11.4, 3.9 Hz, 1H), 4.48 – 4.38 (m, 3H), 4.26 (t, J = 
7.1 Hz, 1H), 3.78 (d, J = 34.9 Hz, 3H), 2.88 (t, J = 7.2 Hz, 2H), 2.38 (h, J = 7.1 Hz, 2H), 2.33 (s, 3H), 1.74 – 
1.57 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 1λ5.88 (s), 172.77 (s), 16λ.λ5 (s), 143.76 (d, J = 12.7 Hz), 
141.33 (s), 127.78 (s), 127.11 (s), 125.11 (s), 120.04 (s), 77.27 (s), 77.06 (s), 76.85 (s), 67.30 (s), 63.91 (s), 
53.44 (s), 52.92 (s), 47.13 (s), 33.30 (s), 30.63 (s), 28.94 (s), 28.52 (s), 23.79 (s), 21.06 (s), 14.22 (s). IR 
3356, 2947, 1738, 1680, 1532, 1444, 1353, 1216, 1136, 1052, 957, 736, 618. 
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5.2.7 Synthesis of compound 6 
 
 
 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(3-(acetylthio)propoxy)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate: To a solution of allyl 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranoside (80.0 mg, 0.21 mmol) and 
thioacetic acid (58 ȝL, 4 mmol) in ethylacetate (700 ȝL) was added 56 ȝL of GO/Bi2O3 nanocomposite. The 
vial was sealed with a Teflon cap and left at room temperature under irradiation with UV lamp for 1 h. Upon 
completion of the reaction, the solution was concentrated in vacuo, and the residue was purified by flash 
column chromatograph ( gradient elution in Hexane to ethylacetate 7:3) to afford the final thiol-ene adduct. 
82% yield. 1H NMR (400 MHz, CDCl3) δ 5.3λ – 5.33 (m, 1H), 5.22 – 5.12 (m, 1H), 5.03 – 4.95 (m, 1H), 4.44 
(t, J = 6.5 Hz, 1H), 4.21 – 4.05 (m, 2H), 3.97 – 3.85 (m, 2H), 3.58 – 3.48 (m, 1H), 2.96 – 2.81 (m, 2H), 2.34 – 
2.25 (m, 3H), 2.11 (d, J = 7.1 Hz, 3H), 2.08 – 2.04 (m, 3H), 2.03 – 2.00 (m, 3H), 1.97 (d, J = 10.3 Hz, 3H), 
1.27 – 1.16 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 1λ5.65 (s), 170.4λ – 170.02 (m), 169.45 (s), 101.30 (s), 
70.89 (s), 70.63 (s), 68.81 (s), 68.22 (s), 67.03 (s), 61.26 (s), 30.61 (s), 29.36 (s), 25.60 (s), 20.87 – 20.45 
(m), 14.03 (m). IR 2959, 1750, 1686, 1437, 1375, 1215, 1133, 1040, 952, 902, 738, 626. HRMS (ES+) m/z 
calcd for C19H29O11S [M + H]+ 465.142660, found 465.142509. 
 
5.3 Results and discussion 
5.3.1 Bismuth Oxide and Tungsten Oxide  
Photocatalytic Initiation of Radical Thiol−Ene Reaction  
We were interested in finding alternative photoredox catalytic initiation conditions to promote hydrothiolation 
with carbon nanomaterials, possibly mild, cheap, and nontoxic beside being more efficient and suitable for 
late-stage functionalization of biologically relevant molecules. Upon review of the literature, we were inspired 
by the work of Peric̀s and co-workers in which inexpensive and nontoxic bismuth-based materials were 
used as photocatalysts for the direct asymmetric alkylation of aldehydes.21 Based on this precedent, at the 
first stage, a mild photocatalytic method for alkene hydrothiolation utilizing UV light activation and two 
inorganic photocatalyst such as bismuth oxide and tungsten oxide has been investigated. Recently, Peric̀s 
reported the use of the bismuth oxide photocatalysts for the atom transfer radical addition (ATRA) reaction of 
organobromides to alkenes.22 We first set out to determine if bismuth oxide (Bi2O3) and tungsten oxide (WO3) 
would catalyze the UV light initiated radical thiol−ene reaction and optimize the reaction conditions (Table 1). 
Initial investigation into the proposed Bi2O3 catalyzed thiol−ene reaction focused on the reaction of ally 
benzoate and thioacetic acid in ethylacetate (Table 1). Irradiation of the alkene and thiol in the presence of 
photocatalyst Bi2O3 (0.02 equiv.) produced only poor conversion to the addition product after 1 h (Table 1, 
entry 2). However, the addition of 0.1 equiv. of a single electron acceptor bromotrichloromethane (BrCCl3) 
provided the desired thioether in higher conversion (Table 1, entry 1) after 1 h. Utilization of BrCCl3 to 
promote the generation of the thiyl radical was previously reported by Stephenson and co-workers.12 It is 
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presumed that the trichloromethyl radical generated from the photocatalyst abstracts the hydrogen atom of 
the mercaptan to give the electrophilic thiyl radical intermediates that undergo addition reaction with the 
alkene to give the desired thioether. Similarly, irradiation of the thiol and the alkene in the presence of WO3 
(0.02 equiv.) gives a final product with an isolated yied of 14% (Table 1, entry 7). Just the utilization of 
BrCCl3 helps to improve the conversion (Table 1, entry 6) highlighting the essential roles of the photocatalyst, 
BrCCl3, and light in this transformation. The background reaction was observed in the absence of the 
bismuth photocatalyst and BrCCl3 (entries 3, 4 and 5). Interestingly, the thiol−ene reaction proceeded highly 
efficiently under sunlight (entry 10). Importantly, increasing of the catalyst loading to 0.04 equiv. had no 
impact on the overall performance of this protocol (entry 5), so due to reaction operational simplicity, 0.02 
equiv. was utilized as the optimal catalyst loading for the next photocatalytic studies.  
 
Table 1. Preliminary optimization studies for the Thiol−Ene Reaction of allyl benzoate with thioacetic acida 
 
 
Entry BrCCl3 Photocatalyst Yield (%)b 
1 0.1 equiv Bi2O3 84 
2 - Bi2O3 27 
3 0.1 euiv - 33 
4 - - 22 
5 - Bi2O3 (0.04 equiv) 16 
6 0.1 equiv WO3 40 
7 - WO3 14 
aReactions were conducted by irradiating allyl benzoate (0.5 mmol), thioacetic acid (2.0 mmol), and the 
photocatalyst (0.02 equiv) in EtOAc (0.7 mL) with 365 nm lamps for 1 h. bIsolated yields. 
 
5.3.2 Nanomaterials screened for the thiol−ene ligation reaction  
Previous studies have found that carbon quantum dots (C QDs) can enhance the photocatalytic activity 
under visible light irradiation.23 Zhuo et al have prepared Graphene QDs/TiO2 nanoparticles,24 Ming et al 
have prepared C QDs/TiO2 nanoparticles,25 Liu et al have prepared C QDs/TiO2 nanosheet, Xu et al have 
prepared Graphene/TiO2 composite to improve the visible light photocatalytic activity.26 Compared with 
traditional nanostructure, porous TiO2 nanotubes are recognized as a high-efficiency photocatalyst due to the 
novel 3-D nanostructure. Titanium dioxide (TiO2) is the most widely used semiconductor in photocatalytic 
applications. Nevertheless, due to its relatively high bandgap (3.2eV corresponding to a wavelength of 388 
nm), TiO2 is marginally activated under solar irradiation, since UV light represents less than 5% of the overall 
solar energy reaching Earth’s surface. Carbon materials are widely employed to couple with conventional 
semiconductors due to properties such as large specific surface area, stability in both acid and basic media, 
and tunable surface chemistry. They have demonstrated to induce some beneficial effects on the 
photocatalytic performance of semiconductor metal oxides by creating synergies between both metal oxide 
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and carbon phases. Generally, this effect is attributed to the decrease of the bandgap energy of the 
composite catalysts, to an enhancement of the adsorptive properties as well as charge separation and 
transportation properties. In porous nanotubes, the double-walled structure possessing high specific surface 
area and porosity, could improve the photon application efficiency, the adsorption of dye and convection of 
solution, which would introduce remarkable photocatalytic abilities. In the second stage of my research, I 
studied the Thiol-Ene reaction utilizing different carbon nanomaterials. Nanodiamonds (ND), pristine-carbon 
nanoonion (p-CNO), oxidized-carbon nanoonion (ox-CNO), pegylated carbon nanoonion (PEG-CNO) and 
graphene oxide (GO) have been tested in this reaction. Initially, carbon nanomaterials have been tested in 
the presence of the photocatalyst (Bi2O3) yielding a final product with an excellent NMR conversion (Table 2, 
entries 1-5). Similarly, utilizing WO3 as photocatalyst in addition to the carbon nanomaterials an NMR 
conversion of >99% has been observed (Table 2, entries 6-10). Interestingly, the nanomaterials by itself in 
the absence of the photocatalyst (both Bi2O3 and WO3) have been found to complete the reaction in high 
conversion (Table 2, entries 11-15).  
 
Table 2. Nanomaterials Screening for the Thiol−Ene Reaction of allyl benzoate with thioacetic acida (Note: 
nanomaterial instead of BrCCl3) 
 
Entry NM Photocatalyst Yield (%)b 
1 ND Bi2O3 >99 
2 p-CNO Bi2O3 >99 
3 Ox-CNO Bi2O3 >99 
4 PEG-CNO Bi2O3 >99 
5 GO Bi2O3 >99 
6 ND WO3 >99 
7 p-CNO WO3 >99 
8 Ox-CNO WO3 >99 
9 PEG-CNO WO3 >99 
10 GO WO3 >99 
11 ND - 89 
12 p-CNO - 65 
13 Ox-CNO - 70 
14 PEG-CNO - 94 
15 GO - 84 
NM = nanomaterial; ND = nanodiamonds; CNO = carbonanoonions; GO = graphene oxide; aReactions 
were conducted by irradiating allyl benzoate (0.5 mmol), thioacetic acid (2.0 mmol), the NM (10 ȝg/mL), 
the photocatalyst (0.02 equiv) in EtOAc (0.7 mL) with 365 nm lamps for 1 h.  
b1H-NMR conversion. 
 
5.3.3 Carbon NM-MO composites investigation 
In order to achieve full conversion using the great potential of the carbon nanomaterials, an optimization 
study with ox-CNO and GO has been carried on. The graphene oxide powder used, (15-20 sheets, 4-10% 
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edge-oxidized) was purchased from Sigma. I first set out to determine if ox-CNO/Bi2O3 nanocomposite and 
GO/Bi2O3 nanocomposite would catalyze the UV light initiated radical thiol−ene reaction and optimize the 
reaction conditions (Table 3). The initial investigation into the nanocomposite catalyzed thiol−ene reaction 
focused on the reaction of allyl benzoate and thioacetic acid in ethylacetate (Table 3). Initially, ox-CNO/Bi2O3 
nanocomposite was synthesized by a two-step process. Firstly, 1 mg of oxidized-carbon nanoonion (ox-
CNO) and 4.6 mg Bi2O3 were dissolved in 1 mL EtOAc. This mixed dispersion was ultrasonicated for 5 min at 
37 kHz and let it stirring for 16 h at room temperature. Subsequently, the mixture was filtered off on a nylon 
syringe filter (pore size 1 ȝm) in order to remove the excess of Bi2O3 and maintain the synthesized product. 
The final product was a transparent and clear solution of oxidized-carbon nanoonion–bismuth oxide 
composite (See figure 2). In the same way, GO/Bi2O3 nanocomposite was synthesized. 1 mg of graphene 
oxide (GO) and 4.6 mg Bi2O3 were dissolved in 1 mL EtOAc. This mixed dispersion was ultrasonicated for 5 
min at 37 kHz and let it stirring for 16 h at room temperature. Subsequently, the mixture was filtered off on a 
nylon syringe filter (pore size 1 ȝm) in order to remove the excess of Bi2O3 and maintain the synthesized 
product. As previously stated, also for GO/Bi2O3 nanocomposite the final product was a transparent and 
optically clear solution.  
 
 
 
Figure 2. Transparent solution of filtered ox-CNO/Bi2O3 nanocomposite. 
 
The photocatalytic initiation of the radical Thiol−Ene Reaction was tested under different concentration of this 
clear solution and the optimized conditions were identified and investigated with a range of  different 
substrates (Table 3). Four different concentrations in ethylacetate were tested for the thiol-ene reaction 
(Table 3, entries 1-4). A stocksolution of 1 mg mL-1 was prepared and consequent dilutions to 10, 20, 40, 80 
ȝg mL-1 were made. If the lowest concentration of ox-CNO/Bi2O3 nanocomposite corresponding to 10 ȝg mL-
1
 (7 ȝL) gives an NMR conversion of λ0% (Table 3, entry 1), the highest concentration corresponding to 80 
ugmL-1 (56 uL)  gives an NMR conversion >99% (Table 3, entry 4). The same behavior is notable also with 
GO/Bi2O3 nanocomposite suggesting a reproducible mechanism  (Table 3, entries 7-8). Irradiation of the 
alkene and thiol in the presence of the nanocomposite produced excellent conversion to the addition product 
after 1 h (Table 3). Finally, an evaluation of solvents has been carried on. The reaction tested in dry 
ethylacetate revealed high NMR conversion (Table 3, entry 5). On the other hand the reaction tested using 
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EtOAc : water (6:1) reveals just a 39% of conversion (Table 3, entry 6). On the basis of these observation I 
selected  EtOAc (non-anhydrous) as the solvent for the next reactions. 
 
Table 3. Optimization study with ox-CNO for the Thiol−Ene Reactiona 
 
Entry NM Bi2O3/NM 
composite solvent Yield (%)
b
 
1 Ox-CNO 10 ȝg/mL EtOAc 90 
2 Ox-CNO 20 ȝg/mL EtOAc 91 
3 Ox-CNO 40 ȝg/mL EtOAc 92 
4 Ox-CNO 80 ȝg/mL EtOAc >99 
5 Ox-CNO 10 ȝg/mL dry EtOAc >99 
6 Ox-CNO 80 ȝg/mL EtOAc + H2O 39 
7 GO 10 ȝg/mL EtOAc 90 
8 GO 80 ȝg/mL EtOAc >99 
NM = nanomaterial; CNO = carbonanoonions; aReactions were conducted by irradiating allyl benzoate 
(0.5 mmol), thioacetic acid (2.0 mmol) and the NM (at indicated concentration) in EtOAc (0.7 mL) with 365 
nm lamps for 1 h; b1H-NMR conversion. 
 
 
5.3.4 Carbon NM-MO composites characterization 
The morphologies and crystallography of the samples were characterized by transmission electron 
microscopy (TEM). Bright-field TEM imaging of Bi2O3/ox-CNO composite and Bi2O3/GO composite was 
performed on a Jeol JEM-1011 instrument equipped with a thermo ionic tungsten source operated at 100 kV. 
Samples were prepared by spreading a droplet of the dispersed composite material in ethanol on a copper 
grid coated with a lacey carbon film. Figure 3, A shows TEM image of Bi2O3 nanoparticles, which display 
mainly a spherical shape with a size ranging from 10 to 20 nm. Figure 3, B shows TEM image of GO, which 
display the typical transparent paper-like structure of GO with a lateral size of about 1 µm and around 15-18 
layers, which is in agreement with the Sigma-Aldrich specifications. Interestingly, in comparison with the 
TEM image of graphene nanosheets, the TEM image of the Bi2O3/GO composites (Figure 3, D) show that 
the surface of the graphene–bismuth oxide composite is much rougher than that of graphene nanosheets. 
This might be attributed to the growth of bismuth oxide nanoparticles on graphene sheets. Moreover, as 
clearly suggested by the TEM images the bismuth oxide nanoparticles (about 10 nm in size) are uniformly 
distributed on 2D graphene nanosheets (Figure 3, D). Similarly, TEM image of ox-CNO composite show 
homogenous black spots onto ox-CNO surfaces in respect to the smooth ox-CNO with size ranging from 20 
to 40 nm (Figure 3, C). For both composites, TEM images indicate that the catalyst is well dispersed and 
attached to the graphene oxide and the oxidized carbon nanoonion surfaces. The structures of the 
composites exhibit porous morphologies, with many projections and outcroppings indicating that the 
nanocomposite exhibit a larger total surface area and a more porous structure than those modified by non-
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modified CNO or GO. This should enable an increase of the effective surface area and facilitate the electron 
transfer during the Thiol-Ene Reaction. 
 
 
 
Figure 3. TEM images of (A) Bi2O3 nanoparticles,(B) GO nanosheets , (C) Bi2O3/ox-CNO composite and (D) 
Bi2O3/GO nanocomposite. 
 
 
5.3.5 Carbon NM-MO composites screened for the thiolene-ligation under visible 
light 
This photoredox process driven by an organic photocatalyst is synthetically complementary to both 
traditional (using UV irradiation or thermolysis) methods of radical initiator and transition-metal-mediated 
approaches. In particular, a metal-free process could potentially benefit peptide and glycoprotein chemistry, 
since certain polypeptide sequences and proteins have been shown to interfere with transition-metal 
mediated processes.27 To test the theory, LED mediated thiol-ene reaction between allyl benzoate and 
thioacetic acid in the presence of ox-CNO and GO by themselves (Table 4, entries 6-10) and the 
nanocomposite ox-CNO/Bi2O3 and GO/Bi2O3 (Table 4, entries 11-13)  has been explored. Surprisingly, ox-
CNO and GO successfully initiated the photocatalytic thiol−ene reaction under blue light-emitting diode 
(LED) irradiation, providing the thiol−ene adduct in 70% and 71% isolated yield respectively, upon 1 hour 
A B
C D
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irradiation (Table 4, entries 8 and 10). An higher NMR conversion has been obtained by using ox-CNO/Bi2O3 
nanocomposite and GO/Bi2O3 nanocomposite giving a final conversion of 79% and 78% respectively (Table 
4, entries 11 and 12). The time extension to 3 hours reaction did not improve the conversion to the final 
adduct (Table 4, entry 13). 
 
Table 4. LEDs mediated Thiol−Ene Reaction of allyl benzoate with thioacetic acida 
 
 
Entry Photocatalyst NM
 
 Yield (%)b 
1 Bi2O3, BrCCl3 - >99 
2 Bi2O3 - 51 
3 - - 40 
4 WO3, BrCCl3 - 80 
5 WO3 -  
6 - ND (10 ȝg/mL) 90 
7 - p-CNO (10 ȝg/mL) 79 
8 - Ox-CNO (10 ȝg/mL) 70 
9 - PEG-CNO (10 ȝg/mL) 78 
10 - GO (10 ȝg/mL) 71 
11 - Bi2O3/Ox-CNO (80 ȝg/mL) 79 
12 - Bi2O3/GO (80 ȝg/mL) 78 
13 - Bi2O3/GO (80 ȝg/mL), 3h 80 
NM = nanomaterial; CNO = carbonanoonions; aReactions were conducted by irradiating allyl benzoate 
(0.5 mmol), thioacetic acid (2.0 mmol), the NM (composite with photocatalyst) in EtOAc (0.7 mL) with 405 
nm lamps for 1 h; b1H-NMR conversion. 
 
 
5.3.6 Scope Expantion 
With the optimized ligation conditions in hand, the general applicability of the composite nanomaterials for 
photocatalysed TEC across a broad variety of structurally varying thioacids/thiols and alkenes has been 
demonstred. As depicted in Figure 4, all the desired thioesters/thioethers were obtained in high isolated 
yields. Alkyl thiols showed a good reactivity in the thiol-ene reactions and the use of the protected cysteines 
and the paracetylated thiosugars demonstrate the synthetic potential of our catalytic approach for the 
preparation of bioconjugates Of particular importance in these synthetic studies was the ease of purification 
of the products, with no purification step required for removal of the catalyst. This offers significant 
advantage over the traditional DPAP/MAP initiated processes where extensive column chromatography is 
required in order to isolate the product from the degraded initiator and photosensitizer. In addition, no 
discoloration of the reaction mixture was observed during UV or visible-light-mediated photolysis, ensuring 
that the photoinitiation was not compromised at any point. This is a major advantage over processes where 
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milligram quantities of metal oxide are utilized and strong discoloration and precipitation of metal oxides is 
observed. (See the experimental paragraph to see the yields for the reactions in Figure 4 and Figure 8). 
 
 
 
Figure 4. Carbon NM-MO catalysed thiolene ligation: expansion of the scope with simple substrate. 
 
 
 
 
Figure 5: NMR spectrum of crude ligation product 1 after photolysis in EtOAc for 1 h in the presence of 
GO/Bi2O3 nanocomposite (Figure 4, Entry 1). 
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Figure 6: NMR spectrum of crude ligation product 2 after photolysis in EtOAc for 1 h in the presence of 
GO/Bi2O3 nanocomposite (Figure 4, Entry 2). 
 
 
 
 
 
Figure 7: NMR spectrum of crude ligation product 4 after photolysis in EtOAc for 1 h in the presence of 
GO/Bi2O3 nanocomposite (Figure 4, Entry 4). 
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Having demonstrated the high efficiency of the visible-light-mediated thiol−ene reaction, I have also  
investigated the applicability of this chemistry to enable the synthesis of glycoconjugates between glycosyl 
thiols and amino acid derivatives (See Figure 8). Glycoconjugates have become important tools for the 
exploration of many biological processes,28,29 and more recently, S-linked glycoconjugates have become 
promising analogues of glycopeptides and glycoproteins because of their enhanced chemical stability and 
enzymatic resistance.30 Happily, the thiol−ene reaction between a Fmoc protected peptide derivative with 
thioacetic acid (Figure 8, 6) and a galactopyranoside with thioacetic acid (Figure 8, 8) occurred smoothly, 
giving the corresponding S-linked coconjugates in good yields. Other complex examples serve to 
demonstrate the potential utility of this method for bioconjugation. Notably, the reaction is compatible with N-
Fmoc protected amino acid and sugars, with no effect on the rate or overall performance of the protocol. This 
demonstrated that a variety of complex drug-like molecules could be accessed via late-stage 
functionalization by employing this mild technology.  
 
 
 
 
Figure 8. Carbon NM-MO catalysed thiolene ligation: expansion of the scope with relevant biological 
substrate. 
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Figure 9. NMR spectrum of crude ligation product 6 after photolysis in EtOAc for 1 h in the presence of 
GO/Bi2O3 nanocomposite (Figure 8, Entry 6). 
 
 
 
Figure 10. NMR spectrum of crude ligation product 8 after photolysis in EtOAc for 1 h in the presence of 
GO/Bi2O3 nanocomposite (Figure 8, Entry 8). 
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5.3.7 Mechanism 
A proposed mechanism for the overall photocatalytic process is outlined in Scheme 1. Initiation relies on the 
photo-excitation of electrons to the conduction band of the Bi2O3 catalyst. The resultant holes in the carbon 
nanomaterial are reductively quenched by the thiol, resulting in formation of a thiyl radical anion, which can 
spontaneously lose a proton to furnish a thiyl radical. Oxygen may function as a sacrificial electron acceptor, 
enhancing reaction efficiency by reducing hole-electron recombination in the nanocomposite. The thiyl 
radical initiates the TEC process through anti-Markovnikov addition onto an alkene and generation of an 
alkyl radical, which propagates the reaction by abstracting a hydrogen atom from the starting thiol. 
 
 
 
 
Scheme 1. Proposed mechanism for nanocomposite catalysed thiol-ene reaction. 
 
 
5.4 Conclusion 
We have developed an efficient, robust and readily accessible photocatalytic process for the thiol-ene ‘click’ 
reaction. Full conversion to the corresponding thioester or thioether product is observed for a range of 
carbon nanomaterial/metal oxide nanocomposites. The process appears to be general for a wide range of 
ligation reaction including, inter- and intramolecular thiol-ene, and thiol-yne ligation. The process is efficient 
with commercially available carbon nanomaterials rendering it easy to use. The nanomaterials were fully 
characterized as bismuth oxide nanoparticles adhered to the surface of the carbon nanomaterials, and a 
putative reaction mechanism for the catalytic cycle is presented. We believe these studies set the stage for 
future development in the area of nanocomposite thiol-ene ligation reactions and may have broader 
implications in photocatlysis of thiyl-radical mediated processes. This highly efficient reaction shows scope 
generality, as demonstrated by the use of a variety of thiols and alkenes to provide thioethers in excellent 
yields. Moreover, this method demonstrates promise for future glycoprotein studies through the successful 
generation of model glycoconjugates and synthesis of relevant pharmaceutical agents.  
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6. Materials and Methods 
 
6.1 Materials 
Analytical thin-layer chromatography was performed using silica gel (precoated sheets, 0.2 mm thick, 20 cm 
× 20 cm) and visualized by UV irradiation or molybdenum staining (heating with a phosphomolybdic acid 
reagent). DCM, MeOH, THF and toluene were dried over flame-dried 3 or 4 Å sieves. Dimethylformamide 
(DMF), triethylamine (Et3N), and trifluoroacetic acid (TFA) were used dry from Sure/Seal bottles. Other 
reagents were purchased from industrial suppliers. All commercially available chemicals were used without 
further purification unless otherwise stated. All UV reactions were carried out in a Luzchem photoreactor, 
LZC-EDU (110 V/60 Hz), containing 10 UVA lamps centered at 350 nm. Yields refer to chromatographically 
and spectroscopically purified compounds.  
 
6.2 Instrumentation 
6.2.1 Thermogravymetric analysis (TGA) 
TGA was conducted on a TA Q500 analyser, using a Pt pan as sample holder. After equilibrating the sample 
at 30 °C for 5 min and then at 100 °C for additional 20 min, the measurement was performed in air using a 
heating rate of 10 °C/min. The sample weight was monitored until 900 °C. 
 
6.2.2 Attenuated total reflectance Fourier transformed infrared (ATR FTIR) 
spectroscopy 
The FTIR spectra were recorded with a Bruker Vertex 70v FTIR spectrometer equipped with a Platinum ATR 
accessory on solid samples.  
 
6.2.3 Raman spectroscopy 
Raman spectra were measured on a Horiba Jobin Yvon HR 800 UV LabRam Raman microscope. For the 
Raman measurements, the samples were excited with a built-in 632 nm laser. The samples were deposited 
by adding the dry compound to a drop of methanol on the glass slide. The slides were dried in air for 2 h. 
 
6.2.4 Absorption and fluorescence spectroscopy 
Absorption spectra were recorded on an Agilent Cary 8454 UV–vis diode array spectrophotometer. 
Fluorescence spectra were taken on a Horiba Jobin Yvon Fluoromax-4 spectrofluorometer in 1.00 cm × 1.00 
cm quartz glass cells. The CNO samples were dispersed in DMSO, PBS 0.01M or cell medium to a final 
concentration of 500 μg ml−1. The dispersion of CNO was sonicated for 15 min at 37 kHz and then diluted 
respectively in DMSO, PBS 0.01M or cell medium to achieve final concentrations of 50, 20, 10, 5 and 1 μg 
ml−1. 
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6.2.5 Fluorescence quantum yields 
The fluorescence quantum yield (ΦF) is determined by the comparative method of Williams et al.1 and is 
calculated using the following equation, 
 
ΦX = (Φst) (Gradx / Gradst) (η2x/η2x) 
 
where st and x denotes the standard and test respectively, Φ is the fluorescence quantum yield, Grad is the 
gradient obtained from the plot of integrated fluorescence intensity vs. absorbance of the dye at the 
excitation wavelength and η represents the refractive index of the used solvents.  
 
6.2.6 Dynamic light scattering (DLS) and zeta-potential measurements 
DLS Measurements were performed on the Malvern Nano-ZS instrument operating in backscattering (173°) 
mode and analysed with the software Zetasizer, with automatic selection of the optimal detector position and 
number of independent measurements. The CNO samples were dispersed in DMSO, PBS 0.01M or cell 
medium to a final concentration of 500 μg ml−1. The samples were sonicated for 30 min at 37 kHz and then 
diluted respectively in DMSO, PBS 0.01M or cell medium to achieve final concentrations of 50, 20, 10, 5 and 
1 μg ml−1. The CNOs samples were sonicated for additional 15 min and the size of the particle was 
measured. Z-potential measurements were performed on the same apparatus using the disposable Z-
potential cuvettes. 
 
6.2.7 Transmission electron microscopy (TEM) 
Bright-field TEM imaging was performed on a Jeol JEM-1011 instrument equipped with a thermoionic 
tungsten source operated at 100 kV. Samples were prepared by spreading a droplet of the dispersed 
material in ethanol on a copper grid coated with a lacey carbon film. 
 
6.2.8 High-resolution mass spectrometry (HRMS) 
The Accurate Mass measurements (HRMS) were performed on a Waters SYNAPT G2 High Resolution 
Mass Spectrometry instrument equipped with an Electrospray Ionization interface and coupled to a Waters 
ACQUITY UPLC. Electrospray ionization in positive mode was applied in the mass scan range 50-1200 Da. 
The analysis were performed on a Waters ACQUITY UPLC BEH C18 column 100 x 2.1 mm ID (particle size 
1.7 ȝm) with an in-line filter. The mobile phase was 0.1% formic acid in H2O and 0.1% formic acid in 
acetonitrile. 
 
6.2.9 Nuclear Magnetic Resonance Spectroscopy (NMR) 
For NMR spectra, a 400 MHz spectrometer was employed for 1H (400.13 MHz) and 13C (100.61 MHz) 
spectra, a 600 MHz spectrometer was employed for 1H (600.13 MHz) and 13C (150.90 MHz) spectra. 
Resonances δ, are in ppm units downfield from an internal reference in CDCl3 (δH = 7.26 ppm, δC = 77.0 
ppm), or MeOH (δH = 3.31 ppm, δC = 4λ.0 ppm). 
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6.2.10 Confocal microscopy 
Confocal imaging was performed with a laser scanning confocal microscope equipped with a resonant 
scanner (Nikon A1R) using a 20 × objective.  
 
6.3 Biological methods 
 
6.3.1 Cell Culture 
HeLa cells (human epithelial cervix adenocarcinoma cell line ATCC CCL2) and MCF-7 cells (human 
mammary gland adenocarcinoma cell line ATCC HTB-22) were cultured on 75 cm2 culture flasks in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS, 2% Penstrep and 1% glutamine. 
Cells were grown in a humidified incubator at 37°C with 5% CO2 and 95% air.  
 
6.3.2 Sample preparation for cell study 
The samples of functionalized-CNO were prepared by suspending 1 mg of CNOs in 1 mL sterile phosphate 
buffered saline (PBS) solution followed by sonication for 30 min at 37 kHz. The samples were then dispersed 
in the cell culture media (DMEM) at final concentrations of 1, 2, 5, 10, 20 μg mL−1. 
 
6.3.3 Cell viability 
Cells were seeded in 24 well chamber slides at a density of 5 × 104 cells/well and incubated in a 500 μl cell 
culture medium to obtain a subconfluent monolayer after 48 h in a humidified atmosphere at 37 °C and 5% 
CO2. The cell culture medium was removed and replaced with 500 μl of medium with dispersions of 
functionalized-CNO at the final concentrations. The viability of the cells was measured after 12, 24, 48 and 
72 h of exposure to the samples of CNO, utilizing the PrestoBlueTM cell viability assay (Life Technologies). 
Prestoblue™ is a blue non-fluorescent, cell permeable compound (resazurin-based solution), that is reduced 
by living cells into a fluorescent compound (resorufin). Assays were performed by measuring the absorbance 
on a microplate reader at a wavelength of 570 nm (experimental wavelength) and 600 nm (normalization 
wavelength). The percent viability was determined by normalizing absorbance values to non-treated cells 
and calculated as: 
 �܊ܛܗܚ܊܉ܖ܋܍��ܖܜ܍ܖܛ�ܜܡ�ܗ܎��ܠܘ܍ܚ�ܕ܍ܖܜ��܉ܕܘܔ܍��܍ܚ܉܏܍�ሺܖ = �ሻ�܊ܛܗܚ܊܉ܖ܋܍��ܖܜ܍ܖܛ�ܜܡ�ܗ܎�܃ܖܜܚ܍܉ܜ܍܌��܉ܕܘܔ܍ ∗ ૚૙૙ = �܍ܚ܋܍ܖܜ�܄�܉܊�ܔ�ܜܡ�ሺ%ሻ 
 
following a procedure previously described2. Each measurement was normalized with the average signal of 
untreated wells to determine the percent cell viability expressed as the mean ± SD. 
 
6.3.4 Cellular imaging 
Cells were grown in subconfluent monolayer (50–60 % confluent) on 25 mm glass bottom dishes at 37 °C 
under a 5% CO2 atmosphere in a humidified environment. The culture medium was removed and replaced 
with 1, 5 and 10, 20 μg ml−1 suspension of functionalized-CNO and incubated for 24 h. After the incubation 
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time, the cells were washed with PBS three times to remove any remaining media and the cells were 
incubated for 7 min at 37 °C with a solution of Hoechst 33342, for live nuclear staining. Excitation of the 
fluorescein on the CNO samples was performed at 488 nm and the emission was acquired in the spectral 
window between 500–560 nm. The Hoechst 33342 was exited at 405 nm and the images were acquired in 
the emission range of 415–480 nm. In the same way, in order to see the plasma membrane, 
after the washinf with PBS, WGA 5λ4 (Life Technologies, 5 ȝg/mL) was added to the cells and the cells were 
incubated for 10 min at 37°C. Then, the cells were washed again with PBS before imaging. Sequential 
optical sections (Z-stacks), 1 ȝm thickness, from the basal-to-apical surfaces of the cells were acquired to 
study the cellular internalization and distribution. Excitation of the fluorescein on the CNO samples was 
performed at 488 nm and the emission was acquired in the spectral window between 500–560 nm. The 
Hoechst 33342 was exited at 405 nm, while the WGA 594 was excited at 577 nm and the images were 
acquired in the emission range of 415–480 nm and 600-680 respectively.  
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Conclusion and Outlook 
The expansion of carbon materials, as demonstrated in the chapters of this thesis, is multidisciplinary and is 
related to physics, chemistry, biology, applied sciences and engineering. With the emergence of 
biopharmaceuticals and immunotherapies at the forefront of modern medicine, there is a particular interest in 
the controlled chemical derivatization of carbon nanomaterials with fluorophores, photosensitizers and 
biomolecules to fully realize the potential of nanomedicine in the treatment of disease. Recently, 
nanotechnology has been applied to address the clear biomimicry challenge inherent to the next generation 
of more potent and sophisticated adjuvants. Although early adjuvants, such as aluminum hydroxide, have 
been successful in stimulating the immune response, the advent of nanoscale antigen delivery platforms has 
catalyzed the transition from these simple immunoactive chemical agents to adjuvants that can engage and 
direct immune responses more akin to the methods employed by pathogens themselves. Furthermore, since 
photocatalytic technologies have been gaining increasing commercial interest worldwide with applications in 
chemical biology, medicinal, and polymer chemistry, a photocatalytic technology using carbon nano-
materials has been explored. A mild, inexpensive and general initiation protocol for thiol-ene ligation 
reactions using carbon nanomaterial/metal oxide (Carbon NM-MO) composites have been described. 
Graphene oxide (GO), nanodiamonds (ND) and carbon nano-onions (CNO) displaying bismuth oxide 
nanoparticles adhered to the surface, were found to be efficient photocatalysts for this process. The 
straightforward and cheap catalyst preparation, excellent overall yields, ease of purification and broad 
substrate scope render this a highly versatile process for biorthogonal thiol-ene ligation. The high efficiency 
of the visible-light mediated thiol−ene reaction, enable the applicability of this chemistry to the synthesis of 
glycoconjugates, pharmaceutical agents and antibody−drug conjugates (ADCs). The simple catalyst 
preparation, high-yields, ease of purification and biocompatibility render this a highly attractive option for 
cytocompatible thiol-ene ligation reactions. These are key relevant topics for the future of our society. In this 
thesis, it has been highlighted how carbon nano-onions, due to their low toxicities and powerful 
characteristics, can be extremely useful not only in various biology-related applications such as 
nanomedicine, drug delivery, bio-labeling but also in important photocatalytic applications especially for the 
synthesis of organosulfur compounds, which play fundamental roles in many biological structures and 
functions. As described in the previous chapters, carbon nano-onions have emerged as a novel platform for 
drug delivery, imaging and sensing, showing enhanced therapeutic efficacy, photostable fluorescence and 
high biocompatibility. This opens new doors in using carbon nano-materials to probe, adjust and control 
biological processes at the cellular and subcellular level and points toward the possible application of carbon 
nano-onions as novel agents for gene therapy. The topics treated defines some of the trends and outlooks in 
this exciting area, with the effort of evidencing some of the possibilities offered from the growing level of 
knowledge and providing bases for a more rational design of carbon nanomaterial based therapeutics. The 
aim is to stimulate ideas and research on a field that is strongly believed and will represent one of the key 
areas for the future of the new generations.  
 
 
